ORGANOMETALLICS

Gyroscope-Like Platinum and Palladium Complexes with Trans-Spanning Bis(pyridine) Ligands

Paul D. Zeits,^{†,§} Giovanni Pietro Rachiero,^{‡,§} Frank Hampel,[‡] Joseph H. Reibenspies,[†] and John A. Gladysz*,[†]

[†]Department of Chemistry, Texas A&M University, P.O. Box 30012, College Station, Texas 77842-3012, United States [‡]Institut für Organische Chemie and Interdisciplinary Center for Molecular Materials, Friedrich-Alexander-Universität Erlangen-Nürnberg, Henkestraße 42, 91054 Erlangen, Germany

Supporting Information



ABSTRACT: Pyridines with one or two substituents terminating in vinyl groups are prepared. Intramolecular ring-closing metatheses of trans-MCl₂ adducts and hydrogenations supply the title compounds. Williamson ether syntheses using the alcohols $HO(CH_2)_nCH=CH_2$ (n = 1 (a), 2 (b), 3 (c), 4 (d), 5 (e), 6 (f), 8 (h), 9 (i)) and appropriate halides give the pyridines $2-NC_5H_4(CH_2O(CH_2)_nCH=CH_2)$ (1a,b), $3-NC_5H_4(CH_2O(CH_2)_nCH=CH_2)$ (2a-e,h,i), and 2,6-NC₅H₃(CH₂O-CH₂)-CH=CH₂) (2a-e,h,i), and 2,6-NC₅H₃(CH₂O-CH₂)-CH₂-CH₂)-CH₂-CH₂) (2a-e,h,i), and 2,6-NC₅H₃(CH₂O-CH₂)-CH₂-CH₂-CH₂) (2a-e,h,i), and 2,6-NC₅H₃(CH₂O-CH₂)-CH₂ $(CH_2)_n CH = CH_2)_2$ (4a-d) in 92-45% yields. Reactions of 3,5-NC₅H₃(COCl)₂ and HO(CH₂)_nCH = CH₂ afford the diesters 3,5-NC₅H₃(COO(CH₂)_nCH=CH₂)₂ (5a-f,h, 90-41%). The reaction of 3,5-NC₅H₃(4-C₆H₄OH)₂, Br(CH₂)₅CH=CH₂, and Cs_2CO_3 yields 3,5-NC₅H₃(4-C₆H₄O(CH₂)₅CH=CH₂)₂ (8; 32%). Reactions of PtCl₂ with 1a,b, 2a-e,h,i, 4a,b (but not 4c,d), 5a,c-f,h, and 8 afford the corresponding bis(pyridine) complexes trans-10a,b (40-12%), trans-12a-e,h,i (84-46%), trans-17a,b (88-22%), trans-19a,c-f,h (94-63%), and trans-22 (96%). Selected adducts are treated with Grubbs' catalyst and then H₂ (Pd/ C) to give trans- $PtCl_2[2,2'-(NC_5H_4(CH_2O(CH_2)_{2n+2}OCH_2)H_4C_5N)]$ (trans-11a,b; 79–63%), trans- $PtCl_2[3,3'-(NC_5H_4(CH_2O(CH_2)_{2n+2}OCH_2)H_4C_5N)]$ $(CH_2)_{2n+2}OCH_2)H_4C_5N)] (trans-13,d,h,i; 93-80\%), trans-PtCl_2[2,6,2',6'-(NC_5H_3(CH_2O(CH_2)_{2n+2}OCH_2)_2H_3C_5N)] (trans-13,d,h,i; 93-80\%), trans-13,d,h,i; 93-80\%), trans-13,d,h,i; 93-80\%), trans-13,d,h,i; 93-80\%), trans-13,d,h,i; 93-80\%), trans-13,d,h,i; 93-80\%), trans-14,d,h,i; 93-$ 18a,b; 22-10%), trans-PtCl₂[3,5,3',5'-(NC₅H₃(COO(CH₂)_{2n+2}OCO)₂H₃C₅N)] (trans-20d-f,h; 45-14%), and trans- $PtCl_2[3,5,3',5'-(NC_5H_3(4-C_6H_4O(CH_2)_{12}O-4-C_6H_4)_2H_3C_5N)]$ (40%). A previously reported ring-closing metathesis of trans-PdCl₂[2,6-NC₅H₃(CH₂CH₂CH=CH₂)₂]₂ is confirmed, and the new hydrogenation product trans-PdCl₂[2,6,2',6'-(NC₅H₃((CH₂)₆)₂H₃C₅N)] (trans-16; 62%) is isolated. Additions of CH₃MgBr to 12b,h and 13d,h afford the corresponding PtClCH₃ species (94-41%), but analogous reactions fail with 2-substituted pyridine adducts. The reaction of trans-19c with PhC=CH and CuI/*i*-Pr₂NH gives the corresponding PtCl(C=CPh) adduct (18%). The crystal structures of *trans*-17a, *trans*-11b, trans-13d, trans-13h CH₂Cl₂, trans-16, trans-18a,b, and trans-20e 2CHCl₃ are determined. Steric effects in the preceding data, especially involving 2-substituents and the MCl₂ or MCl(X) rotators, are analyzed in detail.

INTRODUCTION

As summarized in a review, the term "gyroscope" has been applied to a variety of molecules.¹ The most intensive efforts to craft functional molecular analogues of macroscopic gyroscopes have been described by Garcia-Garibay.^{2,3} In our research group, we have sought to develop transition-metal-based gyroscopes in which trans phosphorus donor atoms are bridged by three methylene chains or related linkers.⁴⁻¹⁰ All of these have been prepared via 3-fold intramolecular ring-closing metatheses, as sketched in Scheme 1 ($I \rightarrow II$). A variety of coordination geometries have proved accessible, as illustrated by III–V.

We have also sought systems based upon other types of trans donor atoms. Arsenic analogues of some of the species in Scheme 1 have been realized.¹¹ However, we were particularly interested in establishing new donor atom coordination

Special Issue: F. Gordon A. Stone Commemorative Issue

Received: November 16, 2011 Published: March 9, 2012

Scheme 1. Syntheses of Gyroscope-Like Complexes with Trans Phosphorus Donor Atoms and $(CH_2)_n$ Linkers



numbers. Toward this end, our attention was drawn to pyridine ligands. An additional motivation was the possibility of introducing functionality in the para or 4-position, which could allow for surface mounting, a subject of much interest within the broad field of molecular rotors.¹²

Further impetus derived from an intriguing preliminary communication by Lambert and Ng.¹³ They reported the synthesis of the palladium bis(2,6-dihomoallylpyridine) complex, **VI** shown in Scheme 2, and its 2-fold intramolecular

Scheme 2. Lambert's Initial Synthesis of a Complex with a Doubly Trans-Spanning Bis(pyridine) Ligand



ring-closing metathesis with Grubbs' catalyst to give the doubly bridged trans-spanning bis(pyridine) complex VII. The crystal structure of VII, which can be viewed as an adduct of a diaza-*m*cyclophane, was mentioned, but the data were not deposited with the Cambridge Crystallographic Data Centre. We sought to explore the generality of this type of process, including extensions to pyridines with other substitution patterns.

In this paper, we report (1) syntheses of a variety of 2-, 3-, 2,6-, and 3,5- mono- and disubstituted pyridine ligands in which the substituents terminate with vinyl groups, (2) the preparation of the corresponding *trans*-dichloroplatinum or *trans*-dichloropalladium bis(pyridine) complexes, (3) intra-molecular ring-closing metatheses that lead to a variety of singly and doubly trans-spanning systems, (4) chloride ligand substitutions that lead to dipolar rotors, (5) crystal structures of representative species, and (6) analyses of numerous steric effects manifested in these data. Additional details can be found elsewhere.¹⁴

RESULTS

1. Syntheses of Alkene-Containing Pyridines. For initial studies, monosubstituted pyridines were sought. Thus, commercial 2-(chloromethyl)pyridine hydrochloride was combined with excesses of the alcohols $HO(CH_2)_nCH=CH_2$ (n = 1 (a), 2 (b)) and 3.0–2.3 equiv of sodium to generate the corresponding alkoxide bases. As shown in Scheme 3, workups

Scheme 3. Syntheses of Complexes with 2-Substituted Trans-Spanning Bis(pyridine) Ligands



gave the alkene-containing monoethers $2\text{-NC}_{5}H_{4}(CH_{2}O-(CH_{2})_{n}CH=CH_{2})$ (1a,b) as yellow or brown oils in 61–59% yields. Compounds 1a,b have previously been prepared from 2-pyridinemethanol and the corresponding chlorides $Cl(CH_{2})_{n}CH=CH_{2}^{-15,16}$ However, these building blocks are more costly.

Given the course of results below, 3-substituted pyridines were also desired. As shown in Scheme 4, analogous reactions of commercial 3-(chloromethyl)pyridine hydrochloride, alcohols HO(CH₂)_nCH=CH₂ (n = 1 (**a**), 2 (**b**), 3 (**c**), 4 (**d**), 5 (**e**), 8 (**h**), 9 (**i**)), and sodium were conducted. Workups gave the new monoethers $3-NC_5H_4(CH_2O(CH_2)_nCH=CH_2)$ ($2\mathbf{a}-\mathbf{e},\mathbf{h},\mathbf{i}$) as yellow-brown oils in 98-42% yields.

Disubstituted pyridines were sought next. As shown in Scheme 5, commercial 2,6-bis(bromomethyl)pyridine, 2,6- $NC_5H_3(CH_2Br)_2$, was combined with 2.5 equiv of the Grignard reagent $H_2C=CHCH_2MgBr$ in THF. A chromatographic workup gave the doubly butenylated pyridine 2,6- $NC_5H_3(CH_2CH_2CH=CH_2)_2$ (3) as a yellow oil in 60% yield. This compound was previously prepared by a similar route by Lambert, but no synthetic details or characterization were given.¹³

Ether-containing analogues were desired. Accordingly, 2, $6\text{-NC}_{5}\text{H}_{3}(\text{CH}_{2}\text{Br})_{2}$ and the alcohols $\text{HO}(\text{CH}_{2})_{n}\text{CH}=\text{CH}_{2}$ (**a**-**d**) were refluxed in the presence of the quaternary ammonium salt $C_{6}\text{H}_{5}\text{CH}_{2}\text{N}(\text{CH}_{3})_{3}^{+}\text{Cl}^{-}$ (20 mol %), as shown in Scheme 6. A related procedure has been previously applied to benzyl halides.¹⁷ Workups gave the dialkenylated diethers 2, $6\text{-NC}_{5}\text{H}_{3}(\text{CH}_{2}\text{O}(\text{CH}_{2})_{n}\text{CH}=\text{CH}_{2})_{2}$ (**4a**-**d**) as light yellow

Scheme 4. Syntheses of Complexes with 3-Substituted Trans-Spanning Bis(pyridine) Ligands



Scheme 5. Additional Chemistry Relating to Scheme 2



oils in 55–45% yields. Compounds **4a,d** had been previously prepared by other Williamson ether syntheses.^{18,19}

Next, 3,5-disubstituted systems were sought. Pyridine-3, 5-dicarboxylic acid, $3,5-NC_5H_3(COOH)_2$, was seen as an

inexpensive building block, and the bis(acid chloride) 3,5-NC₅H₃(COCl)₂ was prepared in quantitative yield as previously described.²⁰ As shown in Scheme 7, this material was combined with a slight excess of HO(CH₂)_nCH=CH₂ (**a**-**f**,**h**) in dry CH₂Cl₂. After basic workups, the dialkenylated diesters 3,5-NC₅H₃(COO(CH₂)_nCH=CH₂)₂ (**5a**-**f**,**h**) were isolated as viscous yellow oils in 90–41% yields. Compounds **5d**,**h** have been previously synthesized by similar routes.^{19,21}

Given certain results below, expanded 3,5-disubstituted pyridine frameworks were also desired. Two known reactions were conducted first. As shown in Scheme 8, the cross coupling of 3,5-dichloropyridine and (4-methoxyphenyl)magnesium bromide, 4-CH₃OC₆H₄MgBr, using the nickel catalyst (dppp)-NiCl₂ (dppp = Ph₂P(CH₂)₃PPh₂), afforded 3,5-bis(4methoxyphenyl)pyridine (6) or 3,5-NC₅H₃(4-C₆H₄OCH₃)₂ in 73% yield.²² Subsequent reaction with BBr₃ gave the bis-(phenol) 3,5-NC₅H₃(4-C₆H₄OH)₂ (7)²³ in 66% yield. Treatment with Br(CH₂)₅CH=CH₂ and Cs₂CO₃ base (DMF, 100 °C) afforded the new dialkenylated diether 3,5-NC₅H₃(4-C₆H₄O(CH₂)₅CH=CH₂)₂ (8) as a white powder in 32% yield.

2. Syntheses of *trans*-Bis(pyridine) Complexes. 2.1. Singly Bridged Complexes. As shown in Scheme 3, reactions of 1a,b with $PtCl_2$ in refluxing benzene afforded the corresponding *trans*-dichloroplatinum bis(pyridine) complexes *trans*-10a,b as light yellow solids in 40–12% yields after workup. These and all other new complexes below were characterized by NMR and IR and (in most cases) microanalyses, as summarized in the Experimental Section. In particular, the sp^{2 1}H and ¹³C NMR signals of the free and coordinated pyridines could be assigned on the basis of well-established chemical shift trends.^{24,25} Coordination shifts have been tabulated elsewhere.^{14a} Some DSC/TGA and mass spectral data are also reported.

Interestingly, CDCl_3 solutions of *trans*-10a exhibited two NCCH_2O ¹H NMR signals (singlets, 1:1 ratio) at room temperature. These were presumed to arise from atropisomers (rotamers) with syn/anti dispositions of the two 2-pyridyl substituents, as shown in Scheme 9 (VIII, VIII). The 2-methylpyridine analogue of *trans*-10a gives a 65:35 mixture of atropisomers, and similar phenomena have been found for closely related complexes.²⁴ The two signals coalesced between 35 and 40 °C. The coalescence temperature (T_c) was extrapolated as 311 K, giving a $\Delta G^{\ddagger}(T_c)$ value of 16.6 kcal/mol.

Next, CH_2Cl_2 solutions of *trans*-10a,b (0.0019–0.0021 M) and Grubbs' catalyst (4 and 8 mol %) were refluxed for 18–42 h as described in the Experimental Section. The crude metathesis products were treated with H_2 (balloon pressure) in the presence of Pd/C (5 mol %). Chromatography gave *trans*-11a,b as light yellow and off-white solids in 79–63% overall yields. These feature 8- and 10-atom linkers connecting the pyridine ligands, or 13- and 15-membered macrocycles. Single crystals of *trans*-11b were obtained as described in the Experimental Section. A crystal structure, described in the following section, confirmed the formulation.

Attention was turned to the analogous 3-substituted pyridines in Scheme 4. Under conditions comparable to those in Scheme 3, the corresponding platinum complexes *trans*-12a-e,h,i were obtained in higher yields (80-46%) as yellow solids. On the basis of additional data below, this was attributed to the absence of a 2-substituent, diminishing steric hindrance. In two cases (12b,h), comparable amounts of cis isomers formed, but these more polar adducts were readily separated by silica gel chromatography.

Scheme 6. Syntheses of Complexes with 2,6-Disubstituted Doubly Trans-Spanning Bis(pyridine) Ligands



Scheme 7. Syntheses of Complexes with 3,5-Disubstituted Doubly Trans-Spanning Bis(pyridine) Ligands



Similar reactions of Grubbs' catalyst with *trans*-12d,h,i and subsequent hydrogenations gave the ring-closing metathesis products *trans*-13d,h,i as light yellow to off-white solids in 93– 80% overall yields. These feature 14-, 22-, and 24-atom linkers connecting the pyridine ligands, or 21-, 29-, and 31-membered macrocycles. The attempted metathesis of *trans*-12c, which would have given a 19-membered macrocycle, did not give any products that could be chromatographed, implicating polymer formation. Single crystals of *trans*-13d and the solvate *trans*-13h·CH₂Cl₂ were obtained as described in the Experimental Section. The crystal structures, described in the following section, confirmed the formulations. 2.2. Doubly Bridged Complexes. An initial objective was to round out and extend the fragmentary data of Lambert (Scheme 2). As shown in Scheme 5, the reaction of *trans*-(PhCN)₂PdCl₂ and 3 (2.3 equiv) afforded the dichloropalladium bis(pyridine) complex *trans*-14 (VI) in 15% yield following chromatography. A CH₂Cl₂ solution of *trans*-14 (0.0301 M) was treated with Grubbs' catalyst (15 mol % added in three equal charges over 24 h). Chromatography gave the metathesis product *trans*-15 (VII) in 58% yield. Lambert obtained an 80% yield and assigned a Z C==C stereochemistry on the basis of the incompletely reported crystal structure mentioned above.¹³

In a new reaction, this material was hydrogenated (balloon pressure, PtO_2 catalyst). Chromatography afforded the saturated analogue *trans*-16 as a light yellow solid in 62% yield. Single crystals were obtained as described in the Experimental Section, and the crystal structure is detailed below. Complex *trans*-16 features 6-atom linkers connecting the pyridine ligands, making for an 11-membered cycle—the smallest ring system in this study.

Analogous sequences were attempted with the 2,6-disubstituted ether containing pyridines, as summarized in Scheme 6. Reactions with $PtCl_2$ with **4a,b** gave the dichloroplatinum bis(pyridine) complexes *trans*-**17a,b** as yellow solids in 88–26% yields after chromatography. The lower yield with **4b** appeared to relate to the size of the 2,6-substituents; the ligands **4c,d** did not give detectable amounts of complexes under comparable conditions, and the yield of *trans*-**14** was also modest. The crystal structure of *trans*-**17a**, which is detailed in the following section, shows that both pyridine ligands are roughly coplanar and orthogonal to the Cl–Pt–Cl vector.

Ring-closing metatheses of *trans*-17a,b were carried out under more dilute conditions (0.001 99–0.002 01 M) with 10 mol % of Grubbs' catalyst. Reactions were monitored by ¹H NMR to ensure that all of the vinyl groups were consumed. However, following hydrogenations and chromatography, the cyclized products *trans*-18a,b were obtained as white or offwhite solids in only 22–10% yields. When the synthesis of Scheme 8. Synthesis of a Complex with an Expanded 3,5-Disubstituted Doubly Trans Spanning Bis(pyridine) Ligand



Scheme 9. Atropisomeric Equilibrium (Top) and Exchange of Diastereotopic Groups via MLL' Rotation (Bottom)



trans-18a was repeated with Grubbs' second-generation catalyst, an 8% yield was obtained. Complexes *trans*-18a,b feature 8- and 10-atom linkers connecting the pyridine ligands, or 13- and 15-membered macrocycles. The crystal structures of both adducts could be determined, as described below.

As shown in Scheme 7, reactions of $PtCl_2$ with the 3,5disubstituted ester containing pyridines 5a,c-f,h gave dichloroplatinum bis(pyridine) complexes *trans*-19a,c-f,h as yellow solids in 94–63% yields after chromatography. These yields are much higher than those for most of the 2,6-disubstituted adducts in the preceding section.

Ring-closing metatheses of *trans*-19d-f,h were carried out under dilute conditions (0.002 00-0.002 02 M) comparable to those used for *trans*-17a,b. Hydrogenations afforded the target

molecules *trans*-**20d**-**f**,**h** as light yellow solids in 45–14% overall yields following chromatography. When the synthesis of *trans*-**20d** was repeated with Grubbs' second-generation catalyst, a 12% yield was obtained. This series of complexes features 14-, 16-, 18-, and 22-atom tethers connecting the two pyridine rings. This corresponds to 21-, 23-, 25-, and 29-membered macrocycles. Single crystals of a solvate of the 23-membered macrocycle *trans*-**20e** were obtained, and the crystal structure is described in the following section.

Finally, $PtCl_2$ and the expanded 3,5-disubstituted pyridine framework **8** were similarly reacted as shown in Scheme 8. Workup gave the dichloroplatinum bis(pyridine) complex **22** as a light yellow solid in 96% yield. Ring-closing metathesis and hydrogenation as above gave **23** as a yellow solid in 40% yield after chromatography. This complex features a 14-atom tether connecting the 3,5-diarylpyridine moieties, making for two 29membered macrocycles.

3. Crystal Structures. Bond lengths and angles around platinum or palladium for the seven crystal structures mentioned above are summarized in Table 1. Additional tables of crystallographic data are presented in the Supporting Information. All bond angles are quite similar, and indicate nearly idealized square-planar coordination geometries. The bond lengths are very close to those found earlier for *trans*-PtCl₂ adducts of pyridine, 3-methylpyridine, 4-methylpyridine, and 2,6-bis(hydroxymethyl)pyridine^{24a,26} and are not analyzed further.

Figure 1 illustrates two views of the molecular structure of the unbridged complex *trans*-17a. There is a 2-fold symmetry axis that contains the N–Pt–N vector and an orthogonal mirror plane containing the Cl–Pt–Cl vector. One methylene carbon atom (C3) was disordered, but this could not be resolved.

Table	1. K	ey I	Bond	Lengths	(A)	and	Angles	(deg)	in	Crystal	lograph	icall	уC	haracterized	Comp	lexes"
-------	------	------	------	---------	-----	-----	--------	-------	----	---------	---------	-------	----	--------------	------	--------

	trans-17a	trans-11b	$trans-13d^b$	$\textit{trans-13h}{\cdot}\text{CH}_2\text{Cl}_2$	trans-16	trans-18a	trans-18b	trans-20e·2CHCl ₃
				Bond Lengths				
M-Cl1	2.2926(14)	2.3204(9)	2.299(2)	2.2968(16)	2.3126(4)	2.3048(8)	2.3060(7)	2.2824(17)
			2.3082(19)					
M-Cl2	2.2926(14)	2.3091(9)	2.293(2)	2.2985(16)	2.3126(4)	2.3048(8)	2.3060(7)	2.2919(16)
			2.288(2)					
M-N1	2.033(5)	2.028(2)	2.026(5)	1.998(5)	2.0637(12)	2.050(3)	2.048(2)	2.004(4)
			2.027(6)					
M-N2	2.033(5)	2.021(2)	2.018(5)	2.002(5)	2.0637(12)	2.050(3)	2.048(2)	2.011(4)
			2.019(6)					
			Bo	nd and Other Angles				
N1-M-N2	180.0	178.4(8)	177.9(2)	178.22(18)	180.0	180.0	180.000(1)	179.20(16)
			178.4(2)					
Cl1-M-Cl2	180.0	179.17(2)	177.77(7)	178.73(6)	180.000(3)	180.00(3)	180.00(2)	178.71(6)
			177.80(9)					
Cl1-M-N1	90.0	90.49(7)	89.54(18)	90.25(14)	90.84(3)	90.66(8)	90.64(7)	90.00(3)
			89.38(19)					
Cl2-M-N2	90.0	89.81(7)	90.64(18)	89.76(14)	90.84(3))	90.66(8)	90.64(7)	90.78(12)
			90.65(19)					
Cl1-M-N2	90.000(1)	90.15(7)	89.43(18)	89.44(14)	89.16(3)	89.34(8)	89.36(7)	89.35(13)
			89.50(19)					
Cl2-M-N1	90.000(1)	90.4(2)	90.47(18)	90.59(14)	89.16(3)	89.34(8)	89.36(7)	89.85(13)
			90.50(19)					
pyridine/pyridine ^c	0.0	27.9	1.7	12.4	0.0	0.0	0.0	0.1
			6.1					
Cl–M–Cl/pyridine ^d	89.2	86.7	52.8	54.9	76.4	79.1	79.2	63.3
			50.3					

 ${}^{a}M = Pt$ except for *trans*-16 (Pd). ${}^{b}The$ doubled values are for two independent molecules in the unit cell. ${}^{c}The$ angle defined by the planes of the two pyridine ligands. ${}^{d}Angle$ defined by the Cl–M–Cl vector and the plane or average plane of the two pyridine ligands.



Figure 1. Thermal ellipsoid plots (50% probability level) of *trans*-17a: (top) view along the Cl-Pt-Cl axis; (bottom) view along the N-Pt-N axis.

Importantly, the pyridine rings are coplanar and essentially orthogonal to the Cl-Pt-Cl vector (89.2°; see Table 1), as

proposed for the atropisomers in Scheme 9 (top). This minimizes steric interactions between the chloride ligands and the 2,6-substituents and in turn "preorganizes" the $CH=CH_2$ moieties with respect to intramolecular metathesis.

The crystal structure of the 13-membered macrocycle *trans*-**11b** is depicted in Figure 2. The pyridine rings are no longer coplanar and define an angle of 27.9° . However, the Cl-Pt-Cl vectors remain approximately orthogonal (86.6–86.7°) to the "average" of the two planes (Figure 2, bottom).

The crystal structure of the 21-membered macrocycle *trans*-**13d** revealed two independent molecules in the unit cell. In one, two of the methylene groups in the $O(CH_2)_{10}O$ segment were disordered (80:20 occupancies), and in the other, six ((70-50):(30-50) occupancies). In the former, which is depicted in Figure 3, the $=C-CH_2-O-CH_2$ bonds are nearly perpendicular to the planes of the pyridine rings, as reflected by torsion angles of 84.0–89.2°. In the latter, the same bonds are nearly coplanar with the pyridine rings, with torsion angles of $4.8-6.6^\circ$. The pyridine rings in both molecules are nearly coplanar ($6.1-1.7^\circ$ angles). However, the Cl-Pt-Cl vectors show the greatest deviations from orthogonality in this series of complexes ($52.8-50.3^\circ$), as readily seen in Figure 3 (bottom).

The crystal structure of the 29-membered macrocycle *trans*-**13h**·CH₂Cl₂ is depicted in Figure 4. The pyridine rings are approximately coplanar (middle view), defining a quite small angle (12.4°). However, the Cl–Pt–Cl vector again shows a large deviation from orthogonality (54.9°). Interestingly, the solvate molecule lies within the macrocycle and, as shown in the bottom view, fills a substantial portion of the enclosed space.



Figure 2. Thermal ellipsoid plots (50% probability level) of *trans*-11b: (top) view in the general direction of the Cl-Pt-Cl axis; (bottom) view along the N-Pt-N axis.

The molecular structure of the doubly bridged 11-membered cycle *trans*-16, derived from the hydrogenation of Lambert's *trans*-15 (VII), is depicted in Figure 5. It exhibits an inversion center at palladium, rendering many of the bond lengths and angles in Table 1 identical. The pyridine rings are coplanar, but the Cl-Pd-Cl vector is not orthogonal (76.4°).

The molecular structures of the 13- and 15-membered macrocycles *trans*-**18a**,**b** are illustrated in Figures 6 and 7, respectively. Both exhibit an inversion center at platinum. For the latter, three methylene groups are disordered and refine to a 81:19 occupancy ratio. Only the dominant conformation is depicted. For both molecules, the pyridine rings are coplanar, and the angles with the Cl-Pt-Cl vectors (79.1 and 79.2°) are close to that of *trans*-**16**.

Three methylene groups of the 23-membered macrocycle trans-20e·2CHCl₃ were disordered (65:35 to 73:27 occupancy ratios). The dominant conformation is shown in Figure 8. The



Figure 3. Thermal ellipsoid plots (50% probability level) of *trans*-13d (dominant conformation of one of two independent molecules in the unit cell): (top) view of the coordination plane; (bottom) view along the N–Pt–N axis.

O=C linkages of all four ester groups are anti to the C⁻C⁻N moieties, as reflected by O-C-C-C(N) torsion angles of 176.5–163.4°. Furthermore, all of the O=C-O-CH₂ linkages exhibit Z conformations, as reflected by torsion angles of 4.0–0.1°. The pyridine rings are essentially coplanar (0.1° angle), but the Cl-Pt-Cl vector shows a large deviation from orthogonality (63.3°). In contrast to *trans*-**13h**·CH₂Cl₂, only one chlorine atom of each solvate molecule projects (partially) into the macrocycle cavity.

4. Other Reactions. For reasons amplified in the Discussion, the substitution chemistry of several complexes was briefly explored. In response to some unanticipated results below, the unbridged 3-substituted pyridine complexes *trans***12b,h** were combined with the Grignard reagent CH₃MgBr (2.5–3.0 equiv), as shown in Scheme 10. Chromatography gave the monosubstituted chloroplatinum methyl complexes *trans***24b,h** as white solids in 94–67% yields. Analogous reactions of the monobridged analogues *trans***-13d,h** afforded the chloroplatinum methyl complexes *trans***-25d,h**, albeit in slightly lower yields of 65–41%. The methyl ligands gave characteristic upfield ¹H and ¹³C NMR signals (δ 0.87 to 0.93 and -6.4 to -6.6 ppm).

In contrast, the 2,6-disubstituted pyridine complex *trans*-17a (Scheme 6) was recovered in at least 80% yield when treated with CH₃MgBr, various cyanide ion sources, or phenylace-tylene in the presence of the catalyst CuI and base *i*-Pr₂NH. However, the 3,5-disubstituted pyridine complex *trans*-19c and





Figure 5. Thermal ellipsoid plots (50% probability level) of *trans*-16: (top) view along the Cl-Pd-Cl axis; (bottom) view along the N-Pd-N axis.

As shown in Scheme 11, reaction of the 2,6-disubstituted pyridine **4a** and the rhodium bis(cyclooctene) complex $[RhCl(coe)_2]_2$ under CO afforded the trans rhodium carbonyl chloride bis(pyridine) complex *trans*-**27a** as an orange solid in 26% yield after chromatography. However, in contrast to the platinum analogues in Scheme 6, reactions of 0.017–0.0020 M CH₂Cl₂ solutions with Grubbs' catalyst never gave a detectable quantity of a monorhodium metathesis product, although the starting material was consumed. Unsuccessful attempts to improve the yield of *trans*-**27a**, or prepare analogous adducts of **4b**-**d**, are described elsewhere.^{14a}

Nonetheless, the ¹H NMR spectrum of *trans*-**27a** proved relevant. The two protons on the methylene group between the pyridine ring and ether oxygen atom (NCCH₂O) gave two significantly separated doublets (δ 5.76 and 5.64 ppm; ²J_{HH} = 15 Hz), indicating a diastereotopic relationship. This is highlighted in the partial structure **IX** in Scheme 9 (bottom). Importantly, the diasteretopic protons (H_a/H_b) would be exchanged when the Cl–Rh–CO moiety rotates by 180°.²⁷ Apparently, this is slow on the NMR time scale, even in this unbridged system.

Figure 4. Structural representations of *trans*-13h-CH₂Cl₂: thermal ellipsoid plots (50% probability level) with the solvate molecule omitted in the general direction of the Cl–Pt–Cl axis (top) and along the N–Pt–N axis (middle); space-filling model (bottom).

phenylacetylene reacted in the presence of CuI and *i*- Pr_2NH to give the phenylacetylide complex *trans*-**26c** (Scheme 10, bottom) as a pale yellow solid in 18% yield after chromatography.



Figure 6. Thermal ellipsoid plots (50% probability level) of *trans*-18a: (top) view along the Cl–Pt–Cl axis; (bottom) view along the N–Pt–N axis.

DISCUSSION

1. Scope of Syntheses. Schemes 3–8 establish that a variety of platinum and palladium complexes with macrocyclic singly and doubly trans-spanning bis(pyridine) ligands can be accessed by ring-closing alkene metatheses of precursors with appropriately functionalized trans pyridine ligands. Although the one rhodium species studied, *trans*-27a (Scheme 11), could not be similarly cyclized, phosphine analogues have been successfully converted to gyroscope-like complexes of the type IV in Scheme 1.^{6,7} Note that the platinum analogue of *trans*-27a, *trans*-17a, gives the lowest yield of all the bis-macrocyclizations reported (10%; Scheme 6). Hence, we believe that rhodium adducts of other disubstituted pyridine ligands employed above would give reasonable yields of doubly transspanning bis(pyridine) complexes.

In relevant earlier work, van Koten, Kang, and Ko have studied metatheses of platinum pincer complexes of dialkenylated pyridines.^{28,29} Three of many examples are collected in Scheme 12. The first two involve *intra*ligand metatheses of 3,5and 2,6-disubstituted systems (eqs i and ii). The third example features a 3-fold *inter*ligand metathesis to a metacyclophane-like macrocycle.

Equation i of Scheme 12 features the same ligand as in *trans*-**19d** (Scheme 7), but we observed only *inter*ligand metathesis to *trans*-**20d** (one chromatographically mobile product). Importantly, no special attempt has been made to establish thermodynamic control in any of our reactions, although this has been unambiguously reached in certain cases.³⁰ Furthermore, Fogg



Figure 7. Thermal ellipsoid plots (50% probability level) of *trans*-18b: (top) view along the Cl-Pt-Cl axis; (bottom) view along the N-Pt-N axis. The three disordered atoms are depicted in their dominant conformations.



Figure 8. Thermal ellipsoid plots (50% probability level) of *trans*-20e-2CHCl₃ with the solvate molecules omitted: (top) view along the Cl-Pt-Cl axis; (bottom) view along the N-Pt-N axis. The disordered atoms are depicted in their dominant conformations.

Scheme 10. Substitution Reactions



Scheme 11. Synthesis of a Rhodium 2,6-Disubstituted Bis(pyridine) Complex



has emphasized that oligomers sometimes dominate kinetically in ring-closing metatheses but can convert to monocyclic products given sufficient time, catalyst, and ethylene coproduct.³¹ Thus, there remains much potential for optimization in the preceding chemistry.

The preparative data in Schemes 3-8 and 10 suggest a myriad of steric effects. For example, the yields of the 3-substituted pyridine complexes in Scheme 4 are higher than those of the 2-substituted homologues in Scheme 3. Similarly, the yields of the 2,6-disubstituted pyridine complexes in Schemes 5 and 6 are generally lower than those of the related 3,5-disubstituted pyridine complexes in Schemes 7 and 8. All attempts to effect substitution of the chloride ligands in

2,6-disubstituted pyridine complexes were unsuccessful, in contrast to the examples involving 3-substituted or 3,5-disubstituted pyridine complexes in Scheme 10.

The congestion inherent in the 2,6-disubstituted pyridine complexes is readily seen in the fragment IX in Figure 9, which is taken from the crystal structure of the unbridged adduct *trans*-17a, including the coplanar pyridine rings (Figure 1). Projection IXa highlights the distance between the carbon atoms bound to the 2,6-positions on opposite pyridine ligands, ca. 3.83 Å. This is somewhat greater than twice the van der Waals radius of an sp³ carbon atom (1.70 Å),³² as illustrated by projection IXc, a perpendicular view with the carbon and chlorine atoms shown at van der Waals radii. The difference,

(i) (ii) 1) Grubbs' catalyst 1) Grubbs' catalyst 2) NaCl 2) NaCl RF. BF₄ >99% 50% 3+ 3+ 3BF₄[−] 3BF₄⁻ NMe₂ -NMe₂ Me₂N Me₂N Me Me Grubbs' catalyst Мe, le₂ (iii)

Scheme 12. Other Alkene Metatheses Involving Pyridine Ligands in Metal Coordination Spheres



Figure 9. Steric relationships between the carbon atoms bound to the 2,6-pyridine positions and the chlorine atoms in *trans*-17a.

0.43 Å, can be viewed as a "top-bottom clearance". As summarized in Table 2, comparable values are found for the other 2,6-disubstituted complexes, all of which have coplanar pyridine rings (0.45-0.63 Å; trans-16, trans-18a,b). The somewhat

Table 2. Distances (Å) Relevant to Rotator Rotation in Crystalline Complexes

complex	MCl ₂ radius	bridge height ^a	top–bottom clearance ^b	closest intermolecular contact
trans-17	4.04		0.43 ^c	3.38
trans-11	4.06	3.40	0.87 ^c	2.62
$trans-13d^d$	4.05	5.37	1.90 ^e	2.51
	4.06	5.00	1.91 ^e	
$trans-13h \cdot CH_2Cl_2$	4.05	7.58	1.92^{e}	1.87
trans-16	4.06 ^{<i>f</i>}	2.58	0.58 ^c	3.59
trans-18a	4.06	2.49	0.63 ^c	3.13
trans-18b	4.06	4.38	0.45 ^c	2.89
trans-20e·2CHCl ₃	4.04	7.66	1.93 ^e	3.21

^aSee Figure 10. ^bSee Figure 9. ^c2- or 2,6-substitution. ^dThe two sets of values correspond to the two independent molecules in the unit cell. ^e3- or 3,5-substitution. ^fPdCl₂ radius; other values are PtCl₂ radii.

greater clearance for the 2-monosubstituted complex *trans*-11b (0.87 Å) arises from the noncoplanarity or skewing of the pyridine rings (Table 1).

2. Feasibility of MCl₂ Rotation. The long-term goal of this project is to synthesize molecular rotors¹² in which a transition-metal-based rotator can turn within a macrocyclic cage (stator) with as low an energy barrier as possible. In this context, a key issue is the interior space available within the macrocycles vis-à-vis the sizes of the ligands on the metal. Analyses of the type in Figure 10 have proven to be particularly helpful



Figure 10. Estimation of "horizontal clearance" or "bridge height" in Table 2, illustrated for *trans*-18b.

in correlating properties of the bis(phosphine) systems in Scheme 1. First, the radius of the MCl_2 moiety is calculated by adding the crystallographically determined metal-chlorine bond distance (Table 1) and the van der Waals radius of



Figure 11. Space-filling representations of the molecular structures of trans-18a, trans-18b, and trans-20e.

chlorine (1.75 Å).³² As summarized in Table 2, essentially the same value is obtained for all the platinum and palladium complexes (average 4.05 Å).

The distances between the metal atom and the remote carbon atoms of each macrocycle chain are then calculated, utilizing the two carbon atoms closest to the plane that would be defined by MCl₂ rotation. As shown in Figure 10, these vary, and the shortest distance among the four possibilities is taken. The van der Waals radius of carbon is then subtracted, giving a "horizontal clearance" or "bridge height". The resulting distances are summarized in Table 2. However, it should be kept in mind that an equilibrium ensemble of macrocycle conformations would be expected in solution, and any impression of a rigid steric barrier is unintended.

In any case, the PtCl₂ radii in *trans*-13d, *trans*-13h·CH₂Cl₂, *trans*-18b, and *trans*-20e·2CHCl₃ are less than the respective bridge heights (Table 2), fulfilling one steric condition for PtCl₂ rotation. These complexes represent the largest macrocycle based upon a 2,6-disubstituted pyridine (*trans*-18b, 15-membered), and all of the macrocycles based upon 3-substituted (*trans*-13d, *trans*-13h·CH₂Cl₂, 21- and 29-membered) and 3,5-disubstituted pyridines (*trans*-20e·2CHCl₃, 23-membered). However, in the 2,6-disubstituted complex *trans*-18b, the top-bottom clearance is much less than the van der Waals *diameter* of a chlorine atom (0.45 Å vs 3.50 Å). This is depicted in projection IXc in Figure 9 and would render rotation a very high energy process.

For the 3-substituted and 3,5-disubstituted complexes, the top-bottom clearance can be estimated as follows. First, the shortest distance between the 2,2'- or 6,6'-carbon atoms is identified. In the case of reference molecule *trans*-17a, this is 5.44 Å (Figure 9, IXa). Next, two times the van der Waals radius of carbon is subtracted. As summarized in Table 2, this gives distances in the range of 1.90–1.98 Å. In the absence of any skewing of the pyridine rings, this would have to accommodate the full diameter of a chlorine atom: ca. 3.50 Å. Obviously, this steric requirement is poorly fulfilled, and none of the compounds in this first-generation synthetic study provide an experimental test of MCl₂ rotation. Per the analysis in Scheme 9 (bottom), the ¹H NMR properties of rhodium carbonyl chloride analogues of any of these complexes would be diagnostic of Cl–Rh–CO rotation.

Furthermore, note that the hydrogen atoms in the 2,2'- or 6,6'-positions have not been taken into account—as was also the case for complexes with 2,6-substituents (Figure 9). Hydrogen atoms have also been omitted in all space-filling representations in this paper. There are many conformational

processes that readily occur in organic molecules despite van der Waals interactions involving hydrogen atoms and/or not being able to execute them with space-filling models. Hence, only non-hydrogen atoms have been considered in this admittedly qualitative analysis.

Figure 11 provides side-by-side comparisons that illustrate the preceding concepts. In 2,6-disubstituted *trans*-18a, the bridge height is smaller than the $PtCl_2$ radius, and the topbottom clearance is much smaller than the diameter of chlorine. In *trans*-18b, the latter still holds, but the bridge height is larger than the $PtCl_2$ radius. With 3,5-disubstituted *trans*-20e, the bridge height is much larger than the $PtCl_2$ radius, and the top-bottom clearance is the maximum possible for this series of compounds. Complexes *trans*-20h and *trans*-23 (Schemes 7 and 8), in which the macrocycles are even larger (29 vs the 23 atoms in *trans*-20e), would make a still more spacious visual impression.

In any case, the top-bottom clearance in *trans*-20e is admittedly snug with respect to a chlorine ligand, especially in view of the hydrogen atoms that have been neglected. However, this can to some extent be ameliorated if the pyridine ligands skew away from coplanarity, as reflected by the trend with *trans*-11b in Table 2. In effect, this would replace an energy maximum with two closely spaced but lower energy maxima. Interactions might also be attenuated by employing second- or third-row donor atoms, which would feature longer metal-heteroatom bonds.

Apart from these intramolecular issues, another question is whether any of the MCl₂ moieties would be able to undergo rotation in the crystal lattice. It is a simple matter to calculate the distance between the metal and the closest atom in a neighboring molecule, and these are summarized in Table 2. In every case, the closest contact is less than the MCl₂ radius. Hence, the rotational barriers should be extremely high, even in the absence of intramolecular contacts. In principle, the onset of any rotation in the solid state could be evidenced by a phase transition. Out of all the macrocyclic complexes for which DSC data were recorded (*trans*-18b, *trans*-20d,e,f,h), only one showed an endotherm considerably below the melting or decomposition point (*trans*-20e).

We note in passing that, for doubly bridged *trans*-18b and *trans*-20e·2CHCl₃, all molecules exhibit parallel Cl-M-Cl axes in the crystal lattice. In contrast, *trans*-16 and *trans*-18a show two sets of molecules with parallel axes. These axes define angles of 44 and 82° , respectively, as calculated from six atom planes generated from two parallel Cl-M-Cl segments. Representative packing diagrams are given elsewhere.¹⁴

Trigonal-bipyramidal systems such as III (Scheme 1) commonly pack in layers with all P-M-P axes parallel,⁴ but other coordination geometries do not appear to exhibit strong preferences.

3. Toward Molecular Gyroscopes. The singly bridged bis (pyridine) complexes belong to a class of compounds that have been referred to as rope-skipping rotors,¹² and the doubly bridged bis(pyridine) complexes belong to a class of compounds that have been termed molecular turnstiles.³⁴ The former are in principle quite numerous, whereas the latter are less common if required to closely approximate "revolving door" symmetry. The prototype would be Moore's system **X** in Figure 12, but the descriptor has also been applied to molecules in the rope-skipping category³⁵ and other assemblies.³⁶



Figure 12. Other relevant molecular rotors.

Regardless of the MCl₂ rotational barriers associated with our complexes, the MCl₂ moieties of individual molecules would exhibit both clockwise and counterclockwise motion. However, in order to attain functional gyroscopic properties, unidirectional rotation is required. One strategy for controlling the direction of a rotator involves introducing a dipole moment, such that it can be oriented by a static applied electric field or driven by a rotating electric field.^{12,33} Both substitution reactions of the types in Scheme 10, and ring-closing metatheses of less symmetrical substrates—such as rhodium carbonyl chloride analogues of the preceding platinum dichloride complexes—should provide practical routes to such species, especially now that certain limitations of these processes have been defined.

Macroscopic gyroscopes are almost always found within housings to shield the moving parts. The rotators in our doubly bridged bis(pyridine) adducts are somewhat more exposed than those in the diphosphine systems in Scheme 1. However, this renders them superior for other purposes such as gearing, i.e. the coupling of rotation between rotors in ordered arrays. In summary, this study has established much valuable baseline data pertaining to the synthesis of molecular rotors based upon bridged trans bis(pyridine) complexes. Key structural, steric, and conformational properties have also been elucidated. Additional studies, including full papers detailing the types of complexes in Scheme 1, will be reported shortly.

EXPERIMENTAL SECTION

General Considerations. All reactions were carried out under inert atmospheres using standard Schlenk and vacuum line techniques. Workups were conducted in air. Reaction solvents were dried and deoxygenated by standard protocols detailed elsewhere.¹⁴ Workup solvents were purified by simple distillation or used as received. Silica (Acros, 60 A) and alumina (neutral, Macherey-Nagel) were used as received.

The CDCl₃ was stored over molecular sieves (Deutero GmbH) or used as received (Cambridge Isotope Laboratories). Other chemicals were used as received: DMSO- d_6 (Aldrich), sodium (J. T. Baker, ACS reagent), allyl alcohol (Alfa Aesar, 98%), 3-buten-1-ol (TCI or Acros Organics, 96-95%), 4-penten-1-ol (TCI or Acros Organics, 98-97%), 5-hexen-1-ol (TCI, 95%), 6-hepten-1-ol (TCI, 95%), 7-octen-1-ol (TCI, >96%), 9-decen-1-ol (TCI or Aldrich, 97%-95%), 10-undecen-1-ol (TCI, 95%), 3-(chloromethyl)pyridine hydrochloride (Alfa Aesar, 97%), 2-(chloromethyl)pyridine hydrochloride (TCI, 98%), $C_6H_5CH_2N(CH_3)_3^+Cl^-$ (Aldrich, 97%), 2,6-bis(bromomethyl)-pyridine (Aldrich, 98%), PtCl₂ (ABCR, 99.9%), *trans*-(PhCN)₂PtCl₂ (Alfa Aesar, 98%), trans-(PhCN)₂PdCl₂ (Acros, 99%), [RhCl(coe)₂]₂ (Acros, 97%), Grubbs' catalyst (Ru(=CHPh)(PCy₃)₂(Cl)₂; Aldrich), CuI (Acros, 99.9%), *i*-Pr₂NH (Fluka, 99%), PhC≡CH (Acros, 98%), PtO2 (Aldrich), Pd/C (Lancaster or Acros, 10%), pyridine-3,5dicarboxylic acid (Aldrich), 3,5-dichloropyridine (TCI or Aldrich, 98%), 4-bromoanisole (Alfa Aesar, 99%), BBr₃ (Aldrich, 1.0 M in CH₂Cl₂), Cs₂CO₃ (Alfa Aesar, 99.9%), 7-bromo-1-heptene (Aldrich, 97%), CH₃MgBr (Acros, 3.0 M in diethyl ether; titration vs I₂ gave 2.94 M),³⁷ H₂C=CHCH₂MgBr (Fluka, 1.0 M in diethyl ether), magnesium (Alfa Aesar, 99.8%), NH4Cl (Mallinckrodt, 99.5%), and (dppp)NiCl₂ (Strem, 99%). The bis(acid chloride) 3,5-NC₅H₃- $(COCl)_2^{38}$ and Grubbs' second-generation catalyst Ru(=CHPh)- $(H_2 IMes)(PCy_3)(Cl)_2^{39}$ were synthesized by literature procedures.

NMR spectra were recorded on 500–300 MHz spectrometers and referenced as follows: ¹H, residual internal CHCl₃ (δ , 7.26 ppm) or DMSO- d_5 (δ , 2.50 ppm); ¹³C, internal CDCl₃ (δ , 77.23 ppm). The ¹H and ¹³C NMR signals of the free and coordinated nitrogen donor ligands were assigned on the basis of literature generalizations.^{24,25} IR spectra were recorded using ATR accessories. DSC data were treated by standard methods.⁴⁰ Instrument models are detailed elsewhere.¹⁴

2-NC5H4(CH2OCH2CH=CH2) (1a). A Schlenk flask was charged with sodium (0.8942 g, 36.94 mmol) and allyl alcohol (15.6510 g, 269.47 mmol). The mixture was stirred at 80 °C (oil bath) until the sodium was consumed and cooled to room temperature. Then 2-(chloromethyl)pyridine hydrochloride (2.4870 g, 15.161 mmol) was added and the mixture kept at 80 °C for 16 h. The excess alcohol was removed by oil pump vacuum at 80 °C. Water and CH₂Cl₂ were added to the residue. The phases were separated and the aqueous phase extracted with CH_2Cl_2 (2 × 50 mL). The combined CH_2Cl_2 layers were dried (MgSO₄). The solvent was removed by oil pump vacuum. The residue was eluted through a silica column $(8 \times 1.5 \text{ cm})$ with ethyl acetate (300 mL). The solvent was removed from the product fraction by oil pump vacuum to give spectroscopically pure 1a as a brown oil (1.3682 g, 9.1776 mmol, 61%). NMR (δ, CDCl₃): ¹H 8.54 (m, 1H, o-HC_{6pyr}), 7.68 (m, 1H, p-HC_{4pyr}), 7.45 (m, 1H, m-HC_{3pyr}), 7.17 (m, 1H, *m*-HC_{5pyr}), 6.01–5.92 (ddt, 1H, ³ $_{J_{\text{HH}\text{trans}}} = 17.3$ Hz, ${}^{3}J_{\text{HHcis}} = 10.3 \text{ Hz}, {}^{3}J_{\text{HH}} = 5.5 \text{ Hz}, \text{CH}=), 5.35-5.19 \text{ (m, 2H, }=\text{CH}_2\text{)},$ 4.64 (s, 2H, CH₂O), 4.11 (m, 2H, OCH₂CH); ¹³C{¹H} 158.7 (s, o- C_{2pyr}), 149.2 (s, o- C_{6pyr}), 136.8 (s, CH=), 134.6 (s, p- C_{4pyr}), 122.5 (s, m- C_{3pyr}), 121.5 (s, m- C_{5pyr}), 117.5 (s, =CH₂), 73.1 (s, CH₂O), 72.0 (s, OCH₂CH). These data agreed with those previously reported for an alternative synthesis.¹⁵ IR (cm⁻¹, neat oil): 3076 (w), 2859 (w), 1717 (m), 1591 (m), 1306 (m), 1244 (m), 1107 (s), 1084 (s), 993 (s), 926 (s), 758 (s).

2-NC₅H₄(CH₂O(CH₂)₂CH=CH₂) (1b). 3-Buten-1-ol (14.0023 g, 194.19 mmol), sodium (0.6338 g, 27.57 mmol), and 2-(chloromethyl)pyridine hydrochloride (1.9507 g, 11.892 mmol) were combined in a procedure similar to that for 1a (12 h reaction time at 80 °C). An analogous workup gave 1b as a yellow oil (1.8179 g, 11.138 mmol, 59%). NMR (δ , CDCl₃): ¹H 8.53 (m, 1H, *o*-HC_{6pyr}), 7.68 (m, 1H, *p*-HC_{4pyr}), 7.44 (m, 1H, *m*-HC_{3pyr}), 7.17 (m, 1H, *m*-HC_{5pyr}), 5.90–5.81 (ddt, 1H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHcis} = 10.1 Hz, ³J_{HH} = 6.9 Hz, CH=), 5.14–5.03 (m, 2H, =CH₂), 4.64 (s, 2H, CH₂O), 3.62 (t, 2H, ³J_{HH} = 6.9 Hz, OCH₂CH₂), 2.41 (m, 2H, OCH₂CH₂); ¹³C{¹H} 158.9 (s, *o*-C_{2pyr}), 149.2 (s, *o*-C_{6pyr}), 136.9 (s, CH=), 135.3 (s, *p*-C_{4pyr}), 122.5 (s, *m*-C_{3pyr}), 121.5 (s, *m*-C_{5pyr}),

116.7 (s, =CH₂), 73.9 (s, CH₂O), 70.6 (s, OCH₂CH₂), 34.4 (s, CH₂CH=). These data agreed with those previously reported for an alternative synthesis.¹⁶ IR (cm⁻¹, neat oil): 2907 (w), 2859 (m), 1717 (m), 1591 (m), 1435 (s), 1121 (s), 1088 (s), 993 (s), 914 (s), 756 (s).

3-NC₅**H**₄(**CH**₂**OCH**₂**CH**=**CH**₂) (2a). Allyl alcohol (14.1138 g, 243.01 mmol), sodium (0.9319 g, 40.54 mmol), and 3-(chloromethyl)pyridine hydrochloride (2.2593 g, 13.773 mmol) were combined in a procedure similar to that for **1a** (12 h reaction time at 80 °C). An analogous workup gave **2a** as a yellow-brown oil (1.7175 g, 11.512 mmol, 84%). NMR (δ , CDCl₃): ¹H 8.58 (m, 1H, *o*-HC_{2pyr}), 8.54 (m, 1H, *o*-HC_{6pyr}), 7.69 (m, 1H, *p*-HC_{4pyr}), 7.28 (m, 1H, *m*-HC_{5pyr}), 6.01–5.88 (ddt, 1H, ³*J*_{HHTans} = 17.3 Hz, ³*J*_{HHCis} = 10.4 Hz, ³*J*_{HH} = 5.6 Hz, CH=), 5.32 (dt, 1H, ³*J*_{HH} = 17.3 Hz, ²*J*_{HH} = 1.7 Hz, = CH_EH₂), 5.23 (dt, 1H, ³*J*_{HH} = 10.4 Hz, ²*J*_{HH} = 1.7 Hz = CH_EH₂), 4.53 (s, 2H, CH₂O), 4.05 (dt, 2H, ³*J*_{HH} = 5.6 Hz, ⁴*J*_{HH} = 1.4 Hz, OCH₂CH); ¹³C{¹H} 149.4 and 149.3 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 135.6 (s, CH=), 134.5 (s, *p*-C_{4pyr}), 133.9 (s, *m*-C_{3pyr}), 123.6 (s, *m*-C_{5pyr}), 117.8 (s, =CH₂), 71.8 (s, CH₂O), 69.7 (s, CH₂CH=). IR (cm⁻¹, neat oil): 2857 (w), 1724 (w), 1578 (m), 1425 (m), 1082 (s), 1026 (m), 926 (m), 791 (m), 712 (s).

3-NC₅H₄(CH₂O(CH₂)₂CH=CH₂) (2b). 3-Buten-1-ol (23.1913 g, 321.62 mmol), sodium (1.0569 g, 45.973 mmol), and 3-(chloromethyl)pyridine hydrochloride (2.4873 g, 15.163 mmol) were combined in a procedure similar to that for 1a (12 h reaction time at 80 °C). An analogous workup gave 2b as a yellow-brown oil (2.2722 g, 13.921 mmol, 92%). NMR (δ , CDCl₃): ¹H 8.57 (m, 1H, *o*-HC_{2pyr}), 8.53 (m, 1H, *o*-HC_{6pyr}), 7.67 (m, 1H, *p*-HC_{4pyr}), 7.27 (m, 1H, *m*-HC_{5pyr}), 5.90–5.76 (ddt, 1H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.2 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.14–5.02 (m, 2H, =CH₂), 4.53 (s, 2H, CH₂O), 3.54 (t, 2H, ³J_{HH} = 6.8 Hz, OCH₂CH₂); ¹³C{¹H} 149.34 and 149.28 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 135.5 (s, CH=), 135.2 (s, *p*-C_{4pyr}), 134.0 (s, *m*-C_{3pyr}), 123.6 (s, *m*-C_{5pyr}), 116.8 (s, =CH₂), 70.6 (s, CH₂O), 70.1 (s, OCH₂CH₂), 34.3 (s, CH₂). IR (cm⁻¹, neat oil): 2860 (w), 1722 (s), 1591 (m), 1427 (m), 1283 (s), 1096 (s), 1024 (s), 916 (s), 791 (m), 743 (s), 712 (s).

3-NC₅H₄(CH₂O(CH₂)₃CH=CH₂) (2c). 4-Penten-1-ol (27.3842 g, 39.793 mmol), sodium (1.0307 g, 44.833 mmol), and 2-(chloromethyl)pyridine hydrochloride (2.9548 g, 18.013 mmol) were combined in a procedure similar to that for 1a (12 h for sodium consumption at 80 °C; 12 h reaction time at 100 °C). An analogous workup gave 2c as a yellow oil (2.2281 g, 12.571 mmol, 70%). NMR (δ , CDCl₃): ¹H 8.57 (m, 1H, *o*-HC_{2pyr}), 8.53 (m, 1H, *o*-HC_{6pyr}), 7.68 (m, 1H, *p*-HC_{4pyr}), 7.28 (m, 1H, *m*-HC_{5pyr}), 5.87–5.73 (ddt, 1H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.05–4.93 (m, 2H, =CH₂), 4.51 (s, 2H, CH₂O), 3.50 (t, 2H, ³J_{HH} = 6.5 Hz, OCH₂CH₂), 2.14 (m, 2H, CH₂CH=CH₂), 1.71 (m, 2H, OCH₂CH₂); ¹³C{¹H} 149.2 and 149.1 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 138.3 (s, CH=), 135.6 (s, *p*-C_{4pyr}), 134.2 (s, *m*-C_{3pyr}), 123.6 (s, *m*-C_{5pyr}), 115.1 (s, = CH₂), 70.5 (s, CH₂O), 70.3 (s, OCH₂CH₂), 30.5 (s, CH₂), 29.0 (s, CH₂). IR (cm⁻¹, neat oil): 2938 (m), 2860 (m), 1722 (s), 1427 (m), 1281 (s), 1097 (s), 912 (s), 712 (s).

3-NC₅H₄(CH₂O(CH₂)₄CH=CH₂) (2d). 5-Hexen-1-ol (12.9850 g, 129.64 mmol), sodium (0.7838 g, 34.09 mmol), and 3-(chloromethyl)pyridine hydrochloride (1.9432 g, 11.846 mmol) were combined in a procedure similar to that for 1a (sodium dissolved at 100 °C; 12 h reaction time at 100 °C). An analogous workup gave 2d as a yellow-brown oil (1.0806 g, 5.6496 mmol, 48%). NMR (δ , CDCl₃): ¹H 8.56 (m, 1H, o-HC_{2pyr}), 8.53 (m, 1H, o-HC_{6pyr}), 7.67 (m, 1H, p-HC_{4pyr}), 7.27 (m, 1H, m-HC_{5pyr}), 5.87–5.72 (ddt, 1H, ${}^{3}J_{\text{HHtrans}} = 17.0 \text{ Hz}, {}^{3}J_{\text{HHcis}} = 10.3 \text{ Hz}, {}^{3}J_{\text{HH}} = 6.6 \text{ Hz}, \text{CH}$, 5.04–4.91 (m, 2H, = CH_2), 4.50 (s, 2H, CH_2O), 3.49 (t, 2H, ${}^{3}J_{HH} = 6.5$ Hz, OCH₂CH₂), 2.06 (m, 2H, CH₂CH=CH₂), 1.63 (m, 2H, OCH₂CH₂), 1.46 (m, 2H, OCH₂CH₂CH₂); $^{13}C{^{1}H}$ 152.7 and 152.5 (2 s, $o-C_{2pyr}$ and $o - C_{6pyr}$), 138.8 (s, CH=), 137.4 (s, $p - C_{4pyr}$), 136.8 (s, $m - C_{3pyr}$), 125.1 (s, $m - C_{5pyr}$), 114.9 (s, =CH₂), 71.2 (s, CH₂O), 69.3 (s, OCH₂CH₂), $\overline{33.7}$, 29.2, and 25.6 (3 s, 3CH₂). IR (cm⁻¹, neat oil): 2934 (m), 2859 (m), 1639 (m), 1429 (m), 1097 (s), 1028 (m), 933 (m), 791 (m), 712 (s).

3-NC₅H₄(CH₂O(CH₂)₅CH=CH₂) (2e). 6-Hepten-1-ol (23.7783 g, 208.24 mmol), sodium (0.6665 g, 28.93 mmol), and 2-(chloromethyl)pyridine hydrochloride (1.9377 g, 11.813 mmol) were combined in a procedure similar to that for **1a** (sodium dissolved at 100 °C; 12 h reaction time at 100 °C). An analogous workup gave **2e** as a yellow-brown oil (1.9577 g, 9.5358 mmol, 81%). NMR (δ , CDCl₃): ¹H 8.56 (m, 1H, *o*-HC_{2pyr}), 8.52 (m, 1H, *o*-HC_{6pyr}), 7.68 (m, 1H, *p*-HC_{4pyr}), 7.28 (m, 1H, *m*-HC_{5pyr}), 5.86–5.73 (ddt, 1H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHtis} = 10.3 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.03–4.90 (m, 2H, =CH₂), 4.50 (s, 2H, CH₂O), 3.48 (t, 2H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.04 (m, 2H, CH₂CH=CH₂), 1.62 (m, 2H, OCH₂CH₂), 1.44–1.34 (m, 4H, CH₂); ¹³C{¹H} 149.2 and 149.0 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.1 (s, CH=), 135.6 (s, *p*-C_{4pyr}), 134.3 (s, *m*-C_{3pyr}), 123.6 (s, *m*-C_{5pyr}), 114.6 (s, =CH₂), 71.0 (s, CH₂O), 70.5 (s, OCH₂CH₂), 33.9, 29.7, 28.9, and 25.8 (4 s, 4CH₂). IR (cm⁻¹, neat oil): 2932 (m), 2859 (m), 1722 (s), 1420 (m), 1281 (s), 1113 (s), 1024 (m), 910 (m), 743 (s), 702 (s).

3-NC₅H₄(CH₂O(CH₂)₈CH=CH₂) (2h). 9-Decen-1-ol (16.7254 g, 107.03 mmol), sodium (0.3096 g, 13.47 mmol), and 3-(chloromethyl)pyridine hydrochloride (0.8856 g, 5.399 mmol) were combined in a procedure similar to that for 1a (sodium dissolved at 100 °C; 16 h reaction time at 125 °C). An analogous workup gave 2h as a yellow-brown oil (1.1231 g, 4.5400 mmol, 84%). NMR (δ , CDCl₃): ¹H 8.57 (m, 1H, o-HC_{2pyr}), 8.53 (m, 1H, o-HC_{6pyr}), 7.68 (m, 1H, p-HC_{4pyr}), 7.27 (m, 1H, m-HC_{5pyr}), 5.87–5.73 (ddt, 1H, ³J_{HHtrans} = 17.1 Hz, ${}^{3}J_{HHcis} = 10.3$ Hz, ${}^{3}J_{HH} = 6.6$ Hz, CH=), 5.02–4.89 (m, 2H, = CH_2), 4.51 (s, 2H, CH_2 O), 3.48 (t, 2H, ${}^{3}J_{HH}$ = 6.6 Hz, OCH_2 CH₂), 2.03 (m, 2H, CH₂CH=CH₂), 1.61 (m, 2H, OCH₂CH₂), 1.45-1.27 (m, 10H, CH₂); $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ 149.4 and 149.2 (2 s, o-C_{2pyr} and o-C_{6pyr}), 139.4 (s, CH=), 135.5 (s, p-C_{4pyr}), 134.2 (s, m-C_{3pyr}), 123.6 (s, m- C_{5pyr}), 114.3 (s, =CH₂), 71.1 (s, CH₂O), 70.5 (s, OCH₂CH₂), 34.0, 29.9, 29.6 (2×), 29.3, 29.1, and 26.3 (6 s, 7CH₂). IR (cm⁻¹, neat oil): 2926 (s), 2854 (s), 1724 (s), 1281 (s), 1111 (s), 1024 (m), 908 (s), 743 (s), 710 (s).

3-NC₅H₄(CH₂O(CH₂)₉CH=CH₂) (2i). 10-Undecen-1-ol (23.3818 g, 137.31 mmol), sodium (0.4430 g, 19.27 mmol), and 2-(chloromethyl)pyridine hydrochloride (1.4139 g, 8.6195 mmol) were combined in a procedure similar to that for 1a (sodium dissolved at 100 °C; 16 h reaction time at 125 °C). An analogous workup gave 2i as a yellowbrown oil (1.7982 g, 6.8791 mmol, 80%). NMR (δ , CDCl₃): ¹H 8.57 (m, 1H, *o*-HC_{2pyr}), 8.53 (m, 1H, *o*-HC_{6pyr}), 7.68 (m, 1H, *p*-HC_{4pyr}), 7.28 (m, 1H, *m*-HC_{5pyr}), 5.85–5.76 (ddt, 1H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.01–4.91 (m, 2H, =CH₂), 4.51 (s, 2H, CH₂O), 3.48 (t, 2H, ³J_{HH} = 6.5 Hz, OCH₂CH₂), 2.03 (m, 2H, CH₂CH=CH₂), 1.61 (m, 2H, OCH₂CH₂), 1.40–1.24 (m, 12H, CH₂); ¹³C{¹H} 148.9 and 148.8 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.2 (s, CH=), 135.5 (s, *p*-C_{4pyr}), 134.1 (s, *m*-C_{3pyr}), 123.4 (s, *m*-C_{5pyr}), 114.1 (*s*, =CH₂), 70.9 (s, CH₂O), 70.3 (s, OCH₂CH₂), 33.8, 29.7, 29.4 (2×), 29.4, 29.1 (2×), and 26.1 (6 s, 8CH₂). IR (cm⁻¹, neat oil): 2924 (s), 2853 (s), 1724 (s), 1427 (m), 1281 (s), 1098 (s), 908 (s), 712 (s).

 $2,6\text{-}NC_5H_3(CH_2CH_2CH_2CH_2)_2$ (3).¹³ A round-bottom flask was charged with 2,6-bis(bromomethyl)pyridine (2000 g, 7.549 mmol) and THF (76 mL). The solution was cooled to 0 °C with stirring. After 15 min, H₂C=CHCH₂MgBr (1.0 M in diethyl ether; 19 mL, 19.0 mmol) was added dropwise over 20 min. The cold bath was removed. After 18 h, cold saturated aqueous NH₄Cl (20 mL) was added dropwise over 20 min. The organic layer was collected, washed with water (3 \times 20 mL), and dried (MgSO₄). The solvent was removed by rotary evaporation. The orange residue was chromatographed on a silica column (40 \times 3 cm, 5/1 v/v hexanes/ethyl acetate). The solvents were removed from the product-containing fractions by rotary evaporation and oil pump vacuum to give 3 as a yellow oil (0.847 g, 4.52 mmol, 60%). NMR (δ , CDCl₃): ¹H 7.50 (t, 1H, ${}^{3}J_{HH} = 7.7$ Hz, p-HC_{4pyr}), 6.96 (d, 2H, ${}^{3}J_{HH} = 7.7$ Hz, m-HC_{3,5pyr}), 5.88 (ddt, 2H, ${}^{3}J_{\text{HHtrans}} = 17.0 \text{ Hz}$, ${}^{3}J_{\text{HHc}} = 10.3 \text{ Hz}$, ${}^{3}J_{\text{HH}} = 6.6 \text{ Hz}$, CH=), 5.05 (dd, 2H, ${}^{3}J_{\text{HHtrans}} = 17.1 \text{ Hz}$, ${}^{2}J_{\text{HH}} = 1.9 \text{ Hz}$, =CH_EH_Z), 4.97 (dd, 2H, ${}^{3}J_{HHcis} = 10.2$ Hz, ${}^{2}J_{HH} = 1.3$ Hz, $=CH_{E}H_{Z}$), 2.87 (t, 4H, ${}^{3}J_{HH} = 7.8$ Hz, CH_{2}), 2.49 (q, 4H, ${}^{3}J_{HH} = 7.4$ Hz, CH_{2}); ${}^{13}C{}^{1}H{}$ 160.9 (s, $o-C_{2,6pyr}$), 137.9 (s, CH=), 136.4 (s, $p-C_{4pyr}$), 120.0 (s, $m-C_{3,5pyr}$),

114.9 (s, =CH₂), 37.8 (s, CH₂), 34.0 (s, CH₂). IR (cm⁻¹, oil film): 3076 (w), 2922 (m), 2853 (w), 1640 (m), 1579 (s), 1455 (s), 996 (s), 911 (s), 804 (m), 749 (m). MS:⁴¹ 188 ($[21 + H]^+$, 80%), 133 ($[21 - CH_2CH_2CH=CH_2]^+$, 100%).

2,6-NC₅H₃(CH₂OCH₂CH=CH₂)₂ (4a). A Schlenk flask was charged with 2,6-bis(bromomethyl)pyridine (3.300 g, 12.45 mmol), allyl alcohol (3.620 g, 62.32 mmol), and C₆H₅CH₂N(CH₃)₃⁺Cl⁻ (0.464 g, 2.50 mmol, 20 mol %) and fitted with a condenser. The solution was refluxed with stirring (24 h), cooled to room temperature, and poured into water (20 mL). The organic layer was separated. The aqueous layer was extracted with CH_2Cl_2 (4 × 10 mL). The organic layer and the extracts were combined, washed with water $(3 \times 20 \text{ mL})$ and saturated aqueous NaHCO₃ (4 \times 20 mL), and dried (MgSO₄). The solvent was removed by rotary evaporation. The yellow residue was chromatographed on a silica column (40 \times 3 cm, 4/1 v/v hexanes/ethyl acetate). The solvents were removed from the productcontaining fractions by rotary evaporation and oil pump vacuum to give 4a as a light yellow oil (1.503 g, 6.86 mmol, 55%). Continued elution of the column afforded the byproduct 2,6-NC5H3(CH2Br)-(CH₂OCH₂CH=CH₂), identified from an ¹H NMR spectrum reported elsewhere.^{14a} NMR (δ , CDCl₃): ¹H 7.68 (t, 1H, ³ J_{HH} = 7.7 Hz, p-HC_{4pyr}), 7.33 (d, 2H, ${}^{3}J_{HH} = 7.7$ Hz, m-HC_{3,5pyr}), 5.98 (ddt, 2H, ${}^{3}J_{\text{HHtrans}} = 17.2 \text{ Hz}, {}^{3}J_{\text{HHcis}} = 10.4 \text{ Hz}, {}^{3}J_{\text{HH}} = 5.6 \text{ Hz}, \text{ CH}$), 5.34 (dd, 2H, ${}^{3}J_{\text{HHtrans}} = 17.2 \text{ Hz}, {}^{2}J_{\text{HH}} = 1.6 \text{ Hz}, =\text{CH}_{E}H_{Z}$), 5.23 (dd, 2H, ${}^{3}J_{\text{HHcis}} = 10.4 \text{ Hz}, {}^{2}J_{\text{HH}} = 1.5 \text{ Hz}, = CH_{E}H_{Z}), 4.64 \text{ (s, 4H, CH}_{2}\text{O}), 4.12$ (dt, 4H, ${}^{3}J_{HH} = 5.6$ Hz, ${}^{4}J_{HH} = 1.4$ Hz, OCH₂CH=); ${}^{13}C{}^{1}H{}$ 157.9 (s, o-C_{2,6pyr}), 137.2 (s, p-C_{4pyr}), 134.4 (s, CH=), 119.8 (s, m-C_{3,5pyr}), 117.3 (s, =CH₂), 72.9 and 71.8 (2 s, CH₂OCH₂). These data agreed with those previously reported for an alternative synthesis.¹⁸ IR (cm⁻¹, oil film): 3084 (w), 2918 (s), 2853 (m), 1648 (w), 1594 (m), 1459 (m), 1347 (m), 1100 (s), 992 (s), 922 (s), 787 (m). MS:⁴¹ 220 ([4a + H]⁺, 100%).

2,6-NC₅**H**₃**(CH**₂**O(CH**₂)₂**CH**=**CH**₂)₂ (**4b**). 2,6-Bis(bromomethyl)pyridine (2.000 g, 7.548 mmol), 3-buten-1-ol (2.721 g, 37.74 mmol), and C₆H₃CH₂N(CH₃)₃+Cl⁻ (0.280 g, 1.51 mmol, 20 mol %) were combined in a procedure similar to that for **4a**. An analogous workup gave **4b** as a light yellow oil (1.020 g, 4.326 mmol, 55%). NMR (δ , CDCl₃): ¹H 7.73 (t, 1H, ³J_{HH} = 7.7 Hz, *p*-HC_{4pyrl}), 7.36 (d, 2H, ³J_{HH} = 7.7 Hz, *m*-HC_{3,5pyr}), 5.87 (ddt, 2H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.09 (dd, 2H, ³J_{HHtrans} = 17.2 Hz, ²J_{HH} = 1.6 Hz, =CH_EH_Z), 4.99 (dd, 2H, ³J_{HHcis} = 10.2 Hz, ²J_{HH} = 1.3 Hz, 2 =CH_EH_Z), 4.64 (s, 4H, CH₂O), 3.63 (t, 4H, ³J_{HH} = 6.7 Hz, OCH₂CH₂), 2.44 (q, 4H, ³J_{HH} = 6.7 Hz, CH₂); ¹³C{¹H} 158.0 (s, *o*-C_{2,6pyr}), 137.2 (s, *p*-C_{4pyr}), 135.1 (s, CH=), 119.7 (s, *m*-C_{3,5pyr}), 116.5 (s, =CH₂), 73.7 (s, CH₂O), 70.3 (s, OCH₂CH₂), 34.2 (s, CH₂). IR (cm⁻¹, oil film): 3080 (w), 2910 (s), 2860 (m), 1640 (w), 1455 (m), 1351 (m), 1112 (s), 992 (s), 915 (s), 787 (s). MS:⁴¹ 248 ([**4b** + H]⁺, 100%).

2,6-NC₅H₃(CH₂O(CH₂)₃CH=CH₂)₂ (4c). 2,6-Bis(bromomethyl)pyridine (3.000 g, 11.32 mmol), 4-penten-1-ol (5.860 g, 68.03 mmol), and C₆H₅CH₂N(CH₃)₃+Cl⁻ (0.420 g, 2.26 mmol, 20 mol %) were combined in a procedure similar to that for 4a. An analogous workup gave 4c as a colorless oil (1.412 g, 5.127 mmol, 45%). NMR (δ , CDCl₃): ¹H 7.71 (t, 1H, ³J_{HH} = 7.7 Hz, *p*-HC_{4pyr}), 7.35 (d, 2H, ³J_{HH} = 7.7 Hz, *m*-HC_{3,5pyr}), 5.83 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.7 Hz, CH=), 5.03 (dd, 2H, ³J_{HHtrans} = 17.2 Hz, ²J_{HH} = 2.0 Hz, =CH_EH_Z), 4.99 (dd, 2H, ³J_{HHcis} = 10.2 Hz, ²J_{HH} = 2.0 Hz, = CH_EH_Z), 4.60 (s, 4H, CH₂O), 3.57 (t, 4H, ³J_{HH} = 6.5 Hz, OCH₂CH₂), 2.20–2.14 (m, 4H, CH₂), 1.79–1.72 (m, 4H, CH₂); ¹³C{¹H} 158.2 (s, *o*-C_{2.6pyr}), 138.2 (s, *p*-C_{4pyr}), 137.2 (s, CH=), 119.7 (s, *m*-C_{3.5pyr}), 114.8 (s, =CH₂), 73.7 (s, CH₂O), 70.6 (s, OCH₂CH₂), 30.3 (s, CH₂), 8.9 (s, CH₂). IR (cm⁻¹, oil film): 3076 (w), 2937 (m), 2864 (m), 1640 (s), 1594 (s), 1445 (s), 1347 (s), 1116 (s), 992 (s), 911 (s), 787 (s). MS: ⁴¹ 276 ([4c + H]⁺, 100%).

2,6-NC₅**H**₃**(CH**₂**O(CH**₂)₄**CH**=**CH**₂)₂ (**4d**). 2,6-Bis(bromomethyl)pyridine (1.000 g, 3.774 mmol), 5-hexen-1-ol (1.512 g, 15.10 mmol), and C₆H₅CH₂N(CH₃)₃+Cl⁻ (0.140 g, 0.754 mmol, 20 mol %) were combined in a procedure similar to that for **4a**. An analogous workup gave **4d** as a light yellow oil (0.542 g, 1.79 mmol, 47%). NMR (δ , CDCl₃): ¹H 7.68 (t, 1H, ³J_{HH} = 7.7 Hz, *p*-HC_{4pyr}), 7.32 (d, 2H, ³J_{HH} = 7.7 Hz, *m*-HC_{3,5pyr}), 5.79 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.3 Hz, ${}^{3}J_{HH} = 6.7$ Hz, CH=), 4.98 (dd, 2H, ${}^{3}J_{HHrans} = 17.1$ Hz, ${}^{2}J_{HH} = 1.8$ Hz, =CH_EH_Z), 4.93 (dd, 2H, ${}^{3}J_{HHcis} = 10.2$ Hz, ${}^{2}J_{HH} = 1.6$ Hz, =CH_EH_Z), 4.59 (s, 4H, CH₂O), 3.54 (t, 4H, ${}^{3}J_{HH} = 6.5$ Hz, OCH₂CH₂), 2.09–2.01 (m, 4H, CH₂), 1.68–1.62 (m, 4H, CH₂), 1.51–1.45 (m, 4H, CH₂); ${}^{13}C{}^{1}H{}$ 157.8 (s, ${}^{o}-C_{2,6pyr}$), 138.5 (s, ${}^{p}-C_{4pyr}$), 136.8 (s, CH=), 120.8 (s, ${}^{m}-C_{3,5pyr}$), 115.1 (s, =CH₂), 74.5 (s, CH₂O), 70.2 (s, OCH₂CH₂), 33.8, 30.3, and 28.7 (3 s, CH₂). These data agreed reasonably well with those previously reported (in acetone- d_{6}) for an alternative synthesis.¹⁹ IR (cm⁻¹, oil film): 3078 (w), 2941 (m), 2870 (m), 1645 (s), 1600 (s), 1448 (s), 1350 (s), 1120 (s), 994 (s), 915 (s), 785 (s). MS: {}^{42} 304 ([4d + H]^{+}, 100\%).

3,5-NC5H3(COOCH2CH=CH2)2 (5a). A round-bottom flask was charged with 3,5-NC₅H₃(COCl)₂ (1.224 g, 6.002 mmol) and CH₂Cl₂ (20 mL) and cooled to 0 °C. Allyl alcohol (0.7442 g, 13.16 mmol) was added dropwise over 20 min with stirring. The cold bath was removed. After 1 h, the flask was fitted with a condenser. The solution was refluxed (5 h) and cooled to room temperature. The solvent was removed by rotary evaporation. Hexanes was added (10 mL). The offwhite residue was collected by filtration and washed with hexanes until a white solid was obtained (8 \times 5 mL). The solid was dissolved in CH_2Cl_2 (20 mL), washed with aqueous NaOH (1.0 M, 4 × 5 mL), and dried (MgSO₄). The solvent was removed by oil pump vacuum to give spectroscopically pure 5a as a light yellow oil (0.8732 g, 3.535 mmol, 59%). NMR (δ , CDCl₃): ¹H 9.35 (d, 2H, ⁴J_{HH} = 2.1 Hz, $o-HC_{2,6pyr}$), 8.85 (t, 1H, ${}^{4}J_{HH}$ = 2.1 Hz, $p-HC_{4pyr}$), 6.02 (ddt, 2H, ${}^{3}J_{\text{HHtrans}} = 17.2 \text{ Hz}, {}^{3}J_{\text{HHcis}} = 10.4 \text{ Hz}, {}^{3}J_{\text{HH}} = 5.8 \text{ Hz}, \text{ CH}$, 5.40 (dd, 2H, ${}^{3}J_{HHtrans} = 17.2$ Hz, ${}^{2}J_{HH} = 1.4$ Hz, $=CH_{E}H_{Z}$), 5.30 (dd, 2H, ${}^{3}J_{\text{HHcis}} = 10.4 \text{ Hz}, {}^{2}J_{\text{HH}} = 1.2 \text{ Hz}, = CH_{E}H_{Z}), 4.85 \text{ (dt, 4H, } {}^{3}J_{\text{HH}} = 5.8$ Hz, ${}^{4}J_{HH} = 1.3$ Hz, OCH₂); ${}^{13}C{}^{1}H{}$ 163.9 (s, CO), 154.1 (s, $o-C_{2,6pyr}$), 137.9 (s, p- C_{4pyr}), 131.4 (s, CH=), 125.9 (s, m- $C_{3,5pyr}$), 119.0 (s, = CH₂), 66.2 (s, OCH₂). IR (cm⁻¹, oil film): 3080 (w), 2931 (m), 2863 (w), 1727 (s), 1312 (m), 1240 (s), 1112 (m), 912 (m), 747 (s). MS:⁴¹ $248 ([5a + H]^+, 100\%).$

3,5-NC₅**H**₃(**COO**(**CH**₂)₂**CH**=**CH**₂)₂ (**5b**). 3,5-NC₅**H**₃(COCl)₂ (0.400 g, 1.96 mmol), CH₂Cl₂ (6.5 mL), and 3-buten-1-ol (0.423 g, 5.88 mmol) were combined in a procedure similar to that for **5a**. An analogous workup gave **5b** as a light yellow oil (0.482 g, 1.75 mmol, 89%). NMR (δ , CDCl₃): ¹H 9.33 (d, 2H, ⁴J_{HH} = 2.1 Hz, *o*-HC_{2,6pyr}), 8.82 (t, 1H, ⁴J_{HH} = 2.1 Hz, *p*-HC_{4pyr}), 5.84 (ddt, 2H, ³J_{HHtrans} = 17.1 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.22 (dd, 2H, ³J_{HHtrans} = 17.1 Hz, ²J_{HH} = 1.3 Hz, =CH_EH_Z), 5.11 (dd, 2H, ³J_{HHcis} = 10.2 Hz, ²J_{HH} = 1.1 Hz, =CH_EH_Z), 4.42 (t, 4H, ³J_{HH} = 6.7 Hz, OCH₂), 2.53 (q, 4H, ³J_{HH} = 6.7 Hz, CH₂CH=); ¹³C{¹H} 165.2 (s, CO), 153.2 (s, *o*-C_{2,6pyr}), 138.0 (s, *p*-C_{4pyr}), 135.7 (s, CH=), 126.0 (s, *m*-C_{3,5pyr}), 115.4 (s, =CH₂), 64.3 (s, OCH₂), 33.5 (s, CH₂CH=). IR (cm⁻¹, oil film): 3082 (w), 2940 (m), 2865 (w), 1730 (s), 1312 (m), 1242 (s), 1112 (m), 913 (m), 746 (s). MS:⁴¹ 276 ([**5b** + H]⁺, 100%).

3,5-NC₅**H**₃(**COO**(**CH**₂)₃**CH**=**CH**₂)₂ (**5c**). 3,5-NC₅**H**₃(COCl)₂ (1.500 g, 7.349 mmol), CH₂Cl₂ (24 mL), and 4-penten-1-ol (1.392 g, 16.16 mmol) were combined in a procedure similar to that for **5a**. An analogous workup gave **5c** as a light yellow oil (1.865 g, 6.148 mmol, 84%). NMR (δ , CDCl₃): ¹H 9.33 (d, 2H, ⁴J_{HH} = 2.1 Hz, *o*-HC_{2,6pyr}), 8.81 (t, 1H, ⁴J_{HH} = 2.1 Hz, *p*-HC_{4pyr}), 5.87 (ddt, 2H, ³J_{HHtrans} = 17.2 Hz, ³J_{HHcis} = 11.0 Hz, ³J_{HH} = 5.9 Hz, CH=), 5.03 (dd, 2H, ³J_{HHtrans} = 17.1 Hz, ²J_{HH} = 1.7 Hz, =CH_EH₂), 4.98 (dd, 2H, ³J_{HHcis} = 10.2 Hz, ²J_{HH} = 1.2 Hz, =CH_EH₂), 4.41 (t, 4H, ³J_{HH} = 6.7 Hz, OCH₂), 2.25–2.20 (m, 4H, CH₂), 1.93–1.86 (m, 4H, CH₂); ¹³C{¹H} 164.8 (s, CO), 154.4 (s, *o*-C_{2,6pyr}), 138.0 (s, *p*-C_{4pyr}), 137.9 (s, CH=), 126.6 (s, *m*-C_{3,5pyr}), 115.4 (s, =CH₂), 65.5 (s, OCH₂), 30.4 (s, CH₂), 28.1 (s, CH₂). IR (cm⁻¹, oil film): 3076 (w), 2932 (m), 2858 (w), 1720 (s), 1312 (m), 1231 (s), 1103 (m), 913 (m), 749 (s). MS:⁴¹ 304 ([**5c** + H]⁺, 100%).

3,5-NC₅**H**₃(**COO**(**CH**₂)₄**CH**=**CH**₂)₂ (**5d**). 3,5-NC₅**H**₃(COCl)₂ (2.000 g, 9.799 mmol), CH₂Cl₂ (32 mL), and 5-hexen-1-ol (2.160 g, 21.57 mmol) were combined in a procedure similar to that for **5a**. An analogous workup gave **5d** as a light yellow oil (2.917 g, 8.802 mmol, 90%). NMR (δ , CDCl₃): ¹H 9.37 (d, 2H, ⁴J_{HH} = 2.1 Hz, *o*-HC_{2,6pyr}), 8.85 (t, 1H, ⁴J_{HH} = 2.1 Hz, *p*-HC_{4pyr}), 5.80 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHtcis} = 10.3 Hz, ³J_{HH} = 6.7 Hz, CH=), 5.02 (dd,

2H, ${}^{3}J_{\text{HHtrans}} = 17.1$ Hz, ${}^{2}J_{\text{HH}} = 1.5$ Hz, $=\text{CH}_{E}H_{Z}$), 4.97 (dd, 2H, ${}^{3}J_{\text{HHcras}} = 10.2$ Hz, ${}^{2}J_{\text{HH}} = 1.1$ Hz, $=\text{CH}_{E}H_{Z}$), 4.41 (t, 4H, ${}^{3}J_{\text{HH}} = 6.7$ Hz, OCH₂), 2.18–2.13 (m, 4H, CH₂), 1.87–1.80 (m, 4H, CH₂), 1.61–1.54 (m, 4H, CH₂); ${}^{13}\text{C}{}^{1}\text{H}{}^{1}$ 164.6 (s, CO), 154.1 (s, $o \cdot C_{2,6\text{pyr}}$), 138.7 (s, $p \cdot C_{4\text{pyr}}$), 137.6 (s, CH==), 126.3 (s, $m \cdot C_{3,5\text{pyr}}$), 114.7 (s, = CH₂), 65.7 (s, OCH₂), 33.6, 25.8, and 25.3 (3 s, 3CH₂). These data agreed reasonably well with those previously reported in other solvents for a similar synthesis.¹⁹ IR (cm⁻¹, oil film): 3078 (w), 2937 (m), 2860 (w), 1724 (s), 1309 (m), 1235 (s), 1107 (m), 909 (m), 745 (s). MS:⁴¹ 332 ([5d + H]⁺, 100%).

3,5-NC₅**H**₃(**COO**(**CH**₂)₅**CH**=**CH**₂)₂ (5e). 3,5-NC₅**H**₃(COCl)₂ (1.500 g, 7.349 mmol), CH₂Cl₂ (24 mL), and 6-hepten-1-ol (1.850 g, 16.20 mmol) were combined in a procedure similar to that for **5a**. An analogous workup gave **5e** as a light yellow oil (1.838 g, 5.113 mmol, 70%). NMR (δ , CDCl₃): ¹H 9.36 (d, 2H, ⁴J_{HH} = 2.1 Hz, *o*-HC_{2,6pyr}), 8.85 (t, 1H, ⁴J_{HH} = 2.1 Hz, *p*-HC_{4pyr}), 5.80 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.7 Hz, CH=), 5.01 (dd, 2H, ³J_{HHtrans} = 17.1 Hz, ²J_{HH} = 1.7 Hz, =CH_EH_Z), 4.96 (dd, 2H, ³J_{HHcis} = 10.2 Hz, ²J_{HH} = 1.0 Hz, =CH_EH_Z), 4.39 (t, 4H, ³J_{HH} = 6.7 Hz, OCH₂), 2.10–2.08 (m, 4H, CH₂), 1.84–1.77 (m, 4H, CH₂), 1.50–1.45 (m, 8H, CH₂); ¹³C{¹H} 164.5 (s, CO), 154.1 (s, *o*-C_{2,6pyr}), 138.5 (s, *p*-C_{4pyr}), 137.9 (s, CH=), 126.2 (s, *m*-C_{3,5pyr}), 114.6 (s, =CH₂), 65.8 (s, OCH₂), 33.5, 28.5, 28.3, and 25.3 (4 s, 4CH₂). IR (cm⁻¹, oil film): 3076 (w), 2934 (m), 2860 (w), 1725 (s), 1309 (m), 1235 (s), 1104 (m), 911 (m), 745 (s). MS:⁴¹ 360 ([**5e** + H]⁺, 100%).

 $3,5-NC_5H_3(COO(CH_2)_6CH=CH_2)_2$ (5f). $3,5-NC_5H_3(COCI)_2$ (1.800 g, 8.819 mmol), CH₂Cl₂ (29 mL), and 7-octen-1-ol (2.488 g, 19.42 mmol) were combined in a procedure similar to that for 5a. After workup, the yellow residue was chromatographed on a silica column (45 \times 3 cm, 4/1 v/v hexanes/ethyl acetate). The solvent was removed from the product-containing fractions by rotary evaporation to give 5f as a light yellow oil (1.408 g, 3.633 mmol, 41%). NMR (δ , $CDCl_3$): ¹H 9.36 (d, 2H, ⁴ J_{HH} = 2.1 Hz, *o*-HC_{2,6pyr}), 8.85 (t, 1H, ⁴ J_{HH} = 2.1 Hz, *p*-HC_{4pyr}), 5.81 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.2 Hz, ${}^{3}J_{\rm HH} = 6.7$ Hz, CH=), 5.00 (dd, 2H, ${}^{3}J_{\rm HHtrans} = 17.2$ Hz, ${}^{2}J_{\rm HH} = 2.1$ Hz, =CH_EH_Z), 4.94 (dd, 2H, ${}^{3}J_{\text{HHcis}}$ = 10.2 Hz, ${}^{2}J_{\text{HH}}$ = 2.1 Hz, = CH_EH_Z), 4.39 (t, 4H, ${}^{3}J_{\text{HH}}$ = 6.7 Hz, OCH₂), 2.07–2.03 (m, 4H, CH_2), 1.85–1.76 (m, 4H, CH_2), 1.45–1.51 (m, 12H, CH_2); ¹³C{¹H} 164.5 (s, CO), 154.1 (s, o-C_{2,6pyr}), 138.8 (s, p-C_{4pyr}), 137.9 (s, CH=), 126.2 (s, m- $C_{3,5pyr}$), 114.4 (s, = CH_2), 65.9 (s, OCH_2), 33.6, 28.7, 28.6, 28.5, and 25.8 (5 s, 5CH₂). IR (cm⁻¹, oil film): 3076 (w), 2930 (s), 2856 (m), 1725 (s), 1309 (s), 1235 (s), 1104 (s), 911 (s), 745 (s).

 $MS_{*}^{41} 388 ([5f + H]^{+}, 100\%).$ 3,5-NC₅H₃(COO(CH₂)₈CH=CH₂)₂ (5h). 3,5-NC₅H₃(COCl)₂ (1.480 g, 7.251 mmol), CH2Cl2 (24 mL), and 9-decen-1-ol (2.503 g, 16.02 mmol) were combined in a procedure similar to that for 5a. An analogous workup gave 5h as a light yellow oil (2.152 g, 4.858 mmol, 67%). NMR (δ , CDCl₃): ¹H 9.36 (d, 2H, ⁴J_{HH} = 2.1 Hz, o- $HC_{2,6pyr}$), 8.86 (t, 1H, ${}^{4}J_{HH}$ = 2.1 Hz, *p*-HC_{4pyr}), 5.81 (ddt, 2H, ${}^{3}J_{HHtrans}$ = 17.0 Hz, ${}^{3}J_{\text{HHcis}} = 10.3$ Hz, ${}^{3}J_{\text{HH}} = 6.7$ Hz, CH=), 5.23 (dd, 2H, ${}^{3}J_{\text{HHcras}} = 17.1$ Hz, ${}^{2}J_{\text{HH}} = 1.8$ Hz, =CH_EH_Z), 4.99 (dd, 2H, ${}^{3}J_{\text{HHcis}} =$ 10.2 Hz, ${}^{2}J_{HH}$ = 1.2 Hz, = $CH_{E}H_{Z}$), 4.39 (t, 4H, ${}^{3}J_{HH}$ = 6.7 Hz, OCH2), 2.06-2.02 (m, 4H, CH2), 1.81-1.76 (m, 4H, CH2), 1.46-1.33 (m, 20H, CH₂); ${}^{13}C{}^{1}H$ 164.5 (s, CO), 154.1 (s, o-C_{2,6pyr}), 139.1 (s, $p-C_{4pyr}$), 137.9 (s, CH=), 126.2 (s, $m-C_{3,5pyr}$), 114.2 (s, =CH₂), 65.9 (s, OCH₂), 33.7, 29.3, 29.1, 29.0, 28.8, 28.6, and 25.9 (7 s, 7CH₂). These data agreed reasonably well with those previously reported for a similar synthesis.²⁰ IR (cm⁻¹, oil film): 3076 (w), 2926 (s), 2856 (m), 1729 (s), 1309 (s), 1235 (s), 1100 (s), 907 (s), 745 (s). MS:⁴¹ 444 $([5h + H]^+, 100\%).$

3,5-NC₅H₃(4-C₆H₄OCH₃)₂ (6).^{23a} A 100 mL three-necked roundbottom flask was charged with magnesium (0.5821 g, 23.95 mmol) and fitted with a septum, a stopper, and a condenser capped with a 180° glass needle valve. The flask was evacuated and back-filled with N₂. THF (30 mL) was added via cannula. Then 1,2-dibromoethane (0.30 mL) was added with stirring. After 10 min, 4-bromoanisole (2.50 mL, 20.0 mmol) was added by syringe. A Schlenk flask was charged with 3,5-dichloropyridine (1.3697 g, 9.2552 mmol), (dppp)-NiCl₂ (0.0503 g, 0.0928 mmol, 1.0 mol %), and THF (20 mL) and cooled to 0 °C. The Grignard mixture from the round-bottom flask was then added dropwise with stirring over 10 min. The cold bath was removed. After 15 h, the sample was refluxed (oil bath). After 2 h, the mixture was cooled (0 °C), and methanol (10 mL) was added. The volatiles were removed by oil pump vacuum. Water (200 mL) was added, which was extracted with CH₂Cl₂ (3 × 200 mL). The combined extracts were washed with water (150 mL) and brine (150 mL) and dried (MgSO₄). The solvent was removed by oil pump vacuum. The residue was recrystallized from toluene to afford **6** as colorless plates (1.8531 g, 6.3606 mmol, 73%). Mp (capillary): 228–231 °C; lit.⁴³ mp 233–235 °C. NMR (δ , CDCl₃): ¹H 8.75 (br s, 2H, *o*-HC_{2,6pyr}), 7.97 (s, 1H, *p*-HC_{4pyr}), 7.58 (d, 4H, ³J_{HH} = 8.6 Hz, MeOCCH), 7.04 (d, 4H, ³J_{HH} = 8.6 Hz, MeOCCHCH), 3.88 (s, 6H, CH₃). These data agreed with those previously reported.⁴³ **3,5-NC₅H₃(4-C₆H₄OH)₂ (7).**^{23b} A round-bottom flask was charged

3,5-NC₅H₃(4-C₆H₄OH)₂ (7).^{23b} A round-bottom flask was charged with 6 (10944 g, 3.7564 mmol), CH₂Cl₂ (25 mL), and BBr₃ (1.0 M in CH₂Cl₂; 16.0 mL, 16.0 mmol) with stirring. After 14 h, methanol (10 mL) was added. The volatiles were removed by oil pump vacuum, and the residue was chromatographed on a silica column (37 × 4 cm, 1/9 v/v petroleum ether/ethyl acetate). The solvent was removed from a faint yellow band by rotary evaporation to give 7 as an off-white solid (0.6539 g, 2.484 mmol, 66%). NMR (δ , DMSO- d_6): ¹H 10.06 (br *s*, 2H, OH), 9.37 (br s, 2H, *o*-HC_{2,6pyr}), 8.90 (t, 1H, ⁴J_{HH} = 2.0 Hz, *p*-HC_{4pyr}), 7.77 (m, 4H, HOCCH), 6.99 (m, 4H, HOCCHCH). These data agreed with those previously reported.^{23b}

3,5-NC₅H₃(4-C₆H₄O(CH₂)₅CH= \hat{C} H₂)₂ (8). A round-bottom flask was charged with 7 (0.5179 g, 1.967 mmol), Cs₂CO₃ (1.5166 g, 4.6549 mmol), and DMF (50 mL). The flask was fitted with a septum connected by a needle to an oil bubbler and purged with N_2 (10 min). Then 7-bromo-1-heptene was added by syringe with stirring. The mixture was kept at 100 °C for 1 h. The solvent was removed by oil pump vacuum. Water (100 mL) and CH2Cl2 (100 mL) were added and the phases separated. The aqueous phase was extracted with CH_2Cl_2 (2 × 100 mL). The combined CH_2Cl_2 layers were dried (MgSO₄). The solvent was removed by oil pump vacuum. The residue was chromatographed on a silica column (37 \times 4 cm, 1/1 v/v ethyl acetate/CH₂Cl₂). The solvent was removed from the productcontaining fraction by rotary evaporation to give 8 as a colorless solid (0.2902 g, 0.6369 mmol, 32%). Mp (capillary): 151-154 °C. NMR $(\delta, CDCI_3)$: ¹H 8.73 (br s, 2H, o-HC_{2,6pyr}), 7.97 (t, 1H, ⁴J_{HH} = 2.3 Hz, p-HC_{4pyr}), 7.56 and 7.01 (2 m, 2 \times 4H, pyr-CCH and pyr-CCHC*H*), 5.87–5.79 (ddt, 2H, ${}^{3}J_{HHtrans} = 17.3 \text{ Hz}$, ${}^{3}J_{HHcis} = 10.3 \text{ Hz}$, ${}^{3}J_{HHcis} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 4.02 (t, 4H, ${}^{3}J_{HH} = 6.4 \text{ Hz}$, CH=), 5.05–4.94 (m, 4H, =CH₂), 5.05–6.94 (m, 4H, = 6.7 Hz, OCH₂), 2.10 (m, 4H, CH₂CH=CH₂), 1.83 (m, 4H, OCH_2CH_2), 1.52–1.47 (m, 8H, CH_2); ¹³C{¹H} 159.6 (s, $COCH_2$), 145.8 (s, o-C_{2,6pyr}), 139.0 (s, CH=), 136.6 (s, m-C_{3,5pyr}), 132.3 (s, p- C_{4pyr}), 130.1 (s, pyr-C(CH)₂), 128.5 (s, pyr-C(CH)₂), 115.4 (s, (CH)₂CO), 114.7 (s, =CH₂), 68.3 (s, C₆H₄OCH₂), 33.9, 29.3, 28.8, and 25.8 (4 s, 4CH2). IR (cm-1, powder film): 2936 (m), 2864 (w), 1715 (w), 1605 (m), 1510 (m), 1287 (m), 1246 (s), 1180 (m), 910 (m), 824 (s), 716 (m).

trans-PtCl₂(2-NC₅H₄(CH₂OCH₂CH=CH₂))₂ (trans-10a). A round-bottom flask was charged with PtCl₂ (0.8468 g, 3.183 mmol) and benzene (50 mL) and fitted with a condenser. Then 1a (1.2956 g, 8.6841 mmol) was added with stirring. The mixture was refluxed (oil bath). After 14 h, the solvent removed by oil pump vacuum. The residue was chromatographed on a silica column (32×2.5 cm, 1/4 v/v ethyl acetate/CH2Cl2). The solvent was removed from the productcontaining fraction by oil pump vacuum to give trans-10a (0.7258 g, 1.286 mmol, 40%) as a light yellow solid and a mixture of atropisomers (ca. 50:50; see text). Mp (capillary): 160-162 °C. Anal. Calcd for C18H22Cl2N2O2Pt: C, 38.31; H, 3.93; N, 4.96. Found: C, 38.35; H, 3.93; N, 4.97. NMR (δ, CDCl₃): ¹H 8.92 (m, 2H, o-HC_{6pyr}), 7.77 (m, 2H, *m*-HC_{4pyr}), 7.69 (m, 2H, *p*-HC_{3pyr}), 7.24 (m, 2H, *m*-HC_{5pyr}), 6.13-5.98 (m, 2H, CH=), 5.65 and 5.63 (2 s, 4H, atropisomers, NC₅H₄CH₂O), 5.50–5.26 (m, 4H, =CH₂), 4.27 (m, 4H, OCH2CH). VT-NMR data (NC5H4CH2O signal): -50 °C, 5.605 and 5.584 (Δ = 6.2 Hz); -30 °C, 5.617 and 5.597 (Δ = 6.0 Hz); -10 °C, 5.624 and 5.606 (Δ = 5.9 Hz); 0 °C, 5.631 and 5.613 (Δ = 5.4 Hz); 10 °C, 5.638 and 5.620 (Δ = 5.2 Hz); 30 °C, 5.650 and 5.636 (Δ = 4.1 Hz); 35 °C,

5.650 and 5.642 (Δ = 3.0 Hz); 40 °C, 5.648 (Δ = 0 Hz). On the basis of the visual appearance of the spectra at 35 and 40 °C, the coalescence temperature (T_c) was extrapolated as 311 K. The $\Delta G^{\ddagger}(T_c)$ value was calculated by standard methods⁴⁴ as detailed elsewhere.^{14b} IR (cm⁻¹, powder film): 3073 (w), 2868 (w), 2837 (w), 1611 (m), 1483 (m), 1431 (m), 1340 (m), 1123 (s), 1094 (s), 926 (m), 768 (s), 719 (s).

trans-PtCl₂(2-NC₅H₄(CH₂O(CH₂)₂CH=CH₂))₂ (*trans*-10b). Pyridine 1b (1.4989 g, 9.1833 mmol) and PtCl₂ (1.1470 g, 4.3120 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-10b as a light yellow solid (0.3065 g, 0.5174 mmol, 12.0%). Mp (capillary): 188–191 °C dec. The broadened CH₂O ¹H NMR signal suggested a mixture of atropisomers. Anal. Calcd for C₂₀H₂₆Cl₂N₂O₂Pt: C, 40.55; H, 4.42; N, 4.73. Found: C, 40.27; H, 4.35; N, 4.49. NMR (δ, CDCl₃): ¹H 8.92 (m, 2H, *o*-HC_{6pyr}), 7.77 (m, 2H, *m*-HC_{4pyr}), 7.67 (m, 2H, *p*-HC_{3pyr}), 7.24 (m, 2H, *m*-HC_{5pyr}), 5.96–5.87 (m, 2H, CH=), 5.64 (br s, 4H, CH₂O), 5.20–5.09 (m, 4H, =CH₂), 3.80 (t, 4H, ³J_{HH} = 6.4 Hz, OCH₂CH₂), 2.50 (m, 4H, OCH₂CH₂). IR (cm⁻¹, powder film): 2164 (w), 2012 (w), 1981 (w), 1611 (w), 1477 (w), 1439 (w), 1356 (m), 1130 (s), 1099 (s), 1001 (m), 924 (m), 773 (s), 721 (m).

trans-PtCl₂[2,2'-(NC₅H₄(CH₂O(CH₂)₄OCH₂)H₄C₅N)] (trans-11a). A two-necked round-bottom flask was charged with trans-10a (0.4344 g, 0.7697 mmol) and CH₂Cl₂ (382 mL), fitted with a condenser, and flushed with N_2 (5 min). A solution of Grubbs' catalyst (0.0251 g, 0.0305 mmol, 4.0 mol %) in CH2Cl2 (5 mL) was added dropwise with stirring (the resulting solution is 0.002 01 M in trans-10a). The mixture was refluxed (24 h) and cooled to room temperature. The solvent was removed by rotary evaporation. The residue was chromatographed on a silica column (15.5 \times 1.5 cm, 1/4 v/v ethyl acetate/CH₂Cl₂). The solvent was removed by rotary evaporation and oil pump vacuum. A round-bottom flask was charged with the residue (metathesis product), 10% Pd/C (0.0325 g of 10% w/w, 0.0305 mmol Pd, 4.0 mol %), toluene (30 mL), and ethanol (30 mL), flushed with H_{22} and fitted with a balloon of H_2 (1.0 atm). After 23 h, CHCl₃ (40 mL) was added and the mixture filtered through a Celite column (5 \times 2 cm). The column was washed with $CHCl_3$ (2 × 40 mL). The solvent was removed from the filtrate by oil pump vacuum, and the residue was chromatographed on a silica column (29×1.5 cm, 1/4 v/v ethyl acetate/CH₂Cl₂) to give trans-11a as a light yellow solid (0.2593 g, 0.4187 mmol, 63%). Mp (capillary): 227-229 °C dec. Anal. Calcd for C₁₆H₂₀Cl ₂N₂O₂Pt: C, 35.70; H, 3.74; N, 5.20. Found: C, 35.39; H, 3.81; N, 5.12. NMR (δ, CDCl₃): ¹H 9.01 (m, 2H, *o*-HC_{6pyr}), 7.76 (m, 2H, p-HC_{4pyr}), 7.54 (m, 2H, m-HC_{3pyr}), 7.28 (m, 2H, m-HC_{5pyr}), 5.63 $(s, 4H, CH_2O)$, 3.90 (m, 4H, OCH₂CH₂), 2.10 (m, 4H, OCH₂CH₂); $^{13}C{^{1}H}$ 160.4 (s, o-C_{2pyr}), 154.7 (s, o-C_{6pyr}), 138.6 (s, p-C_{4pyr}), 126.7 (s, m-C_{3pyr}), 124.8 (s, m-C_{5pyr}), 72.2 (s, CH₂O), 69.8 (s, OCH₂CH₂), 24.6 (s, CH₂). IR (cm⁻¹, powder film): 2966 (w), 2911 (w), 2851 (w), 2149 (w), 1981 (w), 1607 (m), 1437 (m), 1225 (m), 1109 (s), 930 (m), 789 (s), 772 (s)

trans- $\dot{P}tCl_2[2,2'-(NC_5H_4(CH_2O(CH_2)_6OCH_2)H_4C_5\dot{N})]$ (trans-11b). Grubbs' catalyst (two charges 24 h apart, 0.0132 and 0.0126 g, 0.0314 mmol, 8.0 mol %), CH2Cl2 (197 mL), trans-10b (0.2334 g, 0.3940 mmol), and Pd/C (0.0174 g of 10% w/w, 0.0164 mmol Pd, 4.2 mol %) were combined in a procedure similar to that for trans-11a. An analogous workup gave trans-11b as an off-white solid (0.1761 g, 0.3109 mmol, 79%). Mp (capillary): 242-244 °C dec. Anal. Calcd for C18H24Cl2N2O2Pt: C, 38.17; H, 4.27; N, 4.95. Found: C, 38.57; H, 4.29; N, 4.96. NMR (δ, CDCl₃): ¹H 8.91 (m, 2H, *o*-HC_{6pyr}), 7.76 (m, 2H, p-HC_{4pyr}), 7.63 (m, 2H, m-HC_{3pyr}), 7.24 (m, 2H, m-HC_{5pyr}), 5.77 $(s, 4H, CH_2O)$, 3.87 (t, 4H, ${}^{3}J_{HH} = 6.4$ Hz, OCH_2CH_2), 1.89 (m, 4H, OCH2CH2), 1.68 (m, 4H, OCH2CH2CH2); ¹³C{¹H} 161.7 (s, o- C_{2pyr}), 153.5 (s, o- C_{6pyr}), 138.5 (s, p- C_{4pyr}), 124.1 (s, m- C_{3pyr}), 124.0 (s, m-C_{5pyr}), 71.8 (s, CH₂O), 70.2 (s, OCH₂CH₂), 27.3 (s, CH₂), 23.9 (s, CH₂). IR (cm⁻¹, powder film): 3061 (w), 2941 (m), 2859 (m), 1607 (m), 1570 (m), 1477 (m), 1229 (m), 1126 (s), 1101 (s), 787 (s), 768 (s), 719 (s).

trans-PtCl₂(3-NC₅H₄(CH₂OCH₂CH=CH₂))₂ (trans-12a). Pyridine 2a (1.2028 g, 8.0620 mmol) and PtCl₂ (1.0038 g, 3.7738 mmol) were combined in a procedure similar to that for *trans*-**10a**. An analogous workup gave *trans*-**12a** as a yellow solid (1.8265 g, 3.236 mmol, 86%). Mp (capillary): 120–121 °C. Anal. Calcd for $C_{18}H_{22}Cl_2N_2O_2Pt$: C, 38.31; H, 3.93; N, 4.96. Found: C, 38.28; H, 3.81; N, 4.96. NMR (δ , CDCl₃): ¹H 8.84 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, *o*-HC_{6pyr}), 7.80 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 6.00–5.87 (ddt, 2H, ³J_{HHrans} = 17.0 Hz, ³J_{HHcis} = 10.4 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.32–5.18 (m, 4H, =CH₂), 4.54 (s, 4H, CH₂O), 4.07 (m, 4H, OCH₂CH); ¹³C{¹H} 152.8 and 152.6 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 137.6 (s, CH=), 136.6 (s, *p*-C_{4pyr}), 134.1 (s, *m*-C_{3pyr}), 125.1 (s, *m*-C_{5pyr}), 118.3 (s, =CH₂), 72.0 (s, CH₂O), 68.4 (s, OCH₂CH₂). IR (cm⁻¹, powder film): 2924 (w), 2857 (w), 1609 (w), 1423 (m), 1096 (s), 924 (s), 800 (s), 696 (s).

PtCl₂(3-NC₅H₄(CH₂O(CH₂)₂CH=CH₂))₂ (12b). Pyridine 2b (1.3203 g, 8.0891 mmol) and PtCl₂ (1.0233 g, 3.8471 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-12b (1.1204 g, 1.8912 mmol, 49%; mp (capillary) 118-119 °C) and *cis*-12b (0.9764 g, 1.648 mmol, 43%; mp (capillary) 54-56 °C) as yellow solids. Anal. Calcd for $C_{20}H_{26}Cl_2N_2O_2Pt$: C, 40.55; H, 4.42; N, 4.73. Found (*trans*-12b): C, 40.50; H, 4.37; N, 4.71.

Data for *trans*-12b are as follows. NMR (δ , CDCl₃): ¹H 8.83 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, *o*-HC_{6pyr}), 7.78 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 5.91–5.76 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcs} = 10.4 Hz, ³J_{HH} = 6.8 Hz, CH=), 5.16–5.04 (m, 4H, =CH₂), 4.53 (s, 4H, CH₂O), 3.56 (t, 4H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.39 (apparent qt, 4H, ³J_{HH} = 6.6 Hz, ³J_{HH} = 1.4 Hz, CH₂CH=CH₂); ¹³C{¹H} 152.8 and 152.5 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 137.5 (s, CH=), 136.7 (s, *p*-C_{4pyr}), 135.0 (s, *m*-C_{3pyr}), 125.1 (s, *m*-C_{5pyr}), 117.0 (s, =CH₂), 70.5 (s, CH₂O), 69.3 (s, OCH₂CH₂), 34.3 (s, CH₂). IR (cm⁻¹, powder film): 2943 (w), 2870 (m), 1641 (m), 1477 (m), 1436 (s), 1364 (m), 1101 (s), 927 (s), 799 (s).

Data for *cis*-12b are as follows. NMR (δ , CDCl₃): ¹H 8.85 (m, 4H, o-HC_{2,6pyr}), 7.75 (m, 2H, p-HC_{4pyr}), 7.27 (m, 2H, m-HC_{5pyr}), 5.84–5.70 (ddt, 2H, ³J_{HHtrans} = 17.3 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.12–5.01 (m, 4H, =CH₂), 4.47 (s, 4H, CH₂O), 3.50 (t, 4H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.32 (apparent qt, 4H, ³J_{HH} = 6.6 Hz, ³J_{HH} = 1.4 Hz, CH₂CH=CH₂); ¹³C{¹H} 152.1 and 151.7 (2 s, o-C_{2pyr} and o-C_{6pyr}), 137.9 (s, CH=), 137.5 (s, p-C_{4pyr}), 134.9 (s, m-C_{3pyr}), 126.2 (s, m-C_{5pyr}), 117.0 (s, =CH₂), 70.6 (s, CH₂O), 69.0 (s, OCH₂CH₂), 34.2 (s, CH₂). IR (cm⁻¹, powder film): 3068 (w), 2904 (w), 2860 (w), 1608 (m), 1479 (m), 1437 (m), 1098 (s), 912 (s), 702 (s).

trans-PtCl₂(3-NC₅H₄(CH₂O(CH₂)₃CH=CH₂))₂ (*trans*-12c). Pyridine 2c (1.6721 g, 9.4338 mmol) and PtCl₂ (1.1893 g, 4.4711 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-12c as a yellow solid (2.3537 g, 3.793 mmol, 85%). Mp (capillary): 77–79 °C. Anal. Calcd for $C_{22}H_{30}Cl_2N_2O_2Pt$: C, 42.59; H, 4.87; N, 4.51. Found: C, 43.00; H, 4.78; N, 4.10. NMR (δ , CDCl₃): ¹H 8.84 (m, 2H, *o*-HC_{2pyr}), 8.81 (m, 2H, *o*-HC_{6pyr}), 7.78 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 5.86–5.78 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.1 Hz, ³J_{HH} = 6.4 Hz, CH=), 5.07–4.97 (m, 4H, =CH₂), 4.52 (s, 4H, CH₂O), 3.52 (t, 4H, ³J_{HH} = 6.4 Hz, OCH₂CH₂); ¹³C{¹H} 152.8 and 152.6 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 138.2 (s, CH=), 137.4 (s, *p*-C_{4pyr}), 136.8 (s, *m*-C_{3pyr}), 125.1 (s, *m*-C_{5pyr}), 115.2 (s, =CH₂), 70.7 (s, CH₂O), 69.3 (s, OCH₂CH₂), 30.4 (s, CH₂), 29.0 (s, CH₂). IR (cm⁻¹, powder film): 2938 (m), 2872 (m), 1643 (m), 1611 (m), 1441 (m), 1366 (m), 1096 (s), 1078 (s), 988 (m), 926 (m), 816 (s), 698 (s), 638 (m).

trans-PtCl₂(3-NC₅H₄(CH₂O(CH₂)₄CH=CH₂))₂ (*trans*-12d). Pyridine 2d (2.2421 g, 11.722 mmol) and PtCl₂ (1.4588 g, 5.4844 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-12d as a yellow solid (2.9313 g, 4.5199 mmol, 82%). Mp (capillary): 85–87 °C. Anal. Calcd for $C_{24}H_{34}Cl_2N_2O_2Pt$: C, 44.45; H, 5.28; N, 4.32. Found: C, 44.71; H, 4.97; N, 4.24. NMR (δ , CDCl₃): ¹H 8.83 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, *o*-HC_{6pyr}), 7.78 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 5.88–5.74 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.3 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.06–4.93 (m, 4H, =CH₂), 4.51 (s, 4H, CH₂O), 3.50 (t, 4H, ³J_{HH} = 6.4 Hz, OCH₂CH₂), 2.08 (m, 4H, CH₂CH=CH₂), 1.65 (m, 4H, OCH₂CH₂), 1.48 (m, 4H, OCH₂CH₂CH₂); ${}^{13}C{}^{1}H$ 152.7 and 152.5 (2 s, $o - C_{2pyr}$ and $o - C_{6pyr}$), 138.8 (s, CH=), 137.4 (s, $p - C_{4pyr}$), 136.8 (s, $m - C_{3pyr}$), 125.1 (s, $m - C_{5pyr}$), 114.9 (s, =CH₂), 71.2 (s, CH₂O), 69.3 (s, OCH₂CH₂), 33.7, 29.2, and 25.6 (3 s, 3CH₂). IR (cm⁻¹, powder film): 2934 (m), 2872 (m), 1641 (w), 1611 (w), 1483 (w), 1439 (m), 1369 (m), 1084 (s), 995 (m), 920 (s), 808 (s), 698 (s), 650 (m).

trans-PtCl₂(3-NC₅H₄(CH₂O(CH₂)₅CH=CH₂))₂ (trans-12e). Pyridine 2e (1.5794 g, 7.6913 mmol) and PtCl₂ (0.9657 g, 3.630 mmol) were combined in a procedure similar to that for trans-10a. An analogous workup gave trans-12e as a yellow solid (2.2861 g, 3.3789 mmol, 93%). Mp (capillary): 86-88 °C. Anal. Calcd for C26H38Cl2N2O2Pt: C, 46.16; H, 4.91; N, 4.14. Found: C, 46.21; H, 4.91; N, 4.11. NMR (δ , CDCl₃): ¹H 8.83 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, o-HC_{6pyr}), 7.78 (m, 2H, p-HC_{4pyr}), 7.28 (m, 2H, m-HC_{5pyr}), 5.85–5.77 (ddt, 2H, ${}^{3}J_{\rm HHras} = 17.0$ Hz, ${}^{3}J_{\rm HHcis} = 10.1$ Hz, ${}^{3}J_{\rm HH} = 6.9$ Hz, CH=), 5.02-4.92 (m, 4H, =CH₂), 4.51 (s, 4H, CH₂O), 3.49 (t, 4H, ${}^{3}J_{\rm HH} = 6.4$ Hz, OCH₂CH₂), 2.06 (m, 4H, CH₂CH=CH₂), 1.63 (m, 4H, OCH₂CH₂), 1.44–1.36 (m, 8H, CH₂); ¹³C{¹H} 152.7 and 152.5 (2 s, o-C_{2pyr} and o-C_{6pyr}), 139.1 (s, CH=), 137.4 (s, p-C_{4pyr}), 136.9 (s, m- C_{3pyr}), 125.0 (s, m- C_{5pyr}), 114.6 (s, =CH₂), 71.4 (s, CH₂O), 69.3 (s, OCH₂CH₂), 33.9, 29.7, 28.9, and 25.8 (4 s, 4CH₂). IR (cm⁻¹ . powder film): 2931 (m), 2872 (m), 2851 (m), 1643 (w), 1610 (w), 1440 (m), 1089 (s), 986 (m), 924 (s), 816 (s), 698 (s), 648 (m).

PtCl₂(3-NC₅H₄(CH₂O(CH₂)₈CH=CH₂))₂ (12h). Pyridine 2h (1.0658 g, 4.3084 mmol) and PtCl₂ (0.5188 g, 1.950 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-12h (0.6785 g, 0.8919 mmol, 46%; mp (capillary) 101−102 °C) and *cis*-5h (0.6558 g, 0.8621 mmol, 44%) as yellow solids. Anal. Calcd for $C_{32}H_{50}Cl_2N_2O_2Pt$: C, 50.52; H, 6.62; N, 3.68. Found (*trans*-12h): C, 50.64; H, 5.78; N, 3.53.⁴⁵

Data for *trans*-12h are as follows. NMR (δ , CDCl₃): ¹H 8.83 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, *o*-HC_{6pyr}), 7.79 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 5.88–5.74 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.4 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.03–4.89 (m, 4H, =CH₂), 4.51 (s, 4H, CH₂O), 3.49 (t, 4H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.04 (m, 4H, CH₂CH=CH₂), 1.62 (m, 4H, OCH₂CH₂), 1.44–1.25 (m, 24H, CH₂); ¹³C{¹H} 152.7 and 152.5 (2 *s*, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.4 (*s*, CH=), 137.5 (*s*, *c*-C_{4pyr}), 136.9 (*s*, *m*-C_{3pyr}), 125.1 (*s*, *m*-C_{5pyr}), 114.3 (*s*, =CH₂), 71.5 (*s*, CH₂O), 69.3 (*s*, OCH₂CH₂), 34.0, 29.8, 29.6 (2×), 29.3, 29.1, and 26.3 (6 *s*, 7CH₂). IR (cm⁻¹, powder film): 2918 (m), 2849 (m), 2357 (w), 1641 (w), 1464 (w), 1439 (w), 1369 (m), 1258 (w), 1227 (w), 1093 (*s*), 926 (*s*), 810 (*s*), 698 (*s*), 644 (m).

Data for *cis*-12h are as follows. NMR (δ , CDCl₃): ¹H 8.89 (m, 2H, *o*-HC_{2pyr}), 8.86 (m, 2H, *o*-HC_{6pyr}), 7.73 (m, 2H, *p*-HC_{4pyr}), 7.26 (m, 2H, *m*-HC_{5pyr}), 5.85–5.71 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.2 Hz, ³J_{HH} = 6.6 Hz, CH=), 5.00–4.87 (m, 4H, =CH₂), 4.42 (s, 4H, CH₂O), 3.41 (t, 4H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.06–1.97 (m, 4H, CH₂CH=CH₂), 1.59–1.48 (m, 4H, OCH₂CH₂), 1.40–1.22 (m, 24H, CH₂); ¹³C{¹H} 152.1 and 151.7 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.3 (s, CH=), 138.0 (s, *p*-C_{4pyr}), 137.4 (s, *m*-C_{3pyr}), 126.1 (s, *m*-C_{5pyr}), 114.3 (s, =CH₂), 71.5 (s, CH₂O), 68.9 (s, OCH₂CH₂), 33.9, 29.7, 29.5 (2×), 29.2, 29.0, and 26.2 (6 s, 7CH₂).

trans-PtCl₂(3-NC₅H₄(CH₂O(CH₂)₉CH=CH₂))₂ (trans-12i). Pyridine 2i (1.4690 g, 5.6196 mmol) and PtCl₂ (0.7101 g, 2.670 mmol) were combined in a procedure similar to that for *trans*-10a. An analogous workup gave *trans*-12i as a yellow solid (1.8760 g, 2.3783 mmol, 89%). Mp (capillary): 102–103 °C. Anal. Calcd for $C_{34}H_{54}Cl_2N_2O_2Pt$: C, 51.77; H, 6.90; N, 3.55. Found: C, 51.71; H, 6.00; N, 3.40.⁴⁵ NMR (δ , CDCl₃): ¹H 8.83 (m, 2H, *o*-HC_{2pyr}), 8.80 (m, 2H, *o*-HC_{6pyr}), 7.79 (m, 2H, *p*-HC_{4pyr}), 7.29 (m, 2H, *m*-HC_{5pyr}), 5.85–5.77 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHcis} = 10.1 Hz, ³J_{HH} = 6.9 Hz, CH=), 5.01–4.91 (m, 4H, =CH₂), 4.51 (s, 4H, CH₂O), 3.49 (t, 4H, ³J_{HH} = 6.4 Hz, OCH₂CH₂), 2.03 (m, 4H, CH₂CH=CH₂), 1.62 (m, 4H, OCH₂CH₂), 1.40–1.26 (m, 24H, CH₂); ¹³C{¹H} 152.7 and 152.5 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.5 (s, CH=), 137.4 (s, *p*-C_{4pyr}), 136.9 (s, *m*-C_{3pyr}), 125.1 (s, *m*-C_{5pyr}), 114.3 (s, =CH₂), 71.5 (s, CH₂O), 69.3 (s, OCH₂CH₂), 34.0, 29.8, 29.7, 29.6 (2x), 29.3, 29.1, and 26.3 (7 s, 8CH₂). IR (cm⁻¹, powder film): 2920 (s), 2847 (s), 2324 (w), 1641 (w), 1611 (w), 1462 (m), 1366 (m), 1096 (s), 920 (s), 810 (s), 700 (s).

trans- $\dot{P}tCl_2[3,3'-(NC_5H_4(CH_2O(CH_2)_{10}OCH_2)H_4C_5\dot{N})]$ (trans-13d). Grubbs' catalyst (0.0254 g, 0.0306 mmol, 3.9 mol %), CH₂Cl₂ (398 mL), trans-12d (0.5158 g, 0.7953 mmol), and Pd/C (0.0423 g of 10% w/w, 0.0398 mmol Pd, 5.0 mol %) were combined in a procedure similar to that for trans-11a. An analogous workup gave trans-13d as a light yellow solid (0.4615 g, 0.7414 mmol, 93%). Mp (capillary): 204-208 °C. Anal. Calcd for C₂₂H₃₂Cl₂N₂O₂Pt: C, 42.45; H, 5.18; N, 4.50. Found: C, 42.52; H, 4.78; N, 4.45. NMR (δ, CDCl₃): ¹H 9.05 (m, 2H, o-HC_{2pyr}), 8.82 (m, 2H, o-HC_{6pyr}), 7.54 (m, 2H, p-HC_{4pyr}), 7.23 (m, 2H, m-HC_{5pyr}), 4.53 (s, 4H, CH_2O), 3.54 (t, 4H, $^{3}J_{HH} = 5.7$ Hz, OCH₂CH₂), 1.64 (m, 4H, OCH₂CH₂), 1.56 (m, 4H, O(CH₂)₂CH₂), 1.45–1.35 (m, 8H, CH₂); ${}^{13}C{}^{1}H{}$ 153.1 and 152.5 (2 s, o-C_{2pyr} and o- C_{6pyr}), 136.8 (s, $p-C_{4pyr}$), 136.5 (s, $m-C_{3pyr}$), 124.5 (s, $m-C_{5pyr}$), 71.3 (s, CH₂O), 69.6 (s, OCH₂CH₂), 30.1, 29.8, 29.4, and 26.5 (4 s, 4CH₂). IR (cm⁻¹, powder film): 2922 (m), 2853 (m), 1609 (w), 1439 (m), 1358 (m), 1315 (m), 1103 (s), 802 (s), 698 (s).

trans- $\dot{PtCl_2}[3,3'-(NC_5H_4(CH_2O(CH_2)_{18}OCH_2)H_4C_5\dot{N})]$ (*trans*-13h). Grubbs' catalyst (0.0237 g, 0.0288 mmol, 5.0 mol %), CH₂Cl₂ (290 mL), *trans*-12h (0.4409 g, 0.5796 mmol), and Pd/C (0.0316 g of 10% w/w, 0.0297 mmol Pd, 5.1 mol %) were combined in a procedure similar to that for *trans*-11a. An analogous workup gave *trans*-13h as a yellow solid (0.3398 g, 0.4625 mmol, 80%). Mp (capillary): 131–134 °C. Anal. Calcd for C₃₀H₄₈Cl₂N₂O₂Pt: C, 49.04; H, 6.59; N, 3.81. Found: C, 49.16; H, 5.82; N, 3.75.⁴⁵ NMR (δ , CDCl₃): ¹H 8.93 (m, 2H, *o*-HC_{2pyr}), 8.82 (m, 2H, *o*-HC_{6pyr}), 7.71 (m, 2H, *p*-HC_{4pyr}), 7.28 (m, 2H, *m*-HC_{5pyr}), 4.51 (s, 4H, CH₂O), 3.50 (t, 4H, ³J_{HH} = 6.7 Hz, OCH₂CH₂), 1.63 (m, 4H, OCH₂CH₂), 1.41–1.24 (m, 28H, CH₂); ¹³C{¹H} 153.1 and 152.8 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 137.5 (s, *p*-C_{4pyr}), 136.8 (s, *m*-C_{3pyr}), 124.9 (s, *m*-C_{5pyr}), 71.4 (s, CH₂O), 69.5 (s, OCH₂CH₂), 29.7, 29.4 (5 ×), 29.3, and 26.1 (4 s, 8CH₂). IR (cm⁻¹, powder film): 2924 (s), 2851 (s), 1611 (w), 1435 (m), 1364 (m), 1103 (s), 800 (s), 692 (s).

trans- $\dot{PtCl}_{2}[3,3'-(NC_{5}H_{4}(CH_{2}O(CH_{2})_{20}OCH_{2})H_{4}C_{5}\dot{N})]$ (trans-13i). Grubbs' catalyst (two charges 24 h apart, 0.0219 and 0.0196 g, 0.0505 mmol, 7.6 mol %), CH2Cl2 (334 mL), trans-12i (0.5273 g. 0.6685 mmol), and Pd/C (0.0363 g of 10% w/w, 0.0341 mmol Pd, 5.1 mol %) were combined in a procedure similar to that for trans-11a. An analogous workup gave trans-13i as an off-white solid (0.4581 g, 0.6006 mmol, 90%). Mp (capillary): 134-136 °C. Anal. Calcd for C32H52Cl2N2O2Pt: C, 50.39; H, 6.87; N, 3.67. Found: C, 50.40; H, 6.75; N, 3.55. NMR (δ, CDCl₃): ¹H 8.91 (m, 2H, o-HC_{2pyr}), 8.81 (m, 2H, o-HC_{6pyr}), 7.72 (m, 2H, p-HC_{4pyr}), 7.28 (m, 2H, m-HC_{5pyr}), 4.52 (s, 4H, $C\dot{H}_{2}O$), 3.49 (t, 4H, ${}^{3}J_{HH} = 6.4$ Hz, $OCH_{2}CH_{2}$), 1.63 (m, 4H, OCH₂CH₂), 1.40–1.22 (m, 32H, CH₂); ¹³C{¹H} 153.0 and 152.8 (2 s, $o-C_{2pyr}$ and $o-C_{6pyr}$), 137.5 (s, $p-C_{4pyr}$), 136.8 (s, $m-C_{3pyr}$), 124.9 (s, *m*-*C*_{5pyr}), 71.3 (s, CH₂O), 69.4 (s, OCH₂CH₂), 29.7, 29.5 (5 ×), 29.4, 29.3, and 26.1 (5 s, 9CH₂). IR (cm⁻¹, powder film): 2922 (s), 2851 (s), 2341 (w), 2160 (w), 2039 (w), 1981 (w), 1476 (w), 1458 (w), 1435 (m), 1103 (s), 800 (s), 692 (s).

trans-PdCl₂[2,6-NC₅H₃(CH₂CH₂CH=CH₂)₂]₂ (trans-14).⁸ A Schlenk flask was charged with trans-(PhCN)₂PdCl₂ (0.527 g, 1.37 mmol), benzene (15 mL), and 3 (0.565 g, 3.02 mmol) and fitted with a condenser. The solution was refluxed (40 min). A black precipitate formed after 5 min. The mixture was cooled to room temperature and filtered. The solvent was removed by rotary evaporation. The residue was chromatographed on a silica column (30 \times 1 cm, 3/1 v/v hexanes/CH₂Cl₂). The solvents were removed from the productcontaining fractions by rotary evaporation and oil pump vacuum to give trans-14 as a yellow solid (0.112 g, 0.203 mmol, 15%). NMR (δ , $CDCl_3$): ¹H 7.61 (t, 2H, ³ J_{HH} = 7.7 Hz, *p*-HC_{4pyr}), 7.12 (d, 4H, ³ J_{HH} = 7.7 Hz, *m*-HC_{3,5pyr}), 6.05 (ddt, 4H, ${}^{3}J_{HHtrans} = 17.0$ Hz, ${}^{3}J_{HHcis} = 10.4$ Hz, ${}^{3}J_{HH} = 6.5$ Hz, CH==), 5.23 (dd, 4H, ${}^{3}J_{HHtrans} = 17.1$ Hz, ${}^{2}J_{HH} =$ 1.6 Hz, =CH_EH_Z), 5.14 (dd, 4H, ${}^{3}J_{HHcis} = 10.2$ Hz, ${}^{2}J_{HH} = 1.1$ Hz, = CH_EH_Z), 4.42 (t, 8H, $^{3}J_{HH}$ = 7.5 Hz, CH_2), 2.85 (q, 8H, $^{3}J_{HH}$ = 7.2 Hz, CH_2); ¹³C{¹H} 163.3 (s, o- $C_{2,6pyr}$), 138.2 (s, p- C_{4pyr}), 136.8 (s, CH=), 122.2 (s, m- $C_{3,5pyr}$), 116.4 (s, =CH₂), 38.7 (s, CH₂), 32.1 (s, CH₂). IR (cm⁻¹, powder film): 3080 (m), 2964 (m), 2868 (m), 2934 (m), 2856 (m), 1644 (m), 1606 (m), 1575 (m), 1471 (s), 1262 (s), 1096 (s),

Organometallics

915 (s), 807 (s). MS:⁴¹ 517 ([14 – Cl]⁺, 30%), 292 (unknown, 100%), 188 ([3 + H]⁺, 80%).

trans- $\dot{P}dCl_{2}[2,6,2',6'-(NC_{5}H_{3}((CH_{2})_{2}CH=CH(CH_{2})_{2})_{2}H_{3}C_{5}\dot{N})]$ (trans-15).8 A two-necked round-bottom flask was charged with trans-14 (0.108 g, 0.196 mmol) and CH₂Cl₂ (5 mL). A solution of Grubbs' catalyst (0.0081 g, 0.098 mmol, 5.0 mol %) in CH₂Cl₂ (1.5 mL) was added dropwise over 10 min with stirring (the resulting solution is 0.0301 M in trans-14). A precipitate formed after 20 min. After 6 h, a second charge of Grubbs' catalyst (0.0081 g, 5.0 mol %) was added as a solid. After 18 h, a final charge of Grubbs' catalyst (0.0081 g, 5.0 mol %) was added. The mixture was stirred for an additional 6 h. Water (15 mL) and CH₂Cl₂ (15 mL) were added. After 30 min, the organic layer was separated. The aqueous layer was extracted with CH_2Cl_2 (3 × 15 mL). The organic layer and the extracts were combined, dried (MgSO₄), and concentrated by rotary evaporation. The residue was chromatographed on a silica column (25×1 cm, 7/3 v/v hexanes/ethyl acetate). The solvents were removed from the product-containing fractions by rotary evaporation and oil pump vacuum to give trans-15 as a light yellow solid (0.0563 g, 0.114 mmol, 58%). ¹H NMR (δ , CDCl₃): 7.62 (t, 2H, ³ $J_{HH} = 7.7$ Hz, *p*-HC_{4pyr}), 7.12 (d, 4H, ${}^{3}J_{HH} = 7.7$ Hz, $m \cdot HC_{3,5pyr}$), 6.05–5.97 (m, 4H, CH=), 4.00 (t, 8H, ${}^{3}J_{HH}$ = 7.5 Hz, CH₂), 3.28-3.18 (m, 8H, CH₂).

trans- $PdCl_2[2,6,2',6'-(NC_5H_3((CH_2)_6)_2H_3C_5\dot{N})]$ (trans-16). A round-bottom flask was charged with 15 (0.0702 g, 0.142 mmol), PtO₂ (0.0048 g, 0.021 mmol, 15 mol %), and CH₂Cl₂ (14 mL), flushed with H_{22} and fitted with a balloon of H_2 (1.0 atm). The mixture was stirred (3 days). The solvent was removed by rotary evaporation. The residue was chromatographed on alumina $(10 \times 2 \text{ cm column})$ CH₂Cl₂). The solvent was removed from the product-containing fractions by rotary evaporation and oil pump vacuum to give trans-16 as a light yellow solid (0.044 g, 0.088 mmol, 62%). The sample slightly darkened at 150 °C. TGA: onset of mass loss, 159.6 °C. Anal. Calcd for C22H30Cl2N2Pd: C, 52.87; H 6.05; N 5.60. Found: C, 52.42; H, 6.60; N, 4.88. NMR (δ , CDCl₃): ¹H 7.54 (t, 2H, ³J_{HH} = 7.7 Hz, p- HC_{4pyr}), 7.11 (d, 4H, ${}^{3}J_{HH}$ = 7.7 Hz, m-HC_{3,5pyr}), 3.94–3.89 (m, 8H, CH₂), 2.72–2.55 (m, 8H, CH₂), 2.02–1.85 (m, 8H, CH₂); ${}^{13}C{}^{1}H$ 165.1 (s, $o - C_{2,6pyr}$), 139.0 (s, $p - C_{4pyr}$), 123.8 (s, $m - C_{3,5pyr}$), 40.6 (s, CH_2), 26.3 (s, CH_2), 25.2 (s, CH_2). IR (cm⁻¹, powder film): 3069 (w), 2961 (m), 2926 (m), 2868 (m), 1644 (m), 1606 (m), 1575 (m), 1463 (s), 1262 (m), 1092 (s), 1019 (s), 915 (s), 791 (s), 757 (s). MS:⁴¹ 501 $(16^+, 60\%)$, 486 (unknown, 100%), 428 ($[16 - 2Cl]^+$, 20%).

trans-PtCl₂[2,6-NC₅H₃(CH₂OCH₂CH=CH₂)₂]₂ (trans-17a). A Schlenk flask was charged with PtCl₂ (0.513 g, 1.93 mmol), benzene (19 mL), and 4a (0.930 g, 4.24 mmol) and fitted with a condenser. The mixture was refluxed with stirring (5 days; after 2 days, a yellow solution had formed) and cooled to room temperature. The solvent was removed by rotary evaporation and the residue chromatographed on a silica column (10 \times 2 cm, CH₂Cl₂). A single yellow band was collected. The solvent was removed by rotary evaporation. Hexanes was added (10 mL). The residue was collected by filtration, washed with hexanes $(10 \times 3 \text{ mL})$, and dried overnight by oil pump vacuum to give trans-17a as a yellow solid (1.196 g, 1.698 mmol, 88%). Mp (capillary): 148–150 °C. DSC $(T_i/T_e/T_p/T_c/T_f)$: 107.5/152.0/154.9/ 156.5/168.3 °C (endotherm). TGA: onset of mass loss, 163.1 °C. Anal. Calcd for C₂₆H₃₄Cl₂N₂O₄Pt: C, 44.32; H, 4.86; N, 3.98. Found: C, 43.39; H, 4.86; N, 3.79.⁴⁵ NMR (δ , CDCl₃): ¹H 7.78 (t, 2H, ³J_{HH} = 7.9 Hz, p-HC_{4pyr}), 7.58 (d, 4H, ${}^{3}J_{HH} = 7.9$ Hz, m-HC_{3,5pyr}), 6.04 (ddt, 2H, ${}^{3}J_{\text{HHrans}} = 17.2 \text{ Hz}$, ${}^{3}J_{\text{HHcis}} = 10.6 \text{ Hz}$, ${}^{3}J_{\text{HH}} = 5.4 \text{ Hz}$, CH=), 5.82 (s, 8H, CH₂O), 5.44 (dd, 4H, ${}^{3}J_{\text{HHrans}} = 17.2 \text{ Hz}$, ${}^{2}J_{\text{HH}} = 1.6 \text{ Hz}$, = CH_EH_Z), 5.30 (dd, 4H, ${}^{3}J_{HHcis} = 10.4$ Hz, ${}^{2}J_{HH} = 1.5$ Hz, $=CH_EH_Z$), 4.27 (dt, 8H, ${}^{3}J_{HH}$ = 5.5 Hz, ${}^{4}J_{HH}$ = 1.5 Hz, OCH₂); ${}^{13}C{}^{1}H$ 161.5 (s, o-C_{2,6pyr}), 139.0 (s, p-C_{4pyr}), 134.0 (s, CH=), 121.5 (s, m-C_{3,5pyr}), 117.9 (s, = CH_2), 72.2 and 71.3 (2 s, CH_2OCH_2). IR (cm⁻¹, powder film): 3092 (w), 3015 (w), 2868 (m), 2837 (m), 1613 (m), 1471 (m), 1332 (m), 1239 (w), 1123 (s), 1107 (s), 911 (s), 787 (s). MS:⁴¹ 705 $(17a^+, 10\%), 669 ([17a - Cl]^+, 40\%), 220 ([4a + H]^+, 100\%).$

trans-PtCl₂[2,6-NC₅H₃(CH₂O(CH₂)₂CH=CH₂)₂]₂ (trans-17b). A Schlenk flask was charged with PtCl₂ (0.477 g, 1.79 mmol), benzene (15 mL), and 4b (0.914 g, 3.70 mmol) and fitted with a condenser.

The mixture was refluxed with stirring (7 days; after 4 days, a yellow solution had formed) and cooled to room temperature. The solvent was removed by rotary evaporation, and the residue was chromatographed on a silica column (20 \times 2 cm, 4/1 v/v hexanes/ethyl acetate). The solvents were removed by rotary evaporation from the product-containing fractions. Hexanes was added (15 mL). The residue was collected by filtration, washed with hexanes $(10 \times 3 \text{ mL})$, and dried overnight by oil pump vacuum to give trans-17b as a yellow solid (0.354 g, 0.465 mmol, 26%). Mp (capillary): 106-108 °C. DSC $(T_{\rm i}/T_{\rm e}/T_{\rm p}/T_{\rm c}/T_{\rm f})$: 90.7/109.9/110.8/112.1/135.3 °C (endotherm). TGA: onset of mass loss, 167.9 °C. Anal. Calcd for C₃₀H₄₂Cl₂N₂O₄Pt: C, 47.37; H, 5.57; N, 3.68. Found: C, 47.25; H, 5.55; N, 3.62. NMR (δ, CDCl_3) : ¹H 7.78 (t, 2H, ³ $J_{\text{HH}} = 7.9$ Hz, p-HC_{4pyr}), 7.58 (d, 4H, ${}^{3}J_{\text{HH}} = 7.9 \text{ Hz}, m-HC_{3,5\text{pyr}}$), 5.94 (ddt, 4H, ${}^{3}J_{\text{HHtrans}} = 17.1 \text{ Hz}, {}^{3}J_{\text{HHcis}} =$ 10.3 Hz, ${}^{3}J_{HH}$ = 6.8 Hz, CH=), 5.81 (s, 8H, CH₂O), 5.19 (dd, 4H, ${}^{3}J_{\text{HHtrans}} = 17.2 \text{ Hz}, {}^{2}J_{\text{HH}} = 1.8 \text{ Hz}, = \text{CH}_{E}H_{Z}$, 5.12 (dd, 4H, ${}^{3}J_{\text{HHcis}} =$ 10.2 Hz, ${}^{2}J_{HH} = 1.8$ Hz, $=CH_{E}H_{Z}$), 3.84 (t, 8H, ${}^{3}J_{HH} = 6.6$ Hz, OCH₂), 2.55–2.50 (m, 8H, CH₂); ${}^{13}C{}^{1}H{}^{1}$ 161.3 (s, $o - C_{2,6pyr}$), 138.9 (s, p- C_{4pyr}), 134.8 (s, CH=), 121.5 (s, m- $C_{3,5pyr}$), 116.9 (s, =CH₂), 71.9 (s, CH₂O), 70.9 (s, OCH₂CH₂), 34.2 (s, CH₂). IR (cm⁻¹, powder film): 3074 (w), 2981 (w), 2866 (m), 1613 (m), 1475 (m), 1352 (m), 1120 (s), 1027 (m), 911 (s), 796 (s). MS: 41 760 (17b⁺, 5%), 725 $([17b - Cl]^+, 30\%), 248 ([4b + H]^+, 100\%).$

trans-PtCl₂[2,6,2',6'-(NC₅H₃(CH₂O(CH₂)₄OCH₂)₂H₃C₅N)] (trans-18a). A two-necked round-bottom flask was charged with trans-17a (0.250 g, 0.355 mmol) and CH₂Cl₂ (173 mL), fitted with a condenser, and flushed with N2. A solution of Grubbs' catalyst (0.0292 g, 0.0355 mmol, 10 mol %) in CH₂Cl₂ (5 mL) was added dropwise over 30 min with stirring (the resulting solution is 0.001 99 M in trans-17a). The mixture was refluxed (24 h). A precipitate formed after 30 min. The mixture was cooled to room temperature, and the solvent was removed by rotary evaporation. The residue was chromatographed on alumina (15 \times 2 cm column, CH₂Cl₂). A single light yellow band was collected. The solvent was removed by rotary evaporation and oil pump vacuum. A round-bottom flask was charged with the crude metathesis product, 10% Pd/C (0.0263 g, 0.0246 mmol of Pd), toluene (10 mL), and ethanol (10 mL), flushed with H₂, and fitted with a balloon of $\rm H_2$ (1.0 atm). The mixture was stirred (3 days) and passed through a pad of Celite (7 \times 2 cm, rinsed with CH₂Cl₂). The filtrate was concentrated by oil pump vacuum (to ca. 1 mL), carefully layered with hexanes (20 mL), and kept at -4 °C. After 24 h, the supernatant was carefully decanted, and the precipitate was dried by oil pump vacuum to give trans-18a as an off-white solid (0.0221 g, 0.0338 mmol, 10%). The sample slightly darkened at 150 °C. TGA: onset of mass loss, 160.0 °C. Anal. Calcd for $C_{22}H_{30}Cl_2N_2O_4Pt:$ C, 40.50; H, 4.63; N, 4.29. Found: C, 41.08; H, 4.95; N, 4.04. NMR (δ, CDCl₃): ¹H 7.80 (t, 2H, ${}^{3}J_{HH} = 7.7$ Hz, $p-HC_{4pyr}$), 7.53 (d, 4H, ${}^{3}J_{HH} = 7.7$ Hz, m- $HC_{3,5pyr}$), 5.95 (s, 8H, CH_2O), 3.97–3.94 (m, 8H, OCH_2CH_2), 2.08–2.13 (m, 8H, CH_2); ¹³C{¹H} 161.0 (s, *o*- $C_{2,6pyr}$), 139.5 (s, *p*- C_{4pyr}), 125.6 (s, m-C_{3,5pyr}), 72.5 and 69.9 (2 s, CH₂OCH₂), 24.5 (s, CH₂). IR (cm⁻¹, powder film): 2941 (w), 2914 (w), 2856 (m), 1610 (m), 1471 (m), 1370 (m), 1212 (m), 1123 (s), 1108 (s), 984 (s), 803 (s). MS:⁴¹ 617 ([18a - Cl]⁺, 30%), 580 (unknown, 100%).

trans-PtCl₂[2,6,2',6'-(NC₅H₃(CH₂O(CH₂)₆OCH₂)₂H₃C₅N)] (trans-18b). Solutions of trans-17b (0.250 g, 0.328 mmol) in CH_2Cl_2 (160 mL) and of Grubbs' catalyst (0.027 g, 0.0328 mmol, 10 mol %) in CH_2Cl_2 (4 mL) were combined in a procedure similar to that for trans-18a (the resulting solution is 0.002 01 M in trans-17b). After hydrogenation, an analogous workup gave trans-18b as a white solid (0.0501 g, 0.0706 mmol, 22% overall). The sample slightly darkened at 200 °C. DSC $(T_i/T_e/T_p/T_c/T_f)$: 126.7/166.3/170.1/174.7/182.0 °C (endotherm). TGA: onset of mass loss, 231.6 °C. Anal. Calcd for $C_{26}H_{38}Cl_2N_2O_4Pt:$ C, 44.07; H, 5.41; N, 3.95. Found: C, 43.51; H, 5.31; N, 3.66. NMR (δ , CDCl₃): ¹H 7.79 (t, 2H, ³J_{HH} = 7.8 Hz, $p-HC_{4pyr}$), 7.56 (d, 4H, ${}^{3}J_{HH}$ = 7.8 Hz, $m-HC_{3,5pyr}$), 5.90 (s, 8H, CH_2O), 3.89 (t, 8H, ${}^{3}J_{HH} = 6.5$ Hz, OCH_2), 1.92–1.89 (m, 8H, CH_2), 1.70-1.68 (m, 8H, CH_2); ${}^{13}C{}^{1}H{}$ 161.5 (s, $o-C_{2,6pyr}$), 138.9 (s, p-C_{4pyr}), 121.5 (s, m-C_{3,5pyr}), 70.7 and 69.6 (2 s, CH₂OCH₂), 26.1 (s, CH₂), 23.0 (s, CH₂). IR (cm⁻¹, powder film): 2943 (w), 2866 (w),

Organometallics

1614 (m), 1468 (m), 1367 (m), 1213 (w), 1112 (s), 1012 (m), 965 (m), 811 (s). MS: 41 709 (18b⁺, 60%), 673 ([18b - Cl]⁺, 50%), 636 (unknown, 100%).

trans-PtCl₂[3,5-NC₅H₃(COOCH₂CH=CH₂)₂]₂ (trans-19a). A Schlenk flask was charged with 5a (0.790 g, 3.198 mmol), PtCl₂ (0.4051 g, 1.523 mmol), and benzene (15 mL) and fitted with a condenser. The mixture was refluxed with stirring (12 h; after 1 h, a yellow solution had formed) and cooled to room temperature. The solvent was removed by rotary evaporation. The residue was chromatographed on a silica column (20×2 cm, 4/1 v/v hexanes/ ethyl acetate). A single yellow band was collected. The solvent was removed by rotary evaporation. Hexanes was added (15 mL). The residue was collected by filtration, washed with hexanes $(7 \times 2 \text{ mL})$, and dried by oil pump vacuum to give trans-19a as a yellow solid (1.004 g, 1.321 mmol, 87%). Mp (capillary): 178-180 °C. TGA: onset of mass loss, 145.3 °C. Anal. Calcd for C26H26Cl2N2O8Pt: C, 41.06; H, 3.45; N, 3.68. Found: C, 40.65; H, 3.18; N, 3.53. NMR (δ, CDCl₃): ¹H 9.68 (d, 4H, ${}^{4}J_{HH}$ = 1.8 Hz, o-HC_{2,6pyr}), 9.02 (t, 2H, ${}^{4}J_{HH}$ = 1.8 Hz, p- HC_{4pyr}), 6.05 (ddt, 4H, ${}^{3}J_{HHtrans} = 16.9$ Hz, ${}^{3}J_{HHcis} = 10.6$ Hz, ${}^{3}J_{HH} = 6.2$ Hz, CH=), 5.47 (dd, 4H, ${}^{3}J_{HHtrans} = 17.2$ Hz, ${}^{2}J_{HH} = 1.3$ Hz, = CH_EH_Z), 5.39 (dd, 4H, ${}^{3}J_{HHcis} = 10.3 Hz$, ${}^{2}J_{HH} = 1.1 Hz$, $=CH_EH_Z$), 4.92 (dt, 8H, ${}^{3}J_{HH} = 5.9$ Hz, ${}^{4}J_{HH} = 1.2$ Hz, OCH₂); ${}^{13}C{}^{1}H{}$ 162.1 (s, CO), 157.6 (o- $C_{2,6pyr}$), 140.1 (s, p- C_{4pyr}), 130.8 (s, CH=), 128.4 (s, m- $C_{3,5pyr}$), 120.0 (s, =CH₂), 67.1 (s, OCH₂). IR (cm⁻¹, powder film): 3082 (w), 2968 (m), 2895 (m), 1733 (s), 1652 (m), 1598 (m), 1447 (m), 1301 (s), 1251 (s), 1135 (s), 1112 (s), 980 (s), 911 (s), 745 (s). MS:⁴¹ 760 (19a⁺, 20%), 725 ([19a - Cl]⁺, 18%).

trans-PtCl₂[3,5-NC₅H₃(COO(CH₂)₃CH=CH₂)₂]₂ (trans-19c). Pyridine 5c (1.000 g, 3.297 mmol), PtCl₂ (0.400 g, 1.50 mmol), and benzene (33 mL) were combined in a procedure similar to that for trans-19a. An analogous workup gave trans-19c as a yellow solid (1.098 g, 1.258 mmol, 84%). Mp (capillary): 92–94 °C. DSC $(T_i/T_e/$ $T_{\rm p}/T_{\rm c}/T_{\rm f}$: 72.5/95.5/97.6/99.9/133.3 °C (endotherm). TGA: onset of mass loss, 176.3 °C. Anal. Calcd for C34H42Cl2N2O8Pt: C, 46.79; H, 4.85; N, 3.21. Found: C, 46.23; H, 4.56; N, 3.04. NMR (δ , CDCl₃): ¹H 9.68 (d, 4H, ${}^{4}J_{HH}$ = 1.8 Hz, *o*-HC_{2,6pyt}), 8.99 (t, 2H, ${}^{4}J_{HH}$ = 1.8 Hz, *p*-HC_{4pyt}), 5.86 (ddt, 4H, ${}^{3}J_{HHtrans}$ = 17.0 Hz, ${}^{3}J_{HHcis}$ = 10.3 Hz, ${}^{3}J_{HH}$ = 6.7 Hz, CH=), 5.12 (dd, 4H, ${}^{3}J_{HHtrans}$ = 17.2 Hz, ${}^{2}J_{HH}$ = 1.3 Hz, = CH_EH_Z), 5.06 (dd, 4H, ${}^{3}J_{HHcis}$ = 10.3 Hz, ${}^{2}J_{HH}$ = 1.1 Hz, = CH_EH_Z), 4.46 (t, 8H, ³J_{HH} = 6.7 Hz, OCH₂), 2.28-2.23 (m, 8H, CH₂), 1.98-1.91 (m, 8H, CH₂); ¹³C{¹H} 162.0 (s, CO), 157.6 (s, o-C_{2,6pyr}), 140.1 (s, p-C_{4pyr}), 137.0 (s, CH=), 128.5 (s, m-C_{3,5pyr}), 115.8 (s, =CH₂), 66.1 (s, OCH₂), 30.0 (s, CH₂), 27.6 (s, CH₂). IR (cm⁻¹, powder film): 3128 (w), 3082 (w), 2958 (m), 2926 (m), 1722 (s), 1645 (m), 1607 (m), 1447 (s), 1305 (s), 1251 (s), 1112 (s), 981 (s), 911 (s), 742 (s). MS:⁴¹ 872 (19 c^+ , 30%), 836 ([19c - Cl]⁺, 10%), 304 (5 c^+ , 100%).

trans-PtCl₂[3,5-NC₅H₃(COO(CH₂)₄CH=CH₂)₂]₂ (trans-19d). Pyridine 5d (1.002 g, 3.018 mmol), PtCl₂ (0.382 g, 1.437 mmol), and benzene (14 mL) were combined in a procedure similar to that for trans-19a. An analogous workup gave trans-19d as a yellow solid (1.234 g, 1.329 mmol, 92%). Mp (capillary): 74–76 °C. DSC $(T_i/T_e/$ $T_{\rm p}/T_{\rm c}/T_{\rm f}$: 49.4/56.6/58.6/61.8/62.6 °C (endotherm); 63.0/65.7/ 67.3/68.5/68.5 °C (endotherm); 75.5/76.7/79.3/80.8/83.2 °C (endotherm). TGA: onset mass loss, 165.3 °C. Anal. Calcd for C38H50Cl2N2O8Pt: C, 49.14; H, 5.43; N, 3.02. Found: C, 48.69; H, 5.42; N, 2.73. NMR (δ , CDCl₃): ¹H 9.67 (d, 4H, ⁴J_{HH} = 1.8 Hz, o- $HC_{2,6pyr}$), 8.99 (t, 2H, ${}^{4}J_{HH}$ = 1.8 Hz, $p-HC_{4pyr}$), 5.83 (ddt, 4H, ${}^{3}J_{HHtrans}$ = 17.0 Hz, ${}^{3}J_{\text{HHcis}}$ = 10.3 Hz, ${}^{3}J_{\text{HH}}$ = 6.7 Hz, CH=), 5.07 (dd, 4H, ${}^{3}J_{\text{HHrans}}$ = 17.1 Hz, ${}^{2}J_{\text{HH}}$ = 1.9 Hz, = $CH_{E}H_{Z}$), 5.01 (dd, 4H, ${}^{3}J_{\text{HHcis}}$ = 10.2 Hz, ${}^{2}J_{HH}$ = 1.9 Hz, =CH_EH_Z), 4.44 (t, 8H, ${}^{3}J_{HH}$ = 6.7 Hz, OCH2), 2.19-2.13 (m, 8H, CH2), 1.89-1.81 (m, 8H, CH2), 1.61-1.53 (m, 8H, CH₂); ${}^{13}C{}^{1}H{}$ 162.1 (s, CO), 157.5 (s, o-C_{2,6pyr}), 140.0 (s, p-C_{4pyr}), 138.0 (s, CH=), 128.5 (s, m-C_{3,5pyr}), 115.2 (s, =CH₂), 66.6 (s, OCH₂), 33.2, 27.9, and 25.1 (3 s, 3CH₂). IR (cm⁻¹, powder film): 3113 (w), 3075 (w), 2950 (m), 2920 (m), 1730 (s), 1645 (m), 1607 (m), 1452 (s), 1267 (s), 1112 (s), 966 (s), 911 (s), 742 (s). MS:⁴¹ 928 (19d⁺, 30%), 893 ([19d - Cl]⁺, 30%), 332 ([5d + H]⁺, 100%)

trans-PtCl₂[3,5-NC₅H₃(COO(CH₂)₅CH=CH₂)₂]₂ (trans-19e). Pyridine 5e (0.853 g, 2.373 mmol), PtCl₂ (0.300 g, 1.128 mmol), and benzene (11 mL) were combined in a procedure similar to that for trans-19a. An analogous workup gave trans-19e as a yellow solid (1.042 g, 1.058 mmol, 94%). Mp (capillary): 74–76 °C. DSC (T_i/T_e) $T_{\rm p}/T_{\rm c}/T_{\rm f}$: 48.5/52.1/53.6/55.6/57.3 °C (endotherm); 70.4/79.3/ 81.1/82.9/99.8 °C (endotherm). TGA: onset of mass loss, 165.7 °C. Anal. Calcd for C42H58Cl2N2O8Pt: C, 51.22; H, 5.94; N, 2.84. Found: C, 51.71; H, 6.19; N, 2.93. NMR (δ , CDCl₃): ¹H 9.67 (d, 4H, ⁴J_{HH} = 1.8 Hz, o-HC_{2,6pyr}), 8.98 (t, 2H, ${}^{4}J_{\rm HH}$ = 1.8 Hz, p-HC_{4pyr}), 5.83 (ddt, 4H, ${}^{3}J_{\text{HHtrans}} = 17.1 \text{ Hz}$, ${}^{3}J_{\text{HHcis}} = 10.3 \text{ Hz}$, ${}^{3}J_{\text{HH}} = 6.7 \text{ Hz}$, CH=), 5.04 (dd, 4H, ${}^{3}J_{\text{HHtrans}} = 18.1 \text{ Hz}$, ${}^{2}J_{\text{HH}} = 2.5 \text{ Hz}$, = $CH_{E}H_{Z}$), 4.99 (dd, 4H, ${}^{3}J_{\rm HHcis} = 10.2$ Hz, ${}^{2}J_{\rm HH} = 1.2$ Hz, $= CH_{\rm E}H_{\rm Z}$), 4.43 (t, 8H, ${}^{3}J_{\rm HH} = 6.7$ Hz, OCH2), 2.13-2.09 (m, 8H, CH2), 1.88-1.81 (m, 8H, CH2), 1.47-1.50 (m, 16H, CH₂); ¹³C{¹H} 162.1 (s, CO), 157.5 (s, o-C_{2,6pyr}), 140.0 (s, p- C_{4pyr}), 138.5 (s, CH=), 128.6 (s, m- $C_{3,5pyr}$), 114.7 (s, = CH₂), 66.8 (s, OCH₂), 33.5, 28.4, 28.3, and 25.3 (4 s, 4CH₂). IR (cm⁻ , powder film): 3130 (w), 3080 (w), 2926 (m), 2856 (m), 1722 (s), 1447 (m), 1305 (s), 1247 (s), 1127 (s), 984 (s), 907 (s), 741 (s). $MS:^{41} 984 (19e^+, 4\%), 949 ([19e - Cl]^+, 14\%), 360 (5e^+, 100\%).$

trans-PtCl₂[3,5-NC₅H₃(COO(CH₂)₆CH=CH₂)₂]₂ (trans-19f). Pyridine 5f (1.410 g, 3.641 mmol), PtCl₂ (0.440 g, 1.66 mmol), and benzene (15 mL) were combined in a procedure similar to that for trans-19a. An analogous workup gave trans-19f as a yellow solid (0.906 g, 0.870 mmol, 63%). Mp (capillary): 66–68 °C. DSC $(T_i/T_e/T_p/T_c/$ T_f): 60.8/68.5/70.7/72.3/82.7 °C (endotherm). TGA: onset of mass loss, 171.8 °C. Anal. Calcd for C46H66Cl2N2O8Pt: C, 53.07; H, 6.39; N, 2.69. Found: C, 52.62; H, 6.44; N, 2.63. NMR (δ, CDCl₃): ¹H 9.66 (d, 4H, ${}^{4}J_{HH} = 1.8$ Hz, o-HC_{2,6pyr}), 8.98 (t, 2H, ${}^{4}J_{HH} = 1.8$ Hz, p- HC_{4pyr}), 5.82 (ddt, 4H, ${}^{3}J_{HHtrans} = 17.1$ Hz, ${}^{3}J_{HHcis} = 10.2$ Hz, ${}^{3}J_{HH} = 6.8$ Hz, CH=), 5.01 (dd, 4H, ${}^{3}J_{HHtrans} = 17.0$ Hz, ${}^{2}J_{HH} = 2.3$ Hz, = CH_EH_Z), 4.95 (dd, 4H, ${}^{3}J_{HHcis}$ = 10.1 Hz, ${}^{2}J_{HH}$ = 1.1 Hz, $=CH_EH_Z$), 4.43 (t, 8H, ${}^{3}J_{HH} = 6.7$ Hz, OCH₂), 2.09–2.03 (m, 8H, CH₂), 1.83– 1.81 (m, 8H, CH₂), 1.45–1.42 (m, 24H, CH₂); ${}^{13}C{}^{1}H{}^{1}$ 162.1 (s, CO), 157.5 (s, o- $C_{2,6pyr}$), 140.0 (s, p- C_{4pyr}), 138.8 (s, CH=), 128.6 (s, m- $C_{3,5pyr}$), 114.4 (s, = CH_2), 66.8 (s, OCH₂), 33.6, 28.7, 28.6, 28.5, and 25.7 (5 s, 5CH₂). IR (cm⁻¹, powder film): 3127 (w), 3080 (w), 2926 (s), 2856 (m), 1718 (s), 1606 (m), 1447 (s), 1305 (s), 1225 (s), 1127 (s), 968 (s), 911 (s), 741 (s). MS:⁴¹ 1040 (19f⁺, 2%), 1005 ([19f - Cl]⁺, 20%), 388 ([**5f** + H]⁺, 100%).

trans-PtCl₂[3,5-NC₅H₃(COO(CH₂)₈CH=CH₂)₂]₂ (trans-19h). Pyridine 5h (0.652 g, 1.47 mmol), PtCl₂ (0.178 g, 0.668 mmol), and benzene (7 mL) were combined in a procedure similar to that for trans-19a. An analogous workup gave trans-19h as a yellow solid (0.600 g, 0.520 mmol, 78%). Mp (capillary): 68–70 °C. DSC (T_i/T_o/ $T_{\rm p}/T_{\rm c}/T_{\rm f}$): 34.5/39.5/41.6/43.6/47.0 °C (endotherm); 50.6/68.3/ 70.3/72.1/87.2 °C (endotherm). TGA: onset of mass loss, 177.5 °C. Anal. Calcd for $C_{54}H_{82}Cl_2N_2O_8Pt$: C, 56.24; H, 7.17; N, 2.43. Found: C, 55.93; H, 7.12; N, 2.38. NMR (δ , CDCl₃): ¹H 9.66 (d, 4H, ⁴J_{HH} = 1.8 Hz, o-HC_{2,6pyr}), 8.98 (t, 2H, ${}^{4}J_{HH} = 1.8$ Hz, p-HC_{4pyr}), 5.82 (ddt, 4H, ${}^{3}J_{\text{HHtrans}} = 17.0 \text{ Hz}$, ${}^{3}J_{\text{HHcis}} = 10.3 \text{ Hz}$, ${}^{3}J_{\text{HH}} = 6.7 \text{ Hz}$, CH=), 5.00 (dd, 4H, ${}^{3}J_{\text{HHtrans}} = 17.1 \text{ Hz}$, ${}^{2}J_{\text{HH}} = 2.1 \text{ Hz}$, $=CH_{E}H_{Z}$), 4.95 (dd, 4H, ${}^{3}J_{\text{HHcis}} = 10.2 \text{ Hz}, {}^{2}J_{\text{HH}} = 2.1 \text{ Hz}, = CH_{E}H_{Z}), 4.42 \text{ (t, 8H, } {}^{3}J_{\text{HH}} = 6.7$ Hz, OCH2), 2.08-2.04 (m, 8H, CH2), 1.86-1.79 (m, 8H, CH2), 1.45-1.34 (m, 40H, CH₂); ¹³C{¹H} 162.1 (s, CO), 157.4 (s, o-C_{2,6pyr}), 140.1 (s, p- C_{4pyr}), 139.6 (s, CH=), 128.6 (s, m- $C_{3,5pyr}$), 114.6 (s, = CH₂), 67.3 (s, OCH₂), 34.2, 29.9, 29.7, 29.6, 29.4, 28.9, and 26.2 (7 s, 7CH₂). IR (cm⁻¹, powder film): 3127 (w), 3080 (w), 2922 (s), 2853 (m), 1733 (s), 1718 (s), 1606 (m), 1447 (m), 1305 (s), 1262 (s), 1127 (s), 1108 (s), 992 (s), 911 (s), 741 (s). MS:⁴¹ 1152 (19h⁺, 5%), 1117 ($[19h - Cl]^+$, 50%), 444 ($[5h + H]^+$, 100%).

trans- $\dot{PtCl}_2[3,5,3',5'-(NC_5H_3(COO(CH_2)_{10}OCO)_2H_3C_5\dot{N})]$ (trans-20d). A round-bottom flask was charged with trans-19d (0.250 g, 0.269 mmol) and CH₂Cl₂ (130 mL), fitted with a condenser, and flushed with N₂. A solution of Grubbs' catalyst (0.0220 g, 0.0269 mmol, 10 mol %) in CH₂Cl₂ (4 mL) was added dropwise over 30 min with stirring (the resulting solution is 0.002 01 M in trans-19d). The mixture was refluxed (24 h) and cooled to room temperature. The solvent was removed by rotary evaporation. The residue was chromatographed on an alumina column (20 × 2 cm, CH₂Cl₂). A single yellow band was collected. The solvent was removed by rotary evaporation and oil pump vacuum. A round-bottom flask was charged with the crude metathesis product, 10% Pd/C (0.0343 g, 0.0322 mmol of Pd), toluene (10 mL), and ethanol (10 mL), flushed with H₂, and fitted with a balloon of H_2 (1.0 atm). The mixture was stirred (3 days) and passed through a pad of Celite (7 \times 2 cm, CH₂Cl₂). The filtrate was concentrated by oil pump vacuum (to ca. 1 mL), carefully layered with hexanes (20 mL), and kept at -4 °C. After 24 h, the supernatant was carefully decanted, and the precipitate was dried by oil pump vacuum to give trans-20d as a pale yellow solid (0.0469 g, 0.0535 mmol, 20%). The sample slightly darkened at 190 °C. DSC $(T_i/T_e/$ $T_{\rm p}/T_{\rm c}/T_{\rm f}$): 159.5/167.8/194.6/201.7/209.4 °C (endotherm). TGA: onset of mass loss, 253.2 °C. Anal. Calcd for C34H46Cl2N2O8Pt: C, 46.58; H, 5.29; N, 3.20. Found: C, 45.75; H, 5.41; N, 3.09.⁴⁵ NMR (δ, $CDCl_3$): ¹H 9.68 (d, 4H, ⁴ J_{HH} = 1.8 Hz, *o*-HC_{2,6pyr}), 9.12 (t, 2H, ⁴ J_{HH} = 1.8 Hz, p-HC_{4pyr}), 4.44 (t, 8H, ${}^{3}J_{HH} = 5.8$ Hz, OCH₂), 1.87–1.81 (m, 8H, CH_2), 1.71–1.63 (m, 8H, CH_2), 1.54–1.47 (m, 16H, CH_2); ¹³C{¹H} 162.1 (s, CO), 157.1 (s, $o-C_{2,6pyr}$), 141.0 (s, $p-C_{4pyr}$), 128.6 (s, C3,5pyr), 67.2 (s, OCH2), 29.3, 28.6, 28.5, and 26.5 (4 s, 4CH2). IR (cm⁻¹, powder film): 3074 (w), 2935 (m), 2850 (m), 1738 (s), 1599 (w), 1460 (w), 1390 (w), 1267 (s), 1104 (m), 1004 (m), 958 (s), 749 (s). MS:⁴¹ 876 ($20d^+$, 30%), 840 ([20d - Cl]⁺, 60%), 817 (unknown, 100%).

trans-PtCl₂[3,5,3',5'-(NC₅H₃(COO(CH₂)₁₂OCO)₂H₃C₅N)] (trans-**20e).** Solutions of *trans*-**19e** (0.250 g, 0.253 mmol) in CH₂Cl₂ (120 mL) and of Grubbs' catalyst (0.021 g, 0.0253 mmol, 10 mol %) in CH₂Cl₂ (5 mL) were combined in a procedure similar to that for trans-20d (the resulting solution is 0.002 02 M in trans-19e). After hydrogenation, an analogous workup gave trans-20e as a light yellow solid (0.105 g, 0.113 mmol, 45%). Mp (capillary): 214-216 °C. DSC $(T_i/T_e/T_p/T_c/T_f)$: 63.5/63.5/69.8/74.0/74.0 °C (endotherm); 75.0/ 80.4/86.8/91.8/101.0 °C (endotherm); 208.8/213.9/223.9/229.5/ 229.5 °C (endotherm). TGA: onset of mass loss, 220.3 °C. Anal. Calcd for C38H54Cl2N2O8Pt: C, 48.92; H, 5.84; N, 3.00. Found: C, 48.52; H, 5.83; N, 3.00. NMR (δ , CDCl₃): ¹H 9.66 (d, 4H, ⁴J_{HH} = 1.8 Hz, o-HC_{2,6pyr}), 9.12 (t, 2H, ${}^{4}J_{HH} = 1.8$ Hz, p-HC_{4pyr}), 4.45 (t, 8H, ${}^{3}J_{HH} = 5.9$ Hz, OCH₂), 1.82–1.89 (m, 8H, CH₂), 1.60–1.53 (m, 8H, CH₂), 1.48–1.40 (m, 24H, CH₂); ¹³C{¹H} 162.1 (s, CO), 157.0 (s, o-C_{2,6pyr}), 141.2 (s, *p*-C_{4pyr}), 128.9 (s, *m*-C_{3,5pyr}), 67.1 (s, OCH₂), 29.0, 28.6, 28.4, 28.3, and 26.3 (5 s, 5CH₂). IR (cm⁻¹, powder film): 3084 (w), 3061(w), 2926 (m), 2853 (m), 1737 (s), 1463 (w), 1444 (w), 1266 (s), 1243 (s), 1112 (m), 1046 (m), 965 (m), 748 (s), 687 (m). MS:⁴¹ 932 (20e⁺, 100%), 897 ([20e - Cl]⁺, 80%), 859 (unknown, 70%).

trans-PtCl₂[3,5,3',5'-(NC₅H₃(COO(CH₂)₁₄OCO)₂H₃C₅N)] (trans-20f). Solutions of trans-19f (0.250 g, 0.240 mmol) in CH₂Cl₂ (115 mL) and of Grubbs' catalyst (0.0197 g, 0.024 mmol, 10 mol %) in CH_2Cl_2 (5 mL) were combined in a procedure similar to that for trans-20d (the resulting solution is 0.002 00 M in trans-19f). After hydrogenation, an analogous workup gave trans-20f as a light yellow solid (0.0420 g, 0.0425 mmol, 18% overall). Mp (capillary): 150-152 °C. DSC $(T_i/T_e/T_p/T_c/T_f)$: 137.1/146.0/152.4/154.3/154.3 °C (endotherm). TGA: onset of mass loss, 217.6 °C. Anal. Calcd for $C_{42}H_{62}Cl_2N_2O_8Pt:$ C, 51.01; H, 6.32; N, 2.83. Found: C, 49.52, H, 5.78; N, 2.74. NMR (δ , CDCl₃): ¹H 9.65 (d, 4H, ⁴J_{HH} = 1.8 Hz, o- $HC_{2,6pyr}$), 9.10 (t, 2H, ${}^{4}J_{HH}$ = 1.8 Hz, p-HC_{4pyr}), 4.46 (t, 8H, ${}^{3}J_{HH}$ = 5.9 Hz, OCH_2), 1.83–1.81 (m, 8H, CH_2), 1.45–1.40 (m, 40H, CH_2); $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ 162.1 (s, CO), 157.2 (s, o-C_{2,6pyr}), 141.0 (s, p-C_{4pyr}), 128.9 (s, m-C3,5pyr), 66.9 (s, OCH2), 28.9, 28.8, 28.7, 28.6, 28.4, and 25.8 (6 s, 6CH₂). IR (cm⁻¹, powder film): 3127 (w), 3107 (w), 2922 (s), 2853 (m), 1718 (s), 1606 (m), 1447 (m), 1305 (s), 1258 (s), 1108 (s), 799 (s), 741 (s), 683 (s). MS:⁴¹ 988 (**20f**⁺, 50%), 953 ([**20f** - Cl]⁺, 30%), 915 (unknown, 100%).

trans-PtCl₂[3,5,3',5'-(NC₅H₃(COO(CH₂)₁₈OCO)₂H₃C₅N)] (trans-20h). Solutions of trans-19h (0.230 g, 0.20 mmol) in CH₂Cl₂ (95 mL) and of Grubbs' catalyst (0.0248 g, 0.0301 mmol, 15 mol %) in CH₂Cl₂ (5 mL) were combined in a procedure similar to that for trans-19d (the resulting solution is 0.002 00 M in trans-19h). After hydrogenation, an analogous workup gave trans-20h as a light yellow solid (0.0301 g, 0.0272 mmol, 14% overall). Mp (capillary): 182–184 °C. DSC ($T_i/T_e/T_p/T_c/T_f$): 143.5/178.9/187.0/190.3/192.2 °C (endotherm). TGA: onset of mass loss, 202 °C. Anal. Calcd for $C_{50}H_{78}Cl_2N_2O_8Pt$: C, 54.54; H, 7.14; N, 2.54. Found: C, 54.13; H, 7.08; N, 2.33. NMR (δ , CDCl₃): ¹H 9.65 (d, 4H, ⁴J_{HH} = 1.8 Hz, *o*-HC_{2,6pyr}), 9.10 (t, 2H, ⁴J_{HH} = 1.8 Hz, *p*-HC_{4pyr}), 4.45 (t, 8H, ³J_{HH} = 5.9 Hz, OCH₂), 1.85– 1.82 (m, 8H, CH₂), 1.45–1.29 (m, 56H, CH₂); ¹³C{¹H} 162.2 (s, CO), 157.1 (s, *o*-C_{2,6pyr}), 141.6 (s, *p*-C_{4pyr}), 128.8 (s, *m*-C_{3,5pyr}), 66.9 (s, OCH₂), 29.2, 29.0, 28.9, 28.7, 28.5, 27.8, 26.8, and 25.6 (8 s, 8CH₂). IR (cm⁻¹, powder film): 3080 (w), 2926 (s), 2853 (m), 1737 (s), 1598 (m), 1459 (m), 1266 (s), 1243 (s), 1162 (s), 1112 (s), 973 (s), 930 (s), 749 (s), 683 (s). MS:⁴¹ 1101 (**20h**⁺, 25%), 1066 [**20h** – Cl]⁺, 35%), 1027 (unknown, 10%).

trans-PtCl₂(3,5-NC₅H₃(4-C₆H₄O(CH₂)₅CH=CH₂)₂)₂ (trans-22). PtCl₂ (0.0162 g, 0.0609 mmol) and 8 (0.0570 g, 0.125 mmol) were combined in a procedure similar to that for trans-10a. An analogous workup gave trans-22 as a light yellow solid (0.0687 g, 0.0584 mmol, 96%). Mp (capillary): 190–192 °C. Anal. Calcd for $C_{62}H_{74}Cl_2N_2O_4Pt$: C, 63.25; H, 6.34; N, 2.38. Found: C, 62.59; H, 6.31; N, 2.30.45 NMR (δ , CDCl₃): ¹H 9.01 (d, 4H, ⁴J_{HH} = 1.8 Hz, o-HC_{2,6pyr}), 8.00 (t, 2H, ${}^{4}J_{\rm HH}$ = 1.8 Hz, *p*-HC_{4pyr}), 7.57 and 7.01 (2 m, 2 × 8H, pyr-CCH and $C_{pyr}CCHCH$), 5.88–5.79 (ddt, 4H, ${}^{3}J_{HHtrans} = 17.0$ Hz, ${}^{3}J_{HHcis} = 10.1$ $Hz, {}^{3}J_{HH} = 6.4 Hz, CH=$), 5.06–4.94 (m, 8H, =CH₂), 4.02 (t, 8H, ${}^{3}J_{HH} = 6.4 \text{ Hz}, \text{ OCH}_{2}$, 2.11 (m, 8H, CH₂CH=CH₂), 1.83 (m, 8H, OCH₂CH₂), 1.50 (m, 16H, CH₂); ¹³C{¹H} 160.2 (s, COCH₂), 149.6 $(s, o-C_{2.6pyr})$, 139.0 $(s, =CH_2)$, 138.4 $(s, m-C_{3.5pyr})$, 133.9 $(s, p-C_{4pyr})$, 128.7 (s, pyr-C(CH)₂), 128.0 (s, pyr-C(CH)₂), 115.5 (s, (CH)₂CO), 114.7 (s, CH=), 68.3 (s, $C_6H_4OCH_2$), 33.9, 29.3, 28.8, 25.7 (4 s, 4CH₂). IR (cm⁻¹, powder film): 3074 (w), 2930 (m), 2857 (m), 1607 (s), 1512 (s), 1449 (s), 1287 (s), 1240 (s), 1180 (s), 995 (m), 908 (s), 823 (s), 696 (m).

trans- $\dot{P}tCl_{2}[3,5,3',5'-(NC_{5}H_{3}(4-C_{6}H_{4}O(CH_{2})_{12}O-4-C_{6}H_{4})_{2}H_{3}C_{5}\dot{N})]$ (trans-23). Grubbs' catalyst (0.0287 g, 0.0349 mmol, 15 mol %), trans-22 (0.2737 g. 0.2325 mmol), and Pd/C (10% w/w; three hydrogenation cycles using 0.0203, 0.0217, and 0.0217 g or 0.0599 mmol of Pd, 26 mol %) were combined in a procedure similar to that for trans-11a. An analogous workup gave trans-23 as a yellow solid (0.1036 g, 0.09207 mmol, 40%). Mp (capillary): 198-204 °C dec. Anal. Calcd for C₅₈H₇₀Cl ₂N₂O₄Pt: C, 61.91; H, 6.27; N, 2.49. Found: C, 60.58; H, 6.07; N, 2.42. ⁴⁵ NMR (δ , CDCl₃): ¹H 8.83 (d, 4H, ⁴J_{HH} = 2.0 Hz, o- $HC_{2,6pyr}$), 7.96 (t, 2H, ${}^{4}J_{HH}$ = 2.0 Hz, *p*-HC ${}_{4pyr}$), 7.48 and 6.97 (2 m, 2 × 8H, pyr-CCH and C_{pyr}CCHCH), 4.05 (t, 8H, ${}^{3}J_{HH}$ = 6.9 Hz, OCH₂), 1.86–1.76 (m, 8H, OCH₂CH₂), 1.54–1.44 (m, 8H, CH₂), 1.44–1.28 (m, 24H, CH_2); ¹³C{¹H} 160.1 (s, $COCH_2$), 149.2 (s, o- $C_{2,6pyr}$), 137.7 (s, m-C $_{3,5pyr}$), 133.1 (s, p-C $_{4pyr}$), 128.7 (s, pyr-C(CH)₂), 127.5 (s, pyr-C(CH)₂), 115.4 (s, (CH)₂CO), 68.2 (s, C₆H₄OCH₂), 29.2, 29.1, 29.0 (2×), and 25.8 (4 s, 5CH₂). IR (cm⁻¹, powder film): 2924 (s), 2853 (m), 2359 (w), 1607 (s), 1512 (s), 1449 (s), 1287 (s), 1240 (s), 1180 (s), 1028 (m), 824 (s), 698 (m).

trans-PtCl(CH₃)[3-NC₅H₄(CH₂O(CH₂)₂CH=CH₂)]₂ (trans-24b). A round-bottom flask was charged with trans-12b (0.6121 g, 1.033 mmol) and diethyl ether (15 mL) in an argon glovebox. Then CH₃MgBr (2.94 M in ether; 0.86 mL, 2.5 mmol) was added with stirring. After 2 h, saturated aqueous NH₄Cl (5 mL), water (45 mL), and diethyl ether (35 mL) were added, and the phases were separated. The water layer was extracted with diethyl ether $(2 \times 50 \text{ mL})$. The combined ethereal layers were dried (MgSO₄). The solvent was removed by oil pump vacuum. The residue was chromatographed on a silica column (39 × 2.5 cm, 1/4 v/v ethyl acetate/CH₂Cl₂) to give trans-24b as a white solid (0.5549 g, 0.9701 mmol, 94%). NMR (δ , CDCl₃): ¹H 8.89 (m, 2H, o-HC_{2pyr}), 8.85 (m, 2H, o-HC_{6pyr}), 7.74 (m, 2H, p-HC_{4pyr}), 7.23 (m, 2H, m-HC_{5pyr}), 5.90–5.76 (ddt, 2H, ${}^{3}J_{HHtrans}$ = 17.0 Hz, ${}^{3}J_{HHcis}^{-}$ = 10.2 Hz, ${}^{3}J_{HH}$ = 6.6 Hz, CH=), 5.15–5.03 (m, 4H, = CH_2), 4.52 (s, 4H, CH_2O), 3.56 (t, 4H, ${}^{3}J_{HH} = 6.6$ Hz, OCH_2CH_2), 2.39 (apparent qt, 4H, ${}^{3}J_{HH} = 6.6$ Hz, ${}^{4}J_{HH} = 1.4$ Hz, $CH_{2}CH=CH_{2}$), 0.87 (s, 3H, PtCH₃); ${}^{13}C{}^{1}H$ NMR 153.1 and 152.9 (2 s, o-C_{2pyr} and $o-C_{6pyr}$), 136.5 (s, CH=), 136.1 (s, $p-C_{4pyr}$), 135.0 (s, $m-C_{3pyr}$), 125.2 $(s, m-C_{\text{5pyr}}), 117.0 \ (s, =CH_2), 70.5 \ (s, CH_2O), 69.4 \ (s, OCH_2CH_2),$ 34.3 (s, CH_2), -6.6 (s, $PtCH_3$).

trans-PtCl(CH₃)[3-NC₅H₄(CH₂O(CH₂)₈CH=CH₂)]₂ (trans-24h). CH₃MgBr (2.94 M in diethyl ether; 1.50 mL, 4.41 mmol) and *trans*-12h (0.9494 g, 1.248 mmol) were combined in a procedure similar to that for *trans*-24b. An analogous workup gave *trans*-24h as a white waxy solid (0.6175 g, 0.8341 mmol, 67%). NMR (δ , CDCl₃): ¹H 8.89 (m, 2H, *o*-HC_{2pyr}), 8.86 (m, 2H, *o*-HC_{6pyr}), 7.75 (m, 2H, *p*-HC_{4pyr}), 7.24 (m, 2H, *m*-HC_{5pyr}), 5.87–5.74 (ddt, 2H, ³J_{HHtrans} = 17.0 Hz, ³J_{HHts} = 10.4 Hz, ³J_{HH} = 6.6 Hz, CH=), 4.94 (m, 4H, =CH₂), 4.50 (s, 4H, CH₂O), 3.49 (t, 4H, ³J_{HH} = 6.6 Hz, OCH₂CH₂), 2.03 (m, 4H, CH₂CH=CH₂), 1.62 (m, 4H, OCH₂CH₂), 1.42–1.26 (m, 20H, CH₂), 0.88 (s, 3H, PtCH₃); ¹³C{¹H} 153.0 and 152.9 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 139.4 (s, CH=), 136.7 (s, *p*-C_{4pyr}), 136.1 (s, *m*-C_{3pyr}), 125.1 (s, *m*-C_{5pyr}), 114.3 (s, =CH₂), 71.5 (s, CH₂O), 69.4 (s, OCH₂CH₂), 34.0, 29.8, 29.6 (2×), 29.3, 29.1, and 26.3 (6 s, 7CH₂), -6.6 (s, PtCH₃).

trans-PtCl(CH₃)[3,3'-(NC₅H₄(CH₂O(CH₂)₁₀OCH₂)H₄C₅Ň)] (*trans*-25d). CH₃MgBr (2.94 M in diethyl ether; 0.33 mL, 0.97 mmol) and *trans*-13d (0.2038 m, 0.3274 mmol) were combined in a procedure similar to that for *trans*-24b. An analogous workup gave *trans*-25d as a white solid (0.1273 g, 0.2114 mmol, 65%). NMR (δ , CDCl₃): ¹H 9.06 (m, 2H, *o*-HC_{2pyr}), 8.94 (m, 2H, *o*-HC_{6pyr}), 7.51 (m, 2H, *p*-HC_{4pyr}), 7.19 (m, 2H, *m*-HC_{5pyr}), 4.52 (s, 4H, CH₂O), 3.55 (t, 4H, ³J_{HH} = 5.5 Hz, OCH₂CH₂), 1.64 (m, 4H, OCH₂CH₂), 1.54 (m, 4H, CH₂), 1.39 (m, 8H, CH₂), 0.93 (s, 3H, PtCH₃); ¹³C{¹H} 153.6 and 152.7 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 136.7 (s, *p*-C_{4pyr}), 135.2 (s, *m*-C_{3pyr}), 124.5 (s, *m*-C_{5pyr}), 71.2 (s, CH₂O), 69.8 (s, OCH₂CH₂), 30.2, 29.9, 29.6, 26.7 (4 s, 4CH₂), -6.4 (s, PtCH₃).

trans-**P**tCl(CH₃)[3,3'-(NC₅H₄(CH₂O(CH₂)₁₈OCH₂)H₄C₅N)] (*trans*-25h). CH₃MgBr (2.94 M in ether; 0.28 mL, 0.82 mmol) and *trans*-13h (0.2034 g, 0.2768 mmol) were combined in a procedure similar to that for *trans*-24b. An analogous workup gave *trans*-25h as an off-white solid (0.0815 g, 0.114 mmol, 41%). NMR (δ , CDCl₃): ¹H 8.97 (m, 2H, *o*-HC_{2pyr}), 8.91 (m, 2H, *o*-HC_{6pyr}), 7.68 (m, 2H, *p*-HC_{4pyr}), 7.22 (m, 2H, *m*-HC_{5pyr}), 4.50 (s, 4H, CH₂O), 3.50 (t, 4H, ³J_{HH} = 6.4 Hz, OCH₂CH₂), 1.63 (m, 4H, OCH₂CH₂), 1.40–1.22 (m, 28H, CH₂), 0.91 (s, 3H, PtCH₃); ¹³C{¹H} 153.3 and 153.2 (2 s, *o*-C_{2pyr} and *o*-C_{6pyr}), 136.6 (s, *p*-C_{4pyr}), 136.2 (s, *m*-C_{3pyr}), 125.0 (s, *m*-C_{5pyr}), 71.3 (s, CH₂O), 69.7 (s, OCH₂CH₂), 29.6, 29.45, 29.44, 29.41, 29.38, 29.37, 29.25, 26.1 (8 s, 8CH₂), -6.5 (PtCH₃).

trans-Pt(Cl)(C \equiv CPh)[3,5-NC₅H₃(COO(CH₂)₃CH=CH₂)₂]₂ (trans-26c). A round-bottom flask was charged with trans-19c (0.124 g, 0.142 mmol), CuI (0.0027 g, 0.014 mmol), and CH₂Cl₂/*i*-Pr₂NH (10/1 v/v, 12 mL) with stirring. Then PhC=CH (0.0207 g, 0.199 mmol) in CH₂Cl₂/*i*-Pr₂NH (2 mL) was added dropwise over 5 min. The flask was fitted with a condenser. The solution was refluxed (3 days) and cooled to room temperature. The solvents were removed by rotary evaporation and oil pump vacuum. The residue was chromatographed on a silica column (25×2 cm, gradient elution, 8/2to 0/10 v/v hexanes/ethyl acetate). The solvents were removed from the product-containing fractions by rotary evaporation and oil pump vacuum. The residue was dissolved in CH2Cl2 (ca. 1 mL) and carefully layered with hexanes (20 mL). The sample was kept at -4 °C. After 24 h, the supernatant was decanted and the precipitate dried by oil pump vacuum to give trans-26c as a pale yellow solid (0.0245 g, 0.0261 mmol, 18%). NMR (δ , CDCl₃): ¹H 9.96 (d, 4H, ⁴J_{HH} = 1.9 Hz, o- $HC_{2,6pyr}$), 9.01 (t, 2H, ${}^{4}J_{HH}$ = 1.9 Hz, $p-HC_{4pyr}$), 7.24–7.13 (m, 5H, Ph), 5.85 (ddt, 4H, ${}^{3}J_{HHT}$ = 17.1 Hz, ${}^{3}J_{HHcis}$ = 10.3 Hz, ${}^{3}J_{HH}$ = 6.7 Hz, CH=), 5.08 (dd, 4H, ${}^{3}J_{HHtrans}$ = 17.1 Hz, ${}^{3}J_{HHcis}$ = 10.3 Hz, ${}^{3}J_{HH}$ = 6.7 Hz, CH=), 5.08 (dd, 4H, ${}^{3}J_{HHtrans}$ = 17.1 Hz, ${}^{2}J_{HH}$ = 1.9 Hz, = CH_EH_Z), 5.02 (dd, 4H, ${}^{3}J_{HHcis}$ = 10.3 Hz, ${}^{2}J_{HH}$ = 1.9 Hz, =CH_EH_Z), 4.43 (t, 8H, ${}^{3}J_{HH}$ = 6.6 Hz, OCH₂), 2.25–2.20 (m, 8H, CH₂), 1.94– 1.87 (m, 8H, CH_2); ¹³C{¹H} 162.7 (s, CO), 158.6 (s, o- $C_{2,6pyr}$), 140.1 (s, p- C_{4pyr}), 137.7 (s, CH=), 132.1 (s, o- C_{Ph}), 128.9 (s, $C_{3,5pyr}$), 128.3 $(s, p-C_{Ph})$, 127.2 $(s, m-C_{Ph})$, 126.5 $(s, i-C_{Ph})$, 115.7 $(s, =CH_2)$, 94.0 and 85.0 (2 s, $C \equiv C$), 66.4 (s, OCH_2), 30.4 (s, CH_2), 28.1 (s, CH_2). IR (cm⁻¹, powder film): 3076 (w), 2961 (w), 2907 (w), 2351 (m), 2131 (m, $\nu_{C=C}$), 1725 (s), 1640 (m), 1598 (m), 1444 (m), 1305 (s), 1262 (s), 1239 (s), 1112 (s), 984 (s), 911 (s), 741 (s). MS:⁴¹ 938 (26c⁺, 100%

trans-Rh(Cl)(CO)[2,6-NC₅H₃(CH₂OCH₂CH=CH₂)₂]₂ (trans-27a). A Schlenk flask was charged with $[RhCl(coe)_2]_2$ (0.430 g, 0.599 mmol) and methanol/toluene (1/1 v/v, 22 mL). A solution of 4a

(0.564 g, 2.58 mmol) in methanol/toluene (1/1 v/v, 4 mL) was added dropwise over 10 min with stirring. The flask was fitted with a condenser. The mixture was refluxed (2 h), cooled to room temperature, and filtered under N2. The orange solution was aspirated with CO (1 h). The solvents were removed by oil pump vacuum, and the residue was chromatographed on a silica column (10×2 cm, 4/1 v/v hexanes/ethyl acetate). An orange band was collected. The solvents were removed by rotary evaporation and oil pump vacuum. The residue was dissolved in CH₂Cl₂ (ca. 1 mL). The solution was layered with pentane (20 mL) and kept at -4 °C. After 24 h, the supernatant was carefully decanted, and the precipitate was dried by oil pump vacuum to give trans-27a as a light orange solid (0.090 g, 0.149 mmol, 26%). Mp (capillary): 106–108 °C. ĎSC $(T_i/T_e/T_p/T_c/T_f)$: 79.2/ 102.6/106.5/109.1/114.8 °C (endotherm). TGA: onset of mass loss, 114.7 °C. NMR (δ , CDCl₃): ¹H 7.81 (t, 2H, ³ J_{HH} = 7.8 Hz, $p-HC_{4pyr}$), 7.59 (d, 4H, ${}^{3}J_{HH}$ = 7.8 Hz, $m-HC_{3,5pyr}$), 6.08 (ddt, 4H, ${}^{3}J_{\text{HHtrans}} = 17.2 \text{ Hz}, {}^{3}J_{\text{HHcis}} = 10.6 \text{ Hz}, {}^{3}J_{\text{HH}} = 5.4 \text{ Hz}, \text{ CH}$, 5.76 (d, 4H, ${}^{4}J_{RhH}$ = 15.0 Hz, 4CHH'O), 5.64 (d, 4H, ${}^{4}J_{RhH}$ = 15.0 Hz, 4CHH'O), 5.46 (dd, 4H, ${}^{3}J_{HHtrans} = 17.2$ Hz, ${}^{2}J_{HH} = 1.6$ Hz, = CH_EH_Z), 5.33 (dd, 4H, ${}^{3}J_{HHcis} = 10.4 Hz$, ${}^{2}J_{HH} = 1.5 Hz$, $=CH_EH_Z$), 4.29 (dt, 8H, ${}^{3}J_{HH} = 5.5 Hz$, ${}^{4}J_{HH} = 1.4 Hz$, OCH_2); ${}^{13}C{}^{1}H{}$ 183.6 (d, ${}^{1}J_{\text{RhC}} = 70.3 \text{ Hz, CO}, 162.2 \text{ (s, } o-C_{2,6\text{pyr}}), 138.0 \text{ (s, } p-C_{4\text{pyr}}), 134.1 \text{ (s, } CH=), 121.5 \text{ (s, } m-C_{3\text{pyr}}), 117.7 \text{ (s, } =CH_{2}), 73.4 \text{ and } 72.1 \text{ (2 s, } CH=0.1 \text{ N})$ CH₂OCH₂). IR (cm⁻¹, powder film): 3088 (w), 3015 (w), 2860 (m), 2837 (w), 1945 (s, $\nu_{\rm CO}$), 1610 (m), 1583 (w), 1471 (m), 1332 (m), 1239 (w), 1116 (s), 1007 (s), 988 (m), 787 (s). MS:⁴¹ 576 ([27a – $CO]^+$, 40%), 569 ([27a - Cl]⁺, 20%), 321 ([27a - 4a - 2Cl]⁺, 100%), 220 ($[4a + H]^+$, 30%).

Crystallography. A. trans-11b. A saturated CH_2Cl_2 solution was layered with ethyl acetate. After one day, the yellow plates were taken to a Bruker APEX2 X-ray diffractometer for data collection as outlined in Table S1 (Supporting Information). Cell parameters were obtained from 36 frames using a 0.5° scan and refined with 17 016 reflections. Integrated intensity information for each reflection was obtained by reduction of the data frames with the program suite APEX2.⁴⁶ Lorentz, polarization, and absorption corrections⁴⁷ were applied. The space group was determined from systematic reflection conditions and statistical tests. The structure was solved by direct methods using SHELXTL (SHELXS).⁴⁸ Non-hydrogen atoms were refined with anisotropic thermal parameters. The hydrogen atoms were placed in idealized positions. The parameters were refined by weighted least-squares refinement on F^2 to convergence.⁴⁸

B. trans-13*d.* A saturated CH_2Cl_2 solution was layered with ethyl acetate. After 1 day, the yellow plates were analyzed as described for *trans*-11b (cell parameters from 36 frames using a 0.5° scan; refined with 24 911 reflections). The structure was solved and refined as for *trans*-11b. Two independent molecules were found in the unit cell. Both exhibited disordered methylene groups (two in one molecule, 80:20 occupancies; six in the other, (70–50):(30–50) occupancies), which were treated by restraining the bond lengths and angles to idealized values. In the final stages of refinement, additional electron density not associated with either molecule was observed and tentatively assigned to a disordered CH_2Cl_2 molecule (occupancy ca. 50%). After many attempts to model the disorder, the electron density contribution was extracted with the program PLATON/SQUEEZE.⁴⁹

C. trans-13h. A saturated CH_2Cl_2 solution was layered with ethyl acetate. After 1 day, yellow plates of the solvate *trans-13h*· CH_2Cl_2 were analyzed as described for *trans-11b* (cell parameters from 36 frames using a 0.5° scan; refined with 14 813 reflections). The structure was solved and refined as for *trans-11b*.

D. trans-17a. A concentrated CH_2Cl_2 solution was layered with hexanes. After 7 days, the yellow blocks were taken directly to a Nonius KappaCCD area detector for data collection as outlined in Table S2 (Supporting Information). Cell parameters were obtained from 10 frames using a 10° scan and refined with 1788 reflections. Lorentz, polarization, and absorption corrections⁵⁰ were applied. The space group was determined from systematic absences and subsequent least-squares refinement. The structure was solved by

direct methods. The parameters were refined with all data by fullmatrix least squares on F^2 using SHELXL-97.⁵¹ Non-hydrogen atoms were refined with anisotropic thermal parameters. The hydrogen atoms were fixed in idealized positions using a riding model. The complex exhibited a 2-fold symmetry axis containing the N–Pt–N vector and an orthogonal mirror plane containing the Cl–Pt–Cl vector. The data indicated some disorder at C3, but this could not be resolved. Scattering factors were taken from the literature.⁵²

E. trans-**18a**. A concentrated CHCl₃ solution was layered with hexanes. After 3 days, the pale yellow blocks were analyzed as described for *trans*-**17a** (cell parameters from 10 frames using a 10° scan; refined with 2487 reflections). The structure was solved and refined as for *trans*-**17a**. The structure exhibited an inversion center at platinum.

F. trans-18b. A concentrated CHCl₃ solution was layered with hexanes. The sample was kept at -4 °C. After 3 days, the yellow needles were analyzed as described for *trans-17a* (cell parameters from 10 frames using a 10° scan; refined with 2898 reflections). The structure was solved and refined as for *trans-17a*. Three atoms were disordered, which were refined to an 81:19 occupancy ratio (C7/C8/O9 and C7'/C8'/O9'). The structure exhibited an inversion center at platinum.

G. trans-20e. A concentrated CHCl₃ solution was layered with hexanes. The sample was kept at -20 °C. After 7 days, the light yellow blocks of the solvate *trans-20e*·2CHCl₃ were analyzed as described for *trans-17a* (cell parameters from 10 frames using a 10° scan; refined with 10 662 reflections). The structure was solved and refined as for *trans-17a*. Several sets of atoms were disordered, which were refined to 66:34 (C44/C44'), 65:35 (C53/C53'), and 73:27 (C65/C65') occupancy ratios. Large atomic displacement factors for C46–C52 indicated additional disorder, which could not be resolved.

H. trans-16. A concentrated CHCl₃ solution of *trans*-16 was layered with hexanes. After 7 days, the yellow blocks were analyzed as described for *trans*-17a (cell parameters from 10 frames using a 10° scan; refined with 2337 reflections). The structure was solved and refined as for *trans*-17a. The structure exhibited an inversion center at palladium.

ASSOCIATED CONTENT

S Supporting Information

Text giving details of the reactions with Grubbs' secondgeneration catalyst and tables of crystallographic data and CIF files for the complexes in Table 1. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel: 979-845-1399. E-mail: gladysz@mail.chem.tamu.edu.

Author Contributions

[§]Both co-workers contributed equally to the experimental work. **Notes**

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the U.S. National Science Foundation (No. CHE-0719267), the Deutsche Forschungsgemeinschaft (DFG, GL 300/9-1), and Johnson Matthey PMC (precious metal loans) for support.

DEDICATION

This article is dedicated with admiration and affection to the memory of our Texas neighbor, Professor F. G. A. Stone.

REFERENCES

(1) Skopek, K.; Hershberger, M. C.; Gladysz, J. A. Coord. Chem. Rev. 2007, 251, 1723.

(2) Khuong, T.-A. V.; Nunez, J. E.; Godinez, C. E.; Garcia-Garibay, M. A. Acc. Chem. Res. 2006, 39, 413.

(3) Additional literature subsequent to ref 2: (a) Khuong, T.-A. V.; Dang, H.; Jarowski, P. D.; Maverick, E. F.; Garcia-Garibay, M. A. J. Am. Chem. Soc. 2007, 129, 839. (b) Nunez, J. E.; Natarajan, A.; Khan, S. I.; Garcia-Garibay, M. A. Org. Lett. 2007, 9, 3559. (c) Garcia-Garibay, M. A.; Godinez, C. E. Cryst. Growth Des. 2009, 9, 3124. (d) O'Brien, Z. J.; Natarajan, A.; Khan, S.; Garcia-Garibay, M. A. Cryst. Growth Des. 2011, 11, 2654.

(4) Shima, T.; Hampel, F.; Gladysz, J. A. Angew. Chem., Int. Ed. 2004, 43, 5537; Angew. Chem. 2004, 116, 5653.

(5) Nawara, A. J.; Shima, T.; Hampel, F.; Gladysz, J. A. J. Am. Chem. Soc. 2006, 128, 4962.

(6) Wang, L.; Hampel, F.; Gladysz, J. A. Angew. Chem., Int. Ed. 2006, 45, 4372; Angew. Chem. 2006, 118, 4479.

(7) Wang, L.; Shima, T.; Hampel, F.; Gladysz, J. A. Chem. Commun. 2006, 4075.

(8) Heß, G. D.; Hampel, F.; Gladysz, J. A. Organometallics 2007, 26, 5129.

(9) Skopek, K.; Gladysz, J. A. J. Organomet. Chem. 2008, 693, 857.

(10) See also: (a) Skopek, K.; Barbasiewicz, M.; Hampel, F.; Gladysz, J. A. *Inorg. Chem.* **2008**, 47, 3474. (b) Han, J.; Deng, C.; Wang, L.; Gladysz, J. A. *Organometallics* **2010**, 29, 3231. (c) Stollenz, M.; Barbasiewicz, M.; Nawara-Hultzsch, A. J.; Fiedler, T.; Laddusaw, R.; Bhuvanesh, N.; Gladysz, J. A. *Angew. Chem., Int. Ed.* **2011**, 50, 6647; *Angew. Chem.* **2011**, 123, 6777.

(11) Lang, G. Unpublished results, Texas A&M University.

(12) Kottas, G. S.; Clarke, L. I.; Horinek, D.; Michl, J. Chem. Rev. 2005, 105, 1281.

(13) Ng, P. L.; Lambert, J. N. Synlett 1999, 1749.

(14) (a) Rachiero, G. P. Doctoral dissertation, University of Erlangen-Nürnberg, 2008 (see http://www.opus.ub.uni-erlangen.de/opus/volltexte/2008/1125/). (b) Zeits, P. D. Doctoral dissertation, Texas A&M University, 2011. This thesis will become available on the web in August of 2013 (http://library.tamu.edu/about/collections/ theses-dissertations); prior to that date copies are available from the corresponding author.

(15) Capriati, V.; Florio, S.; Ingrosso, G.; Granito, C.; Troisi, L. *Eur. J. Org. Chem.* **2002**, 478.

(16) Westwell, A. D.; Williams, J. M. J. *Tetrahedron* **1997**, *53*, 13063. (17) Yuncheng, Y.; Yulin, J.; Jun, P.; Xiaohui, Z.; Conggui, Y. Gazz. *Chim. Ital.* **1993**, *123*, *519*.

(18) Lockemeyer, J. R.; Rheingold, A. L.; Bulkowski, J. E. Organometallics 1993, 12, 256.

(19) Dijkstra, H. P.; Chuchuryukin, A.; Suijkerbuijk, B. M. J. M.; van Klink, G. P. M.; Mills, A. M.; Spek, A. L.; van Koten, G. *Adv. Synth. Catal.* **2002**, 344, 771.

(20) Chuchuryukin, A. V.; Chase, P. A.; Dijkstra, H. P.; Suijkerbuijk, B. M. J. M.; Mills, A. M.; Spek, A. L.; van Klink, G. P. M.; van Koten, G. Adv. Synth. Catal. 2005, 347, 447.

(21) Lanfranchi, M.; Nobile, C. F.; Pellinghelli, M. A.; Vasapollo, G.; Sacco, A. J. Organomet. Chem. 1986, 312, 249.

(22) Tamao, K.; Kodama, S.; Nakajima, I.; Kumada, M. *Tetrahedron* **1982**, 38, 3347.

(23) (a) Tagat, J. R.; McCombie, S. W.; Barton, B. E.; Jackson, J.; Shortail, J. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2143. (b) Jacquemard, U.; Routier, S.; Dias, N.; Lansiaux, A.; Goossens, J.-F.; Bailly, C.; Mérour, J.-Y. *Eur. J. Med. Chem.* **2005**, *40*, 1087.

(24) (a) Rochon, F. D.; Beauchamp, A. L.; Bensimon, C. Can. J. Chem. **1996**, 74, 2121. (b) Tessier, C.; Rochon, F. D. Inorg. Chim. Acta **1999**, 295, 25.

(25) Silverstein, R. M.; Bassler, G. C.; Morrill, T. Spectrometric Identification of Organic Compounds, 5th ed.; Wiley: New York, 1991; pp 239–241.

(26) (a) Colamarino, P.; Orioli, P. L. J. Chem. Soc., Dalton Trans. 1975, 1656. (b) Tessier, C.; Rochon, F. D. Inorg. Chim. Acta 1999, 295, 25.

(27) The diastereotopic protons in *trans*-27a would also be exchanged by two independent 180° rotations of the pyridine ligands

about the N-Rh-N axis. In bridged bis(pyridine) systems, these rotations would be correlated and equivalent to Cl-Rh-CO rotation.

(28) Chase, P. A.; Lutz, M.; Spek, A. L.; van Klink, G. P. M; van Koten, G. J. Mol. Catal. A: Chem. 2006, 254, 2 and papers reviewed therein.

(29) Song, K. H.; Kang, S. O.; Ko, J. *Chem. Eur. J.* **2007**, *13*, 5129. (30) Shima, T.; Bauer, E. B.; Hampel, F.; Gladysz, J. A. *Dalton Trans.* **2004**, 1012 The product/catalyst system in ref 19 therein rapidly attains monomer/oligomer equilibrium, which can be reversibly varied as a function of concentration.

(31) (a) Conrad, J. C.; Eelman, M. D.; Duarte Silva, J. A.; Monfette, S.; Parnas, H. H.; Snelgrove, J. L.; Fogg, D. E. *J. Am. Chem. Soc.* 2007, *129*, 1024. (b) Monfette, S.; Fogg, D. E. *Chem. Rev.* 2009, *109*, 3783. (32) Bondi, A. *J. Phys. Chem.* 1964, *68*, 441.

(33) (a) Horansky, R. D.; Clarke, L. I.; Price, J. C.; Khuong, T.-A. V.;
Jarowski, P. D.; Garcia-Garibay, M. A. *Phys. Rev. B* 2005, *B72*, 0143021.
(b) Horansky, R. D.; Clarke, L. I.; Winston, E. B.; Price, J. C.; Karlen, S. D.; Jarowski, P. D.; Santillan, R.; Garcia-Garibay, M. A. *Phys. Rev. B* 2006, *74*, 054306-1.

(34) Bedard, T. C.; Moore, J. S. J. Am. Chem. Soc. 1995, 117, 10662.
(35) (a) Lang, T.; Graf, E.; Kyritsakas, N.; Hosseini, M. W. Dalton Trans. 2011, 40, 3517. (b) Lang, T.; Graf, E.; Kyritsakas, N.; Hosseini, M. W. Dalton Trans. 2011, 40, 5244. (c) Guenet, A.; Graf, E.; Kyritsakas, N.; Hosseini, M. W. Chem. Eur. J. 2011, 17, 6443.

(36) Ananchenko, G. S.; Udachin, K. A.; Pojarova, M.; Jehors, S.; Coleman, A. W.; Ripmeester, J. A. *Chem. Commun.* **200**7, 707.

(37) Krasovskiy, A.; Knochel, P. Synthesis 2006, 5, 890.

(38) Collman, J. P.; Decréau, R. Á.; Costanzo, S. Org. Lett. 2004, 6, 1033. See also refs 19 and 20.

(39) (a) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953. (b) Trnka, T. M.; Morgan, J. P.; Sanford, M. S.; Wilhelm, T. E.; Scholl, M.; Choi, T.; Ding, S.; Day, M. W.; Grubbs, R. H. J. Am. Chem. Soc. 2003, 125, 2546.

(40) Cammenga, H. K.; Epple, M. Angew. Chem., Int. Ed. Engl. 1995, 34, 1171; Angew. Chem. 1995, 107, 1284.

(41) FAB, 3-NBA or 2-NPOE (*trans*-16), m/z (relative intensity, %); the peaks correspond to the most intense peak of the isotope envelope.

(42) MALDI, 2,5-DHB, m/z (relative intensity, %); the peaks correspond to the most intense peak of the isotope envelope.

(43) Chuang, T.-H.; Chen, Y.-C.; Pola, S. J. Org. Chem. 2010, 75, 6625.

(44) Dynamic NMR Spectroscopy, Sandström, J., Ed.; Academic Press: New York, 1982.

(45) For one element, this microanalysis only marginally agrees with the empirical formula but is nonetheless reported as the best obtained to date. The NMR spectra indicate high purities.

(46) APEX2 Program for Data Collection on Area Detectors; Bruker AXS Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA.

(47) Sheldrick, G. M. SADABS, Program for Absorption Correction of Area Detector Frames; Bruker AXS Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA.

(48) Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112.

(49) Spek, A. L. J. Appl. Crystallogr. 2003, 36, 7.

(50) (a) Collect Data Collection Software; Nonius BV, Delft, The Netherlands, 1998. (b) Scalepack data processing software: Otwinowski, Z.; Minor, W. In Methods in Enzymology; Elsevier: Amsterdam, 1997; Vol. 276 (Macromolecular Crystallography, Part A), p 307.

(51) Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112.

(52) Cromer, D. T.; Waber, J. T. In *International Tables for X-ray Crystallography*; Ibers, J. A., Hamilton, W. C., Eds.; Kynoch: Birmingham, England, 1974.